{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "5eb29d91",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[✓] Loaded: ABACAVIR_and_LAMIVUDINE_ABACAVIR_SULFATE_LAMIVUDINE_TABLET_ORAL_204311_MYLAN_LABORATORIES_LIMITED_12-22-2023.pdf (129316 chars)\n",
      "[✓] Loaded: ABILIFY_ARIPIPRAZOLE_INJECTABLE_INTRAMUSCULAR_21866_OTSUKA_02-05-2020.pdf (211116 chars)\n",
      "[✓] Loaded: ABILIFY_ARIPIPRAZOLE_SOLUTION_ORAL_21713_OTSUKA_02-05-2020.pdf (211116 chars)\n",
      "[✓] Loaded: ABILIFY_ARIPIPRAZOLE_TABLET,_ORALLY_DISINTEGRATING_ORAL_21729_OTSUKA_02-05-2020.pdf (211116 chars)\n",
      "[✓] Loaded: ABILIFY_ARIPIPRAZOLE_TABLET_ORAL_21436_OTSUKA_01-22-2025.pdf (183565 chars)\n",
      "[✓] Loaded: ABILIFY_ASIMTUFII_ARIPIPRAZOLE_MONOHYDRATE_EXTENDED-RELEASE,_INJECTABLE_SUSPENSION__INTRAMUSCULAR_217006_OTSUKA_PHARMACEUTICAL_CO.,_LTD_01-22-2025.pdf (122753 chars)\n",
      "[✓] Loaded: ABILIFY_MAINTENA_KIT_ARIPIPRAZOLE_FOR_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_202971_OTSUKA_PHARM_CO_LTD_01-22-2025.pdf (130144 chars)\n",
      "[✓] Loaded: ABILIFY_MYCITE_KIT_ARIPIPRAZOLE_TABLET_ORAL_207202_OTSUKA_01-22-2025.pdf (146255 chars)\n",
      "[✓] Loaded: ABRILADA_ADALIMUMAB-AFZB_INJECTABLE_INJECTION_761118_PFIZER_INC_10-04-2023.pdf (189277 chars)\n",
      "[✓] Loaded: ABSORICA_ISOTRETINOIN_CAPSULE_ORAL_21951_SUN_PHARM_INDS_INC_07-18-2023.pdf (108726 chars)\n",
      "[✓] Loaded: ABSTRAL_FENTANYL_CITRATE_TABLET_SUBLINGUAL_22510_SENTYNL_THERAPS_INC_10-07-2019.pdf (114185 chars)\n",
      "[✓] Loaded: ACCUTANE_ISOTRETINOIN_CAPSULE_ORAL_18662_HOFFMANN_LA_ROCHE_10-22-2010.pdf (16629 chars)\n",
      "[✓] Loaded: ACIPHEX_RABEPRAZOLE_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_20973_WOODWARD_07-18-2023.pdf (104937 chars)\n",
      "[✓] Loaded: ACIPHEX_SPRINKLE_RABEPRAZOLE_SODIUM_CAPSULE,_DELAYED_RELEASE_ORAL_204736_AYTU_11-27-2020.pdf (71236 chars)\n",
      "[✓] Loaded: ACTEMRA_TOCILIZUMAB_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_125472_GENENTECH_09-20-2024.pdf (240084 chars)\n",
      "[✓] Loaded: ACTEMRA_TOCILIZUMAB_INJECTABLE__INJECTION_125276_GENENTECH_09-20-2024.pdf (240084 chars)\n",
      "[✓] Loaded: ACTHAR_GEL_CORTICOTROPIN_INJECTABLE_INJECTION_8372_MALLINCKRODT_ARD_02-29-2024.pdf (59566 chars)\n",
      "[✓] Loaded: ACTIQ_FENTANYL_CITRATE_TROCHE-LOZENGE_TRANSMUCOSAL_20747_CEPHALON_12-15-2023.pdf (156103 chars)\n",
      "[✓] Loaded: ACTONEL_RISEDRONATE_SODIUM_TABLET_ORAL_20835_APIL_11-05-2019.pdf (120367 chars)\n",
      "[✓] Loaded: ACTONEL_WITH_CALCIUM_(COPACKAGED)_CALCIUM_CARBONATE__RISEDRONATE_SODIUM_TABLET_ORAL_21823_WARNER_CHILCOTT_04-08-2015.pdf (82353 chars)\n",
      "[✓] Loaded: ACTOPLUS_MET_METFORMIN_HYDROCHLORIDE__PIOGLITAZONE_HYDROCHLORIDE_TABLET_ORAL_21842_TAKEDA_PHARMS_USA_12-21-2017.pdf (133188 chars)\n",
      "[✓] Loaded: ACTOPLUS_MET_XR_METFORMIN_HYDROCHLORIDE__PIOGLITAZONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_22024_TAKEDA_PHARMS_USA_12-21-2017.pdf (132922 chars)\n",
      "[✓] Loaded: ACTOS_PIOGLITAZONE_HYDROCHLORIDE_TABLET_ORAL_21073_TAKEDA_PHARMS_USA_12-21-2017.pdf (104240 chars)\n",
      "[✓] Loaded: ADASUVE_LOXAPINE_POWDER_INHALATION_22549_ALEXZA_PHARMS_02-01-2022.pdf (70773 chars)\n",
      "[✓] Loaded: ADDERALL_10_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf (48079 chars)\n",
      "[✓] Loaded: ADDERALL_12.5_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf (48079 chars)\n",
      "[✓] Loaded: ADDERALL_15_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf (48079 chars)\n",
      "[✓] Loaded: ADDERALL_20_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf (48079 chars)\n",
      "[✓] Loaded: ADDERALL_30_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_02-25-2022.pdf (50311 chars)\n",
      "[✓] Loaded: ADDERALL_5_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_02-25-2022.pdf (50311 chars)\n",
      "[✓] Loaded: ADDERALL_7.5_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_02-25-2022.pdf (50311 chars)\n",
      "[✓] Loaded: ADDYI_FLIBANSERIN_TABLET_ORAL_22526_SPROUT_PHARMS_09-29-2021.pdf (85517 chars)\n",
      "[✓] Loaded: ADEMPAS_RIOCIGUAT_TABLET_ORAL_204819_BAYER_HLTHCARE_09-10-2021.pdf (73931 chars)\n",
      "[✓] Loaded: ADHANSIA_XR_METHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_212038_PURDUE_PHARMA_LP_06-28-2021.pdf (86695 chars)\n",
      "[✓] Loaded: ADLYXIN_LIXISENATIDE_SOLUTION_SUBCUTANEOUS_208471_SANOFI-AVENTIS_US_09-28-2023.pdf (112137 chars)\n",
      "[✓] Loaded: ADUHELM_ADUCANUMAB-AVWA_INJECTABLE__INJECTION_761178_BIOGEN_INC_08-30-2023.pdf (63678 chars)\n",
      "[✓] Loaded: ADZENYS_ER_AMPHETAMINE_SUSPENSION,_EXTENDED_RELEASE_ORAL_204325_NEOS_THERAPS_INC_02-25-2022.pdf (79541 chars)\n",
      "[✓] Loaded: ADZENYS_XR-ODT_AMPHETAMINE_TABLET,_ORALLY_DISINTEGRATING,_EXTENDED_RELEASE_ORAL_204326_NEOS_THERAPS_03-12-2024.pdf (78633 chars)\n",
      "[✓] Loaded: AFREZZA_INSULIN_RECOMBINANT_HUMAN_POWDER_INHALATION_22472_MANNKIND_02-03-2023.pdf (72571 chars)\n",
      "[✓] Loaded: ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf (64839 chars)\n",
      "[✓] Loaded: ALVAIZ_ELTROMBOPAG_CHOLINE_TABLET_ORAL_216677_TEVA_PHARMACEUTICALS_11-29-2023.pdf (105613 chars)\n",
      "[✓] Loaded: AMBIEN_CR_ZOLPIDEM_TARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_21774_SANOFI_AVENTIS_US_02-23-2022.pdf (85079 chars)\n",
      "[✓] Loaded: AMBIEN_ZOLPIDEM_TARTRATE_TABLET_ORAL_19908_SANOFI_AVENTIS_US_02-23-2022.pdf (78287 chars)\n",
      "[✓] Loaded: AMJEVITA_ADALIMUMAB-ATTO_INJECTABLE_INJECTION_761024_AMGEN_INC_08-14-2023.pdf (209135 chars)\n",
      "[✓] Loaded: AMPYRA_DALFAMPRIDINE_TABLET,_EXTENDED_RELEASE_ORAL_22250_ACORDA_11-18-2021.pdf (44395 chars)\n",
      "[✓] Loaded: ANAFRANIL_CLOMIPRAMINE_HYDROCHLORIDE_CAPSULE_ORAL_19906_SPECGX_LLC_05-10-2019.pdf (80968 chars)\n",
      "[✓] Loaded: ANAPROX_DS_NAPROXEN_SODIUM_TABLET_ORAL_18164_ATNAHS_PHARMA_US_05-13-2024.pdf (109402 chars)\n",
      "[✓] Loaded: ANAPROX_NAPROXEN_SODIUM_TABLET_ORAL_18164_ATNAHS_PHARMA_US_11-21-2024.pdf (106262 chars)\n",
      "[✓] Loaded: ANDROGEL_TESTOSTERONE_GEL,_METERED_TRANSDERMAL_21015_ABBVIE_05-30-2019.pdf (71848 chars)\n",
      "[✓] Loaded: ANDROGEL_TESTOSTERONE_GEL,_METERED_TRANSDERMAL_22309_ABBVIE_05-30-2019.pdf (80949 chars)\n",
      "[✓] Loaded: ANDROGEL_TESTOSTERONE_GEL_TRANSDERMAL_21015_ABBVIE_05-30-2019.pdf (71848 chars)\n",
      "[✓] Loaded: ANDROGEL_TESTOSTERONE_GEL_TRANSDERMAL_22309_ABBVIE_05-30-2019.pdf (80949 chars)\n",
      "[✓] Loaded: ANSAID_FLURBIPROFEN_TABLET_ORAL_18766_PHARMACIA_AND_UPJOHN_05-09-2016.pdf (5987 chars)\n",
      "[✓] Loaded: APADAZ_ACETAMINOPHEN__BENZHYDROCODONE_HYDROCHLORIDE_TABLET_ORAL_208653_KVK_TECH_INC_12-15-2023.pdf (125621 chars)\n",
      "[✓] Loaded: APLENZIN_BUPROPION_HYDROBROMIDE_TABLET,_EXTENDED_RELEASE_ORAL_22108_BAUSCH_05-07-2024.pdf (117561 chars)\n",
      "[✓] Loaded: APTENSIO_XR_METHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_205831_RHODES_PHARMS_10-13-2023.pdf (71255 chars)\n",
      "[✓] Loaded: APTIOM_ESLICARBAZEPINE_ACETATE_TABLET_ORAL_22416_SUNOVION_PHARMS_INC_03-15-2019.pdf (87735 chars)\n",
      "[✓] Loaded: APTRYXOL_DESVENLAFAXINE_TABLET,EXTENDED_RELEASE_ORAL_205583_SUN_PHARMACEUTICAL_08-18-2023.pdf (99606 chars)\n",
      "[✓] Loaded: ARANESP_DARBEPOETIN_ALFA_VIAL__INTRAVENOUS_103951_AMGEN_01-30-2019.pdf (91947 chars)\n",
      "[✓] Loaded: ARANESP_DARBEPOETIN_ALFA_VIAL__SUBCUTANEOUS_103951_AMGEN_01-30-2019.pdf (91947 chars)\n",
      "[✓] Loaded: ARCAPTA_NEOHALER_INDACATEROL_MALEATE_POWDER_INHALATION_22383_NOVARTIS_07-30-2021.pdf (14626 chars)\n",
      "[✓] Loaded: ARIKAYCE_KIT_AMIKACIN_SULFATE_SUSPENSION,_LIPOSOMAL_INHALATION_207356_INSMED_INC_02-10-2023.pdf (62098 chars)\n",
      "[✓] Loaded: ARISTADA_ARIPIPRAZOLE_LAUROXIL_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_207533_ALKERMES_INC_01-22-2025.pdf (91134 chars)\n",
      "[✓] Loaded: ARISTADA_INITIO_KIT_ARIPIPRAZOLE_LAUROXIL_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_209830_ALKERMES_INC_01-22-2025.pdf (80087 chars)\n",
      "[✓] Loaded: ARTHROTEC_DICLOFENAC_SODIUM__MISOPROSTOL_TABLET,_DELAYED_RELEASE_ORAL_20607_PFIZER_11-21-2024.pdf (105743 chars)\n",
      "[✓] Loaded: ARYMO_ER_MORPHINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_208603_ZYLA_10-07-2019.pdf (109655 chars)\n",
      "[✓] Loaded: ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_204096_ASTELLAS_09-14-2023.pdf (125171 chars)\n",
      "[✓] Loaded: ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf (124002 chars)\n",
      "[✓] Loaded: ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_50708_ASTELLAS_09-14-2023.pdf (307319 chars)\n",
      "[✓] Loaded: ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_50709_ASTELLAS_11-22-2022.pdf (307319 chars)\n",
      "[✓] Loaded: ATELVIA_RISEDRONATE_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_22560_APIL_08-18-2020.pdf (80678 chars)\n",
      "[✓] Loaded: ATIVAN_LORAZEPAM_TABLET_ORAL_17794_BAUSCH_01-13-2023.pdf (45551 chars)\n",
      "[✓] Loaded: AUBAGIO_TERIFLUNOMIDE_TABLET_ORAL_202992_SANOFI_AVENTIS_US_06-10-2024.pdf (86128 chars)\n",
      "[✓] Loaded: AUSTEDO_DEUTETRABENAZINE_TABLET_ORAL_208082_TEVA_BRANDED_PHARM_02-28-2025.pdf (84883 chars)\n",
      "[✓] Loaded: AUSTEDO_DEUTETRABENAZINE_TABLET_ORAL_216354_TEVA_NEUROSCIENCE_02-28-2025.pdf (84883 chars)\n",
      "[✓] Loaded: AUVELITY_BUPROPION__DEXTROMETHORPHAN_TABLET,_EXTENDED_RELEASE__ORAL_215430_AXSOME_INC_05-07-2024.pdf (99461 chars)\n",
      "[✓] Loaded: AVANDAMET_METFORMIN_HYDROCHLORIDE__ROSIGLITAZONE_MALEATE_TABLET_ORAL_21410_SB_PHARMCO_04-05-2017.pdf (133474 chars)\n",
      "[✓] Loaded: AVANDARYL_GLIMEPIRIDE__ROSIGLITAZONE_MALEATE_TABLET_ORAL_21700_SB_PHARMCO_04-27-2023.pdf (117272 chars)\n",
      "[✓] Loaded: AVANDIA_ROSIGLITAZONE_MALEATE_TABLET_ORAL_21071_WOODWARD_02-05-2019.pdf (100387 chars)\n",
      "[✓] Loaded: AVEED_TESTOSTERONE_UNDECANOATE_INJECTABLE_INTRAMUSCULAR_22219_ENDO_PHARMS_INC_08-16-2021.pdf (66562 chars)\n",
      "[✓] Loaded: AVELOX_IN_SODIUM_CHLORIDE_0.8%_IN_PLASTIC_CONTAINER_MOXIFLOXACIN_HYDROCHLORIDE_SOLUTION_INTRAVENOUS_21277_BAYER_HLTHCARE_05-06-2020.pdf (140060 chars)\n",
      "[✓] Loaded: AVELOX_MOXIFLOXACIN_HYDROCHLORIDE_TABLET_ORAL_21085_BAYER_HLTHCARE_05-06-2020.pdf (140060 chars)\n",
      "[✓] Loaded: AVONEX_INTERFERON_BETA-1A_VIAL_103628_BIOGEN_07-28-2023.pdf (92934 chars)\n",
      "[✓] Loaded: AVSOLA_INFLIXIMAB-AXXQ_INJECTABLE_INJECTION_761086_AMGEN_INC_09-09-2021.pdf (189382 chars)\n",
      "[✓] Loaded: AVTOZMA_TOCILIZUMAB-ANOH_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_761420_CELLTRION_01-24-2025.pdf (457255 chars)\n",
      "[✓] Loaded: AXIRON_TESTOSTERONE_SOLUTION,_METERED_TRANSDERMAL_22504_ELI_LILLY_AND_CO_07-13-2017.pdf (91188 chars)\n",
      "[✓] Loaded: AZSTARYS_DEXMETHYLPHENIDATE_HYDROCHLORIDE__SERDEXMETHYLPHENIDATE_CHLORIDE_CAPSULE_ORAL_212994_COMMAVE_THERAP_10-13-2023.pdf (71612 chars)\n",
      "[✓] Loaded: BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf (70811 chars)\n",
      "[✓] Loaded: BANZEL_RUFINAMIDE_TABLET_ORAL_21911_EISAI_INC_11-28-2019.pdf (73640 chars)\n",
      "[✓] Loaded: BAVENCIO_AVELUMAB_INJECTABLE_INJECTION_761049_EMD_SERONO_INC_11-26-2024.pdf (104245 chars)\n",
      "[✓] Loaded: BAVENCIO_AVELUMAB_INJECTABLE_INTRAVENOUS_761078_EMD_SERONO_INC_05-09-2017.pdf (73199 chars)\n",
      "[✓] Loaded: BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf (109885 chars)\n",
      "[✓] Loaded: BAXDELA_DELAFLOXACIN_MEGLUMINE_TABLET_ORAL_208610_MELINTA_06-19-2017.pdf (101818 chars)\n",
      "[✓] Loaded: BELBUCA_BUPRENORPHINE_HYDROCHLORIDE_FILM_BUCCAL_207932_BDSI_12-15-2023.pdf (141072 chars)\n",
      "[✓] Loaded: BELSOMRA_SUVOREXANT_TABLET_ORAL_204569_MERCK_SHARP_DOHME_03-25-2021.pdf (68968 chars)\n",
      "[✓] Loaded: BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf (131646 chars)\n",
      "[✓] Loaded: BENLYSTA_BELIMUMAB_INJECTABLE__INJECTION_125370_HUMAN_GENOME_SCIENCES_INC._05-16-2024.pdf (131646 chars)\n",
      "[✓] Loaded: BESREMI_ROPEGINTERFERON_ALFA-2B-NJFT_INJECTABLE_SUBCUTANEOUS_761166_PHARMAESSENTIA_CORP_04-29-2024.pdf (85554 chars)\n",
      "[✓] Loaded: BETASERON_INTERFERON_BETA-1B_VIAL__SUBCUTANEOUS_103471_BAYER_HEALTHCARE_PHARMS_07-28-2023.pdf (80429 chars)\n",
      "[✓] Loaded: BEVYXXA_BETRIXABAN_CAPSULE_ORAL_208383_PORTOLA_PHARMS_INC_08-24-2020.pdf (53344 chars)\n",
      "[✓] Loaded: BIMZELX_BIMEKIZUMAB-BKZX_INJECTABLE__SUBCUTANEOUS_761151_UCB_INC_09-20-2024.pdf (112612 chars)\n",
      "[✓] Loaded: BINOSTO_ALENDRONATE_SODIUM_TABLET,_EFFERVESCENT_ORAL_202344_ASCEND_THERAPS_US_10-13-2020.pdf (87381 chars)\n",
      "[✓] Loaded: BLENREP_BELANTAMAB_MAFODOTIN-BLMF_INJECTABLE_INTRAVENOUS_761158_GLAXOSMITHKLINE_02-28-2022.pdf (60470 chars)\n",
      "[✓] Loaded: BLINCYTO_BLINATUMOMAB_INJECTABLE_INJECTION_125557_AMGEN_06-14-2024.pdf (117794 chars)\n",
      "[✓] Loaded: BONIVA_IBANDRONATE_SODIUM_INJECTABLE_INTRAVENOUS_21858_ROCHE_01-11-2022.pdf (64662 chars)\n",
      "[✓] Loaded: BONIVA_IBANDRONATE_SODIUM_TABLET_ORAL_21455_HOFFMANN_LA_ROCHE_12-07-2016.pdf (71211 chars)\n",
      "[✓] Loaded: BONSITY_TERIPARATIDE_SOLUTION_SUBCUTANEOUS_211939_ALVOGEN_11-16-2023.pdf (72700 chars)\n",
      "[✓] Loaded: BOTOX_COSMETIC_OnabotulinumtoxinA_VIAL__SINGLE-USE_103000_ALLERGAN_08-10-2023.pdf (185744 chars)\n",
      "[✓] Loaded: BOTOX_OnabotulinumtoxinA_VIAL__SINGLE-USE_103000_ALLERGAN_08-10-2023.pdf (185744 chars)\n",
      "[✓] Loaded: BRAFTOVI_ENCORAFENIB_CAPSULE_ORAL_210496_ARRAY_BIOPHARMA_INC_09-12-2024.pdf (98669 chars)\n",
      "[✓] Loaded: BRENZAVVY_BEXAGLIFLOZIN_TABLET_ORAL_214373_THERACOS_BIO_09-12-2023.pdf (104847 chars)\n",
      "[✓] Loaded: BREXAFEMME_IBREXAFUNGERP_TABLET_ORAL_214900_SCYNEXIS_11-30-2022.pdf (50398 chars)\n",
      "[✓] Loaded: BRILINTA_TICAGRELOR_TABLET_ORAL_22433_ASTRAZENECA_03-22-2024.pdf (78111 chars)\n",
      "[✓] Loaded: BRISDELLE_PAROXETINE_MESYLATE_CAPSULE_ORAL_204516_SEBELA_IRELAND_LTD_02-11-2025.pdf (74744 chars)\n",
      "[✓] Loaded: BRIUMVI_UBLITUXIMAB-XIIY_INJECTABLE_INJECTION_761238_TG_Therapeutics_12-28-2022.pdf (62139 chars)\n",
      "[✓] Loaded: BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf (68381 chars)\n",
      "[✓] Loaded: BRIVIACT_BRIVARACETAM_SOLUTION_ORAL_205838_UCB_INC_05-17-2023.pdf (68381 chars)\n",
      "[✓] Loaded: BRIVIACT_BRIVARACETAM_TABLET_ORAL_205836_UCB_INC_05-17-2023.pdf (68381 chars)\n",
      "[✓] Loaded: BRIXADI_BUPRENORPHINE_INJECTION,_EXTENDED_RELEASE_SUBCUTANEOUS_210136_BRAEBURN_05-23-2023.pdf (154979 chars)\n",
      "[✓] Loaded: BROVANA_ARFORMOTEROL_TARTRATE_SOLUTION_INHALATION_21912_SUNOVION_05-29-2019.pdf (82295 chars)\n",
      "[✓] Loaded: BRYNOVIN_SITAGLIPTIN_SOLUTION_ORAL_219122_AZURITY_PHARMACEUTICALS,_INC_01-16-2025.pdf (98658 chars)\n",
      "[✓] Loaded: BUNAVAIL_BUPRENORPHINE_HYDROCHLORIDE__NALOXONE_HYDROCHLORIDE_FILM_BUCCAL_205637_BDSI_06-17-2022.pdf (120151 chars)\n",
      "[✓] Loaded: BUTRANS_BUPRENORPHINE_FILM,_EXTENDED_RELEASE_TRANSDERMAL_21306_PURDUE_PHARMA_LP_12-15-2023.pdf (143687 chars)\n",
      "[✓] Loaded: BYDUREON_BCISE_EXENATIDE_SYNTHETIC_SUSPENSION,_EXTENDED_RELEASE_SUBCUTANEOUS_209210_ASTRAZENECA_AB_03-06-2024.pdf (123802 chars)\n",
      "[✓] Loaded: BYDUREON_EXENATIDE_SYNTHETIC_FOR_SUSPENSION,_EXTENDED_RELEASE_SUBCUTANEOUS_22200_ASTRAZENECA_AB_12-21-2022.pdf (121952 chars)\n",
      "[✓] Loaded: BYDUREON_PEN_EXENATIDE_SYNTHETIC_FOR_SUSPENSION,_EXTENDED_RELEASE_SUBCUTANEOUS_22200_ASTRAZENECA_AB_12-21-2022.pdf (121952 chars)\n",
      "[✓] Loaded: BYETTA_EXENATIDE_SYNTHETIC_INJECTABLE_SUBCUTANEOUS_21773_ASTRAZENECA_AB_12-21-2022.pdf (120546 chars)\n",
      "[✓] Loaded: CAMBIA_DICLOFENAC_POTASSIUM_FOR_SOLUTION_ORAL_22165_ASSERTIO_11-21-2024.pdf (71629 chars)\n",
      "[✓] Loaded: CAMZYOS_MAVACAMTEN_CAPSULE_ORAL_214998_BRISTOL_MYERS_SQUIBB_06-15-2023.pdf (72306 chars)\n",
      "[✓] Loaded: CAPLYTA_LUMATEPERONE_TOSYLATE_CAPSULE_ORAL_209500_INTRA-CELLULAR_06-28-2023.pdf (92339 chars)\n",
      "[✓] Loaded: CAPRELSA_VANDETANIB_TABLET_ORAL_22405_GENZYME_CORP_03-28-2022.pdf (65289 chars)\n",
      "[✓] Loaded: CARBATROL_CARBAMAZEPINE_CAPSULE,_EXTENDED_RELEASE_ORAL_20712_TAKEDA_PHARMS_USA_04-11-2023.pdf (82955 chars)\n",
      "[✓] Loaded: CASSIPA_BUPRENORPHINE_HYDROCHLORIDE__NALOXONE_HYDROCHLORIDE_FILM_SUBLINGUAL_208042_TEVA_PHARMS_USA_12-15-2023.pdf (118207 chars)\n",
      "[✓] Loaded: CATAFLAM_DICLOFENAC_POTASSIUM_TABLET_ORAL_20142_NOVARTIS_04-28-2021.pdf (66652 chars)\n",
      "[✓] Loaded: CELEBREX_CELECOXIB_CAPSULE_ORAL_20998_UPJOHN_11-21-2024.pdf (120010 chars)\n",
      "[✓] Loaded: CELEBREX_CELECOXIB_CAPSULE_ORAL_21156_GD_SEARLE_LLC_02-04-2011.pdf (6094 chars)\n",
      "[✓] Loaded: CELEXA_CITALOPRAM_HYDROBROMIDE_SOLUTION_ORAL_21046_FOREST_LABS_12-03-2012.pdf (100529 chars)\n",
      "[✓] Loaded: CELEXA_CITALOPRAM_HYDROBROMIDE_TABLET_ORAL_20822_ALLERGAN_08-18-2023.pdf (90184 chars)\n",
      "[✓] Loaded: CELLCEPT_MYCOPHENOLATE_MOFETIL_CAPSULE_ORAL_50722_ROCHE_PALO_08-10-2022.pdf (132889 chars)\n",
      "[✓] Loaded: CELLCEPT_MYCOPHENOLATE_MOFETIL_FOR_SUSPENSION_ORAL_50759_ROCHE_PALO_08-10-2022.pdf (132889 chars)\n",
      "[✓] Loaded: CELLCEPT_MYCOPHENOLATE_MOFETIL_HYDROCHLORIDE_INJECTABLE_INJECTION_50758_ROCHE_PALO_08-10-2022.pdf (132889 chars)\n",
      "[✓] Loaded: CELLCEPT_MYCOPHENOLATE_MOFETIL_TABLET_ORAL_50723_ROCHE_PALO_08-10-2022.pdf (132889 chars)\n",
      "[✓] Loaded: CERDELGA_ELIGLUSTAT_TARTRATE_CAPSULE_ORAL_205494_GENZYME_CORP_08-29-2018.pdf (52788 chars)\n",
      "[✓] Loaded: CHANTIX_VARENICLINE_TARTRATE_TABLET_ORAL_21928_PF_PRISM_CV_02-22-2019.pdf (113031 chars)\n",
      "[✓] Loaded: CHLORDIAZEPOXIDE_AND_AMITRIPTYLINE_HYDROCHLORIDE_AMITRIPTYLINE_HYDROCHLORIDE__CHLORDIAZEPOXIDE_TABLET_ORAL_71297_MYLAN_PHARMS_INC_02-05-2021.pdf (1581 chars)\n",
      "[✓] Loaded: CIBINQO_ABROCITINIB_TABLET__ORAL_213871_PFIZER_INC_12-15-2023.pdf (91304 chars)\n",
      "[✓] Loaded: CIMZIA_CERTOLIZUMAB_PEGOL_INJECTABLE__INJECTION_125160_UCB_INC_09-13-2024.pdf (150869 chars)\n",
      "[✓] Loaded: CIPRO_CIPROFLOXACIN_FOR_SUSPENSION_ORAL_20780_BAYER_HLTHCARE_09-20-2024.pdf (152037 chars)\n",
      "[✓] Loaded: CIPRO_CIPROFLOXACIN_HYDROCHLORIDE_TABLET_ORAL_19537_BAYER_HLTHCARE_09-20-2024.pdf (152037 chars)\n",
      "[✓] Loaded: CIPRO_CIPROFLOXACIN_INJECTABLE_INJECTION_19847_BAYER_HLTHCARE_03-25-2022.pdf (134714 chars)\n",
      "[✓] Loaded: CIPRO_IN_DEXTROSE_5%_IN_PLASTIC_CONTAINER_CIPROFLOXACIN_INJECTABLE_INJECTION_19857_BAYER_HLTHCARE_03-25-2022.pdf (135301 chars)\n",
      "[✓] Loaded: CIPRO_XR_CIPROFLOXACIN__CIPROFLOXACIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21473_BAYER_HLTHCARE_03-30-2021.pdf (127547 chars)\n",
      "[✓] Loaded: CITALOPRAM_CITALOPRAM_HYDROBROMIDE_CAPSULE__ORAL_215428_ALMATICA_08-18-2023.pdf (92705 chars)\n",
      "[✓] Loaded: CLENPIQ_CITRIC_ACID__MAGNESIUM_OXIDE__SODIUM_PICOSULFATE_SOLUTION_ORAL_209589_FERRING_PHARMS_INC_08-29-2023.pdf (69211 chars)\n",
      "[✓] Loaded: CODEINE_SULFATE_CODEINE_SULFATE_SOLUTION_ORAL_202245_HIKMA_12-15-2023.pdf (122308 chars)\n",
      "[✓] Loaded: CODEINE_SULFATE_CODEINE_SULFATE_TABLET_ORAL_22402_HIKMA_12-15-2023.pdf (112257 chars)\n",
      "[✓] Loaded: COLCRYS_COLCHICINE_TABLET_ORAL_22352_TAKEDA_PHARMS_USA_05-14-2020.pdf (79809 chars)\n",
      "[✓] Loaded: COLCRYS_COLCHICINE_TABLET__ORAL_22353_AR_HOLDING_CO_INC_10-16-2019.pdf (66294 chars)\n",
      "[✓] Loaded: COLUMVI_GLOFITAMAB-GXBM_INJECTABLE_INTRAVENOUS_761309_GENETECH_06-15-2023.pdf (63271 chars)\n",
      "[✓] Loaded: COMBOGESIC_ACETAMINOPHEN__IBUPROFEN_TABLET_ORAL_209471_AFT_Pharmaceuticals_11-21-2024.pdf (86563 chars)\n",
      "[✓] Loaded: COMBUNOX_IBUPROFEN__OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_21378_FOREST_LABS_09-02-2010.pdf (55666 chars)\n",
      "[✓] Loaded: CONCERTA_METHYLPHENIDATE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21121_JANSSEN_PHARMS_10-13-2023.pdf (82693 chars)\n",
      "[✓] Loaded: CONSENSI_AMLODIPINE_BESYLATE__CELECOXIB_TABLET_ORAL_210045_PURPLE_BIOTECH_04-28-2021.pdf (135986 chars)\n",
      "[✓] Loaded: CONTRAVE_BUPROPION_HYDROCHLORIDE__NALTREXONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_200063_NALPROPION_05-07-2024.pdf (125496 chars)\n",
      "[✓] Loaded: CONZIP_TRAMADOL_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22370_CIPHER_PHARMS_INC_12-15-2023.pdf (137762 chars)\n",
      "[✓] Loaded: COPAXONE_GLATIRAMER_ACETATE_INJECTABLE_SUBCUTANEOUS_20622_TEVA_NEUROSCIENCE_INC_01-22-2025.pdf (66725 chars)\n",
      "[✓] Loaded: COPEGUS_RIBAVIRIN_TABLET_ORAL_21511_ROCHE_08-11-2015.pdf (96147 chars)\n",
      "[✓] Loaded: COPIKTRA_DUVELISIB_CAPSULE_ORAL_211155_SECURA_12-17-2021.pdf (72994 chars)\n",
      "[✓] Loaded: CORDARONE_AMIODARONE_HYDROCHLORIDE_TABLET_ORAL_18972_WYETH_PHARMS_10-17-2018.pdf (55846 chars)\n",
      "[✓] Loaded: CORLANOR_IVABRADINE_HYDROCHLORIDE_TABLET_ORAL_206143_AMGEN_INC_08-04-2021.pdf (65435 chars)\n",
      "[✓] Loaded: CORLANOR_IVABRADINE_SOLUTION_ORAL_209964_AMGEN_INC_08-04-2021.pdf (65435 chars)\n",
      "[✓] Loaded: COSENTYX_SECUKINUMAB_INJECTABLE_INJECTION_125504_NOVARTIS_PHARMS_CORP_08-16-2024.pdf (123170 chars)\n",
      "[✓] Loaded: COSENTYX_SECUKINUMAB_INJECTABLE_SUBCUTANEOUS,_INTRAVENOUS_761349_NOVARTIS_PHARMACEUTICALS_CORPORATION_10-06-2023.pdf (157979 chars)\n",
      "[✓] Loaded: COTEMPLA_XR-ODT_METHYLPHENIDATE_TABLET,_ORALLY_DISINTEGRATING,_EXTENDED_RELEASE_ORAL_205489_NEOS_THERAPS_INC_10-13-2023.pdf (67303 chars)\n",
      "[✓] Loaded: COUMADIN_WARFARIN_SODIUM_INJECTABLE_INJECTION_9218_BRISTOL_MYERS_SQUIBB_08-14-2017.pdf (83318 chars)\n",
      "[✓] Loaded: COUMADIN_WARFARIN_SODIUM_TABLET_ORAL_9218_BRISTOL_MYERS_SQUIBB_08-14-2017.pdf (83318 chars)\n",
      "[✓] Loaded: COXANTO_OXAPROZIN_CAPSULE_ORAL_217927_SOLUBIOMIX_11-21-2024.pdf (84358 chars)\n",
      "[✓] Loaded: CREON_PANCRELIPASE_(AMYLASE_LIPASE_PROTEASE)_CAPSULE,_DELAYED_RELEASE_ORAL_20725_ABBVIE_06-02-2024.pdf (54338 chars)\n",
      "[✓] Loaded: CYLTEZO_ADALIMUMAB-ADBM_INJECTABLE_INJECTION_761058_BOEHRINGER_INGELHEIM_04-30-2024.pdf (182379 chars)\n",
      "[✓] Loaded: CYMBALTA_DULOXETINE_HYDROCHLORIDE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_21427_LILLY_08-18-2023.pdf (168671 chars)\n",
      "[✓] Loaded: DALIRESP_ROFLUMILAST_TABLET_ORAL_22522_ASTRAZENECA_01-23-2018.pdf (59454 chars)\n",
      "[✓] Loaded: DALMANE_FLURAZEPAM_HYDROCHLORIDE_CAPSULE_ORAL_16721_VALEANT_PHARM_INTL_03-27-2009.pdf (7846 chars)\n",
      "[✓] Loaded: DATROWAY_DATOPOTAMAB_DERUXTECAN-DLNK_INJECTABLE_INTRAVENOUS_761394_DAIICHI_SANKYO_COMPANY,_LTD_01-17-2025.pdf (55382 chars)\n",
      "[✓] Loaded: DAURISMO_GLASDEGIB_MALEATE_TABLET_ORAL_210656_PFIZER_03-27-2023.pdf (60820 chars)\n",
      "[✓] Loaded: DAXXIFY_daxibotulinumtoxinA-lanm_INJECTABLE_INTRAMUSCULAR_761127_REVANCE_THERAPEUTICS,_INC_08-11-2023.pdf (59860 chars)\n",
      "[✓] Loaded: DAYPRO_ALTA_OXAPROZIN_POTASSIUM_TABLET_ORAL_20776_PFIZER_11-21-2024.pdf (75683 chars)\n",
      "[✓] Loaded: DAYPRO_OXAPROZIN_TABLET_ORAL_18841_PFIZER_11-21-2024.pdf (82316 chars)\n",
      "[✓] Loaded: DAYTRANA_METHYLPHENIDATE_FILM,_EXTENDED_RELEASE_TRANSDERMAL_21514_NOVEN_PHARMS_INC_10-13-2023.pdf (103264 chars)\n",
      "[✓] Loaded: DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf (104076 chars)\n",
      "[✓] Loaded: DAYVIGO_LEMBOREXANT_TABLET_ORAL_212028_EISAI_INC_02-19-2025.pdf (65325 chars)\n",
      "[✓] Loaded: DEMEROL_MEPERIDINE_HYDROCHLORIDE_INJECTABLE_INJECTION_5010_VALIDUS_PHARMS_12-15-2023.pdf (117783 chars)\n",
      "[✓] Loaded: DEMEROL_MEPERIDINE_HYDROCHLORIDE_SYRUP_ORAL_5010_VALIDUS_PHARMS_12-15-2023.pdf (117783 chars)\n",
      "[✓] Loaded: DEMEROL_MEPERIDINE_HYDROCHLORIDE_TABLET_ORAL_5010_VALIDUS_PHARMS_12-15-2023.pdf (117783 chars)\n",
      "[✓] Loaded: DEPAKENE_VALPROIC_ACID_CAPSULE_ORAL_18081_ABBVIE_05-19-2020.pdf (136380 chars)\n",
      "[✓] Loaded: DEPAKENE_VALPROIC_ACID_SYRUP_ORAL_18082_ABBVIE_05-19-2020.pdf (123439 chars)\n",
      "[✓] Loaded: DEPAKOTE_DIVALPROEX_SODIUM_CAPSULE,_DELAYED_REL_PELLETS_ORAL_19680_ABBVIE_01-23-2025.pdf (136676 chars)\n",
      "[✓] Loaded: DEPAKOTE_DIVALPROEX_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_18723_ABBVIE_01-23-2025.pdf (151480 chars)\n",
      "[✓] Loaded: DEPAKOTE_ER_DIVALPROEX_SODIUM_TABLET,_EXTENDED_RELEASE_ORAL_21168_ABBVIE_01-23-2025.pdf (151172 chars)\n",
      "[✓] Loaded: DESCOVY_EMTRICITABINE__TENOFOVIR_ALAFENAMIDE_FUMARATE_TABLET_ORAL_208215_GILEAD_SCIENCES_INC_01-07-2022.pdf (116850 chars)\n",
      "[✓] Loaded: DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_5378_RECORDATI_RARE_09-24-2024.pdf (52131 chars)\n",
      "[✓] Loaded: DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET_ORAL_5378_RECORDATI_RARE_10-13-2023.pdf (39821 chars)\n",
      "[✓] Loaded: DESVENLAFAXINE_DESVENLAFAXINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_205208_TEVA_PHARMS_USA_07-18-2014.pdf (109539 chars)\n",
      "[✓] Loaded: DESVENLAFAXINE_DESVENLAFAXINE_TABLET,_EXTENDED_RELEASE_ORAL_204150_ALEMBIC_PHARMS_LTD_08-18-2023.pdf (101222 chars)\n",
      "[✓] Loaded: DESYREL_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_18207_PRAGMA_10-18-2018.pdf (56625 chars)\n",
      "[✓] Loaded: DEXEDRINE_DEXTROAMPHETAMINE_SULFATE_CAPSULE,_EXTENDED_RELEASE_ORAL_17078_IMPAX_LABS_INC_10-13-2023.pdf (46336 chars)\n",
      "[✓] Loaded: DEXILANT_DEXLANSOPRAZOLE_CAPSULE,_DELAYED_RELEASE_ORAL_22287_TAKEDA_PHARMS_USA_07-18-2023.pdf (97860 chars)\n",
      "[✓] Loaded: DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf (60707 chars)\n",
      "[✓] Loaded: DIACOMIT_STIRIPENTOL_FOR_SUSPENSION_ORAL_207223_BIOCODEX_SA_08-20-2018.pdf (60707 chars)\n",
      "[✓] Loaded: DILANTIN-125_PHENYTOIN_SUSPENSION_ORAL_8762_UPJOHN_03-03-2022.pdf (72657 chars)\n",
      "[✓] Loaded: DILANTIN-30_PHENYTOIN_SUSPENSION_ORAL_8762_UPJOHN_03-03-2022.pdf (72657 chars)\n",
      "[✓] Loaded: DILANTIN_PHENYTOIN_SODIUM_CAPSULE_ORAL_84349_UPJOHN_09-07-2022.pdf (72947 chars)\n",
      "[✓] Loaded: DILANTIN_PHENYTOIN_TABLET,_CHEWABLE_ORAL_84427_PHARMACIA_10-22-2021.pdf (62835 chars)\n",
      "[✓] Loaded: DILAUDID_HYDROMORPHONE_HYDROCHLORIDE_SOLUTION_ORAL_19891_RHODES_PHARMS_12-15-2023.pdf (109157 chars)\n",
      "[✓] Loaded: DILAUDID_HYDROMORPHONE_HYDROCHLORIDE_TABLET_ORAL_19892_RHODES_PHARMS_12-15-2023.pdf (109157 chars)\n",
      "[✓] Loaded: DOLOPHINE_HYDROCHLORIDE_METHADONE_HYDROCHLORIDE_SYRUP_ORAL_6134_HIKMA_06-02-2021.pdf (144906 chars)\n",
      "[✓] Loaded: DOLOPHINE_HYDROCHLORIDE_METHADONE_HYDROCHLORIDE_TABLET_ORAL_6134_HIKMA_06-02-2021.pdf (144906 chars)\n",
      "[✓] Loaded: DORAL_QUAZEPAM_TABLET_ORAL_18708_GALT_PHARMS_01-13-2023.pdf (64365 chars)\n",
      "[✓] Loaded: DOTAREM_GADOTERATE_MEGLUMINE_SOLUTION_INTRAVENOUS_204781_GUERBET_03-05-2025.pdf (124267 chars)\n",
      "[✓] Loaded: DRIZALMA_SPRINKLE_DULOXETINE_HYDROCHLORIDE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_212516_SUN_PHARMA_GLOBAL_08-18-2023.pdf (168297 chars)\n",
      "[✓] Loaded: DROXIA_HYDROXYUREA_CAPSULE_ORAL_16295_BRISTOL_MYERS_SQUIBB_11-28-2023.pdf (86127 chars)\n",
      "[✓] Loaded: DUETACT_GLIMEPIRIDE__PIOGLITAZONE_HYDROCHLORIDE_TABLET_ORAL_21925_TAKEDA_PHARMS_USA_12-21-2017.pdf (129940 chars)\n",
      "[✓] Loaded: DUEXIS_FAMOTIDINE__IBUPROFEN_TABLET_ORAL_22519_HORIZON_11-21-2024.pdf (107810 chars)\n",
      "[✓] Loaded: DURAGESIC-100_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DURAGESIC-12_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DURAGESIC-25_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DURAGESIC-37_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DURAGESIC-50_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DURAGESIC-75_FENTANYL_FILM,_EXTENDED_RELEASE_TRANSDERMAL_19813_JANSSEN_PHARMS_03-04-2021.pdf (142615 chars)\n",
      "[✓] Loaded: DUZALLO_ALLOPURINOL__LESINURAD_TABLET_ORAL_209203_IRONWOOD_PHARMS_INC_08-18-2017.pdf (83562 chars)\n",
      "[✓] Loaded: DYANAVEL_XR_10_AMPHETAMINE__AMPHETAMINE_ASPARTATE-DEXTROAMPHETAMINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_210526_TRIS_PHARMA_INC_10-13-2023.pdf (75577 chars)\n",
      "[✓] Loaded: DYANAVEL_XR_15_AMPHETAMINE__AMPHETAMINE_ASPARTATE-DEXTROAMPHETAMINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_210526_TRIS_PHARMA_INC_10-13-2023.pdf (75577 chars)\n",
      "[✓] Loaded: DYANAVEL_XR_20_AMPHETAMINE__AMPHETAMINE_ASPARTATE-DEXTROAMPHETAMINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_210526_TRIS_PHARMA_INC_10-13-2023.pdf (75577 chars)\n",
      "[✓] Loaded: DYANAVEL_XR_5_AMPHETAMINE__AMPHETAMINE_ASPARTATE-DEXTROAMPHETAMINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_210526_TRIS_PHARMA_INC_10-13-2023.pdf (75577 chars)\n",
      "[✓] Loaded: DYANAVEL_XR_AMPHETAMINE_SUSPENSION,_EXTENDED_RELEASE_ORAL_208147_TRIS_PHARMA_INC_10-13-2023.pdf (75577 chars)\n",
      "[✓] Loaded: DYSPORT_abobotulinumtoxinA_INJECTABLE__INJECTION_125274_IPSEN_BIOPHARM_LTD_09-21-2023.pdf (115996 chars)\n",
      "[✓] Loaded: EC-NAPROSYN_NAPROXEN_TABLET,_DELAYED_RELEASE_ORAL_20067_ATNAHS_PHARMA_US_11-21-2024.pdf (106262 chars)\n",
      "[✓] Loaded: EDLUAR_ZOLPIDEM_TARTRATE_TABLET_SUBLINGUAL_21997_MYLAN_SPECIALITY_LP_08-18-2019.pdf (78689 chars)\n",
      "[✓] Loaded: EFFEXOR_VENLAFAXINE_HYDROCHLORIDE_TABLET_ORAL_20151_WYETH_PHARMS_INC_12-12-2012.pdf (112218 chars)\n",
      "[✓] Loaded: EFFEXOR_XR_VENLAFAXINE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_20699_UPJOHN_08-18-2023.pdf (113027 chars)\n",
      "[✓] Loaded: EFFIENT_PRASUGREL_HYDROCHLORIDE_TABLET_ORAL_22307_DAIICHI_SANKYO_INC_12-22-2020.pdf (74292 chars)\n",
      "[✓] Loaded: ELEPSIA_XR_LEVETIRACETAM_TABLET,_EXTENDED_RELEASE_ORAL_204417_TRIPOINT_03-12-2024.pdf (91490 chars)\n",
      "[✓] Loaded: ELIQUIS_APIXABAN_TABLET_ORAL_202155_BRISTOL_MYERS_SQUIBB_10-12-2021.pdf (101965 chars)\n",
      "[✓] Loaded: ELMIRON_PENTOSAN_POLYSULFATE_SODIUM_CAPSULE_ORAL_20193_JANSSEN_PHARMS_03-12-2021.pdf (31841 chars)\n",
      "[✓] Loaded: ELREXFIO_ELRANATAMAB-BCMM_INJECTABLE__SUBCUTANEOUS_761345_PFIZER_08-14-2023.pdf (78633 chars)\n",
      "[✓] Loaded: ELUCIREM_GADOPICLENOL_INJECTABLE_INTRAVENOUS_216986_LIEBEL-FLARSHEIM_COMPANY_03-05-2025.pdf (61773 chars)\n",
      "[✓] Loaded: ELYXYB_CELECOXIB_SOLUTION_ORAL_212157_BDSI_11-21-2024.pdf (85363 chars)\n",
      "[✓] Loaded: EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf (126285 chars)\n",
      "[✓] Loaded: EMPAVEL_PEGCETACOPLAN_INJECTABLE_SUBCUTANEOUS_215014_APELLIS_PHARMACEUTICALS_02-08-2024.pdf (106431 chars)\n",
      "[✓] Loaded: EMSAM_SELEGILINE_FILM,_EXTENDED_RELEASE_TRANSDERMAL_21336_SOMERSET_07-14-2017.pdf (103280 chars)\n",
      "[✓] Loaded: ENBREL_ETANERCEPT_SYRINGE_103795_IMMUNEX_06-09-2023.pdf (211720 chars)\n",
      "[✓] Loaded: ENBREL_ETANERCEPT_VIAL__SUBCUTANEOUS_103795_IMMUNEX_09-12-2024.pdf (214861 chars)\n",
      "[✓] Loaded: ENHERTU_FAM-TRASTUZUMAB_DERUXTECAN-NXKI_INJECTABLE_INJECTION_761139_DAIICHI_SANKYO_01-27-2025.pdf (141019 chars)\n",
      "[✓] Loaded: ENJAYMO_Sutimlimab-Jome_INJECTABLE_INJECTION_761164_nan_02-08-2024.pdf (41816 chars)\n",
      "[✓] Loaded: ENSPRYNG_SATRALIZUMAB-MWGE_INJECTABLE_SUBCUTANEOUS_761149_GENETECH,_INC_09-14-2022.pdf (64690 chars)\n",
      "[✓] Loaded: ENTYVIO_PEN_VEDOLIZUMAB_INJECTABLE_SUBCUTANEOUS_761133_TAKEDA_PHARMACEUTICALS_USA_INC_04-18-2024.pdf (110927 chars)\n",
      "[✓] Loaded: ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf (70108 chars)\n",
      "[✓] Loaded: ENTYVIO_VEDOLIZUMAB_INJECTABLE_INTRAVENOUS_761133_TAKEDA_PHARMACEUTICALS_USA_INC_04-18-2024.pdf (110927 chars)\n",
      "[✓] Loaded: ENTYVIO_VEDOLIZUMAB_INJECTABLE_SUBCUTANEOUS_761133_TAKEDA_PHARMACEUTICALS_USA_INC_04-18-2024.pdf (110927 chars)\n",
      "[✓] Loaded: ENVARSUS_XR_TACROLIMUS_TABLET,_EXTENDED_RELEASE_ORAL_206406_VELOXIS_PHARMS_INC_04-08-2024.pdf (109781 chars)\n",
      "[✓] Loaded: EOVIST_GADOXETATE_DISODIUM_SOLUTION_INTRAVENOUS_22090_BAYER_HLTHCARE_03-05-2025.pdf (55872 chars)\n",
      "[✓] Loaded: EPIDIOLEX_CANNABIDIOL_SOLUTION_ORAL_210365_GW_RES_LTD_03-04-2024.pdf (94831 chars)\n",
      "[✓] Loaded: EPKINLY_EPCORITAMAB-BYSP_INJECTABLE_SUBCUTANEOUS_761324_GENMAB_US_06-26-2024.pdf (67697 chars)\n",
      "[✓] Loaded: EPOGEN_EPOETIN_ALFA_VIAL__SINGLE-USE_103234_AMGEN_04-30-2024.pdf (234735 chars)\n",
      "[✓] Loaded: EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf (89792 chars)\n",
      "[✓] Loaded: EQUETRO_CARBAMAZEPINE_CAPSULE,_EXTENDED_RELEASE_ORAL_21710_VALIDUS_PHARMS_10-14-2022.pdf (98061 chars)\n",
      "[✓] Loaded: ERELZI_ETANERCEPT-SZZS_INJECTABLE__INJECTION_761042_SANDOZ_11-10-2022.pdf (180876 chars)\n",
      "[✓] Loaded: ERIVEDGE_VISMODEGIB_CAPSULE_ORAL_203388_GENENTECH_03-27-2023.pdf (42862 chars)\n",
      "[✓] Loaded: ESOMEPRAZOLE_STRONTIUM_ESOMEPRAZOLE_STRONTIUM_CAPSULE,_DELAYED_RELEASE_ORAL_202342_BELCHER_03-04-2022.pdf (116970 chars)\n",
      "[✓] Loaded: ETICOVO_ETANERCEPT-YKRO_INJECTABLE_INJECTION_761066_SAMSUNG_BIOEPIS_CO_LTD_05-03-2024.pdf (145067 chars)\n",
      "[✓] Loaded: EVEKEO_ODT_AMPHETAMINE_SULFATE_TABLET,_ORALLY_DISINTEGRATING_ORAL_209905_ARBOR_PHARMS_LLC_10-13-2023.pdf (62650 chars)\n",
      "[✓] Loaded: EVENITY_ROMOSOZUMAB-AQQG_INJECTABLE_INJECTION_761062_AMGEN_INC_12-20-2019.pdf (64263 chars)\n",
      "[✓] Loaded: EXALGO_HYDROMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21217_SPECGX_LLC_10-07-2019.pdf (110808 chars)\n",
      "[✓] Loaded: EXJADE_DEFERASIROX_TABLET,_FOR_SUSPENSION_ORAL_21882_NOVARTIS_07-23-2020.pdf (119715 chars)\n",
      "[✓] Loaded: EXTAVIA_INTERFERON_BETA-1B_INJECTABLE__SUBCUTANEOUS_125290_NOVARTIS_PHARMS_07-28-2023.pdf (86949 chars)\n",
      "[✓] Loaded: FABHALTA_IPTACOPAN_CAPSULE_ORAL_218276_NOVARTIS_PHARMACEUTICALS_08-07-2024.pdf (64539 chars)\n",
      "[✓] Loaded: FACTIVE_GEMIFLOXACIN_MESYLATE_TABLET_ORAL_21158_LG_CHEM_LTD_07-26-2016.pdf (114108 chars)\n",
      "[✓] Loaded: FARXIGA_DAPAGLIFLOZIN_TABLET_ORAL_202293_ASTRAZENECA_AB_06-12-2024.pdf (130238 chars)\n",
      "[✓] Loaded: FELBATOL_FELBAMATE_SUSPENSION_ORAL_20189_MYLAN_SPECIALITY_LP_08-31-2012.pdf (10656 chars)\n",
      "[✓] Loaded: FELBATOL_FELBAMATE_TABLET_ORAL_20189_MYLAN_SPECIALITY_LP_08-31-2012.pdf (10656 chars)\n",
      "[✓] Loaded: FELDENE_PIROXICAM_CAPSULE_ORAL_18147_PFIZER_11-21-2024.pdf (72714 chars)\n",
      "[✓] Loaded: FENSOLVI_KIT_LEUPROLIDE_ACETATE_POWDER_SUBCUTANEOUS_213150_TOLMAR_04-22-2022.pdf (41456 chars)\n",
      "[✓] Loaded: FENTANYL_CITRATE_FENTANYL_CITRATE_TROCHE-LOZENGE_TRANSMUCOSAL_77312_PAR_PHARM_09-07-2017.pdf (16535 chars)\n",
      "[✓] Loaded: FENTANYL_CITRATE_FENTANYL_CITRATE_TROCHE-LOZENGE_TRANSMUCOSAL_78907_SPECGX_LLC_12-03-2021.pdf (18681 chars)\n",
      "[✓] Loaded: FENTORA_FENTANYL_CITRATE_TABLET_BUCCAL,_SUBLINGUAL_21947_CEPHALON_12-15-2023.pdf (138333 chars)\n",
      "[✓] Loaded: FERRIPROX_DEFERIPRONE_SOLUTION_ORAL_208030_CHIESI_11-30-2021.pdf (58106 chars)\n",
      "[✓] Loaded: FERRIPROX_DEFERIPRONE_TABLET_ORAL_212269_CHIESI_11-30-2021.pdf (72925 chars)\n",
      "[✓] Loaded: FERRIPROX_DEFERIPRONE_TABLET_ORAL_21825_CHIESI_11-30-2021.pdf (72925 chars)\n",
      "[✓] Loaded: FETZIMA_LEVOMILNACIPRAN_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_204168_ALLERGAN_04-19-2024.pdf (86140 chars)\n",
      "[✓] Loaded: FILSPARI_SPARSENTAN_TABLET_ORAL_216403_TRAVERE_THERAPEUTICS_02-17-2023.pdf (67540 chars)\n",
      "[✓] Loaded: FINTEPLA_FENFLURAMINE_HYDROCHLORIDE_SOLUTION_ORAL_212102_ZOGENIX_INC_12-15-2023.pdf (107366 chars)\n",
      "[✓] Loaded: FIORICET_W-_CODEINE_ACETAMINOPHEN__BUTALBITAL__CAFFEINE__CODEINE_PHOSPHATE_CAPSULE_ORAL_20232_ACTAVIS_LABS_UT_INC_12-15-2023.pdf (156691 chars)\n",
      "[✓] Loaded: FIORINAL_W-CODEINE_ASPIRIN__BUTALBITAL__CAFFEINE__CODEINE_PHOSPHATE_CAPSULE_ORAL_19429_ALLERGAN_04-28-2021.pdf (134508 chars)\n",
      "[✓] Loaded: FIRDAPSE_AMIFAMPRIDINE_PHOSPHATE_TABLET_ORAL_208078_CATALYST_PHARMS_05-30-2024.pdf (58864 chars)\n",
      "[✓] Loaded: FLECTOR_DICLOFENAC_EPOLAMINE_SYSTEM_TOPICAL_21234_INST_BIOCHEM_11-21-2024.pdf (78000 chars)\n",
      "[✓] Loaded: FLOWTUSS_GUAIFENESIN__HYDROCODONE_BITARTRATE_SOLUTION_ORAL_22424_BKK_PHARMS_12-15-2023.pdf (104396 chars)\n",
      "[✓] Loaded: FLOXIN_OFLOXACIN_TABLET_ORAL_19735_JANSSEN_PHARMS_02-25-2011.pdf (16262 chars)\n",
      "[✓] Loaded: FLUOXETINE_HYDROCHLORIDE_FLUOXETINE_HYDROCHLORIDE_TABLET_ORAL_202133_ALMATICA_08-18-2023.pdf (153496 chars)\n",
      "[✓] Loaded: FOCALIN_DEXMETHYLPHENIDATE_HYDROCHLORIDE_TABLET_ORAL_21278_NOVARTIS_10-13-2023.pdf (65183 chars)\n",
      "[✓] Loaded: FOCALIN_XR_DEXMETHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_21802_NOVARTIS_10-13-2023.pdf (78578 chars)\n",
      "[✓] Loaded: FORADIL_CERTIHALER_FORMOTEROL_FUMARATE_POWDER_INHALATION_21592_NOVARTIS_06-02-2010.pdf (80794 chars)\n",
      "[✓] Loaded: FORFIVO_XL_BUPROPION_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_22497_ALMATICA_05-07-2024.pdf (108284 chars)\n",
      "[✓] Loaded: FORTEO_TERIPARATIDE_SOLUTION_SUBCUTANEOUS_21318_LILLY_09-07-2021.pdf (69055 chars)\n",
      "[✓] Loaded: FORTESTA_TESTOSTERONE_GEL,_METERED_TRANSDERMAL_21463_ENDO_PHARMS_06-30-2020.pdf (63999 chars)\n",
      "[✓] Loaded: FOSAMAX_ALENDRONATE_SODIUM_SOLUTION_ORAL_21575_MERCK_11-30-2015.pdf (103889 chars)\n",
      "[✓] Loaded: FOSAMAX_ALENDRONATE_SODIUM_TABLET_ORAL_20560_MERCK_AND_CO_INC_08-16-2019.pdf (103889 chars)\n",
      "[✓] Loaded: FOSAMAX_PLUS_D_ALENDRONATE_SODIUM__CHOLECALCIFEROL_TABLET_ORAL_21762_ORGANON_08-16-2019.pdf (101971 chars)\n",
      "[✓] Loaded: FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf (42162 chars)\n",
      "[✓] Loaded: FOSRENOL_LANTHANUM_CARBONATE_TABLET,_CHEWABLE_ORAL_21468_TAKEDA_PHARMS_USA_08-29-2024.pdf (42162 chars)\n",
      "[✓] Loaded: FYCOMPA_PERAMPANEL_SUSPENSION_ORAL_208277_EISAI_INC_02-23-2021.pdf (104086 chars)\n",
      "[✓] Loaded: FYCOMPA_PERAMPANEL_TABLET_ORAL_202834_EISAI_INC_05-30-2019.pdf (107621 chars)\n",
      "[✓] Loaded: GADAVIST_GADOBUTROL_SOLUTION_INTRAVENOUS_201277_BAYER_HLTHCARE_03-05-2025.pdf (262601 chars)\n",
      "[✓] Loaded: GATTEX_KIT_TEDUGLUTIDE_RECOMBINANT_POWDER_SUBCUTANEOUS_203441_NPS_PHARMS_INC_09-19-2024.pdf (96913 chars)\n",
      "[✓] Loaded: GILENYA_FINGOLIMOD_HYDROCHLORIDE_CAPSULE_ORAL_22527_NOVARTIS_06-05-2024.pdf (122692 chars)\n",
      "[✓] Loaded: GIMOTI_METOCLOPRAMIDE_HYDROCHLORIDE_SPRAY,_METERED_NASAL_209388_EVOKE_PHARMA_INC_01-14-2021.pdf (67003 chars)\n",
      "[✓] Loaded: GLOPERBA_COLCHICINE_SOLUTION_ORAL_210942_ROMEG_08-28-2024.pdf (49652 chars)\n",
      "[✓] Loaded: GLYXAMBI_EMPAGLIFLOZIN__LINAGLIPTIN_TABLET_ORAL_206073_BOEHRINGER_INGELHEIM_10-30-2023.pdf (113894 chars)\n",
      "[✓] Loaded: GOLYTELY_POLYETHYLENE_GLYCOL_3350__POTASSIUM_CHLORIDE__SODIUM_BICARBONATE__SODIUM_CHLORIDE__SODIUM_SULFATE_ANHYDROUS_FOR_SOLUTION_ORAL_19011_BRAINTREE_05-14-2021.pdf (38334 chars)\n",
      "[✓] Loaded: GRALISE_GABAPENTIN_TABLET_ORAL_22544_ALMATICA_04-18-2023.pdf (63223 chars)\n",
      "[✓] Loaded: HADLIMA_ADALIMUMAB-BWWD_INJECTABLE_INJECTION_761059_SAMSUNG_BIOEPIS_CO_LTD_06-28-2024.pdf (209697 chars)\n",
      "[✓] Loaded: HALCION_TRIAZOLAM_TABLET_ORAL_17892_PFIZER_01-13-2023.pdf (70488 chars)\n",
      "[✓] Loaded: HEMANGEOL_PROPRANOLOL_HYDROCHLORIDE_SOLUTION_ORAL_205410_PIERRE_FABRE_DERMA_06-22-2021.pdf (41566 chars)\n",
      "[✓] Loaded: HEMLIBRA_EMICIZUMAB_INJECTABLE_INJECTION_761083_GENENTECH_INC_01-31-2024.pdf (73574 chars)\n",
      "[✓] Loaded: HORIZANT_GABAPENTIN_ENACARBIL_TABLET,_EXTENDED_RELEASE_ORAL_22399_ARBOR_PHARMS_LLC_04-17-2020.pdf (77139 chars)\n",
      "[✓] Loaded: HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf (204704 chars)\n",
      "[✓] Loaded: HUMIRA_ADALIMUMAB_SYRINGE_125057_ABBVIE_INC_11-03-2023.pdf (211615 chars)\n",
      "[✓] Loaded: HUMIRA_ADALIMUMAB_VIAL_125057_ABBVIE_INC_02-24-2021.pdf (251840 chars)\n",
      "[✓] Loaded: HYCODAN_HOMATROPINE_METHYLBROMIDE__HYDROCODONE_BITARTRATE_SYRUP_ORAL_5213_GENUS_12-15-2023.pdf (98038 chars)\n",
      "[✓] Loaded: HYCODAN_HOMATROPINE_METHYLBROMIDE__HYDROCODONE_BITARTRATE_TABLET_ORAL_5213_GENUS_12-15-2023.pdf (98038 chars)\n",
      "[✓] Loaded: HYCOFENIX_HYDROCODONE_BITARTRATE_PSEUDOEPHEDRINE_HYDROCHLORIDE_GUAIFENESIN_SOLUTION_ORAL_22279_BKK_PHARMACEUTICALS_12-15-2023.pdf (117036 chars)\n",
      "[✓] Loaded: HYDROMORPHONE_HYDROCHLORIDE_HYDROMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_204278_PADAGIS_US_03-04-2021.pdf (129 chars)\n",
      "[✓] Loaded: HYRIMOZ_ADALIMUMAB-ADAZ_INJECTABLE_INJECTION_761071_SANDOZ_INC_06-12-2024.pdf (237143 chars)\n",
      "[✓] Loaded: HYSINGLA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_206627_PURDUE_PHARMA_LP_12-15-2023.pdf (137203 chars)\n",
      "[✓] Loaded: IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf (40208 chars)\n",
      "[✓] Loaded: ICLUSIG_PONATINIB_HYDROCHLORIDE_TABLET_ORAL_203469_TAKEDA_PHARMS_USA_03-19-2024.pdf (121344 chars)\n",
      "[✓] Loaded: IDACIO_ADALIMUMAB-AACF_INJECTABLE_SUBCUTANEOUS_761255_FRESENIUS_KABI_USA_06-04-2024.pdf (181593 chars)\n",
      "[✓] Loaded: IDHIFA_ENASIDENIB_MESYLATE_TABLET_ORAL_209606_CELGENE_CORP_01-16-2025.pdf (50255 chars)\n",
      "[✓] Loaded: ILARIS_CANAKINUMAB_INJECTABLE__SUBCUTANEOUS_125319_NOVARTIS_PHARMS_08-25-2023.pdf (121114 chars)\n",
      "[✓] Loaded: ILUMYA_TILDRAKIZUMAB-ASMN_INJECTABLE_INJECTION_761067_SUN_PHARMA_GLOBAL_04-03-2024.pdf (34198 chars)\n",
      "[✓] Loaded: IMFINZI_DURVALUMAB_INJECTABLE_INJECTION_761069_ASTRAZENECA_UK_LTD_02-28-2025.pdf (195951 chars)\n",
      "[✓] Loaded: IMIPRAMINE_HYDROCHLORIDE_IMIPRAMINE_HYDROCHLORIDE_TABLET_ORAL_87846_SPECGX_LLC_06-29-2017.pdf (48972 chars)\n",
      "[✓] Loaded: IMJUDO_TREMELIMUMAB-ACTL_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_761270_ASTRAZENECA_11-10-2022.pdf (88485 chars)\n",
      "[✓] Loaded: IMJUDO_TREMELIMUMAB-ACTL_INJECTABLE_INTRAVENOUS_761289_ASTRAZENECA_01-25-2024.pdf (85475 chars)\n",
      "[✓] Loaded: INDOCIN_INDOMETHACIN_CAPSULE_ORAL_16059_EGALET_11-21-2024.pdf (73914 chars)\n",
      "[✓] Loaded: INDOCIN_INDOMETHACIN_SUPPOSITORY_RECTAL_17814_EGALET_11-21-2024.pdf (88606 chars)\n",
      "[✓] Loaded: INDOCIN_INDOMETHACIN_SUSPENSION_ORAL_18332_EGALET_11-21-2024.pdf (73933 chars)\n",
      "[✓] Loaded: INDOCIN_SR_INDOMETHACIN_CAPSULE,_EXTENDED_RELEASE_ORAL_18185_EGALET_11-21-2024.pdf (81298 chars)\n",
      "[✓] Loaded: INDOMETHACIN_INDOMETHACIN_CAPSULE_ORAL_18829_CHARTWELL_MOLECULES_11-21-2024.pdf (64459 chars)\n",
      "[✓] Loaded: INDOMETHACIN_INDOMETHACIN_CAPSULE_ORAL_18851_HERITAGE_11-21-2024.pdf (84327 chars)\n",
      "[✓] Loaded: INDOMETHACIN_INDOMETHACIN_CAPSULE_ORAL_18858_RISING_11-21-2024.pdf (80935 chars)\n",
      "[✓] Loaded: INFLECTRA_INFLIXIMAB-DYYB_INJECTABLE_INJECTION_125544_CELLTRION_INC_06-17-2021.pdf (193313 chars)\n",
      "[✓] Loaded: INGREZZA_VALBENAZINE_CAPSULE_ORAL_209241_NEUROCRINE_BIOSCIENCES_INC_02-05-2025.pdf (78211 chars)\n",
      "[✓] Loaded: INPEFA_SOTAGLIFLOZIN_TABLET__ORAL_216203_LEXICON_PHARMACEUTICALS_05-26-2023.pdf (66911 chars)\n",
      "[✓] Loaded: INREBIC_FEDRATINIB_HYDROCHLORIDE_CAPSULE_ORAL_212327_IMPACT_05-15-2023.pdf (61529 chars)\n",
      "[✓] Loaded: INTERMEZZO_ZOLPIDEM_TARTRATE_TABLET_SUBLINGUAL_22328_PURDUE_PHARMA_08-18-2019.pdf (70169 chars)\n",
      "[✓] Loaded: INTRON_A_INTERFERON_ALFA-2B_VIAL_103132_SCHERING_11-26-2021.pdf (139078 chars)\n",
      "[✓] Loaded: INVIRASE_SAQUINAVIR_MESYLATE_CAPSULE_ORAL_20628_HOFFMANN_LA_ROCHE_03-28-2019.pdf (114521 chars)\n",
      "[✓] Loaded: INVIRASE_SAQUINAVIR_MESYLATE_TABLET_ORAL_21785_HOFFMANN-LA_ROCHE_09-18-2020.pdf (115846 chars)\n",
      "[✓] Loaded: INVOKAMET_CANAGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET_ORAL_204353_JANSSEN_PHARMS_08-23-2024.pdf (190315 chars)\n",
      "[✓] Loaded: INVOKAMET_XR_CANAGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_205879_JANSSEN_PHARMS_08-23-2024.pdf (190315 chars)\n",
      "[✓] Loaded: INVOKANA_CANAGLIFLOZIN_TABLET_ORAL_204042_JANSSEN_PHARMS_08-23-2024.pdf (127412 chars)\n",
      "[✓] Loaded: IXIFI_INFLIXIMAB-QBTX_INJECTABLE_INJECTION_761072_PFIZER_INC_12-26-2023.pdf (175720 chars)\n",
      "[✓] Loaded: JADENU_DEFERASIROX_TABLET_ORAL_206910_NOVARTIS_PHARMS_CORP_07-23-2020.pdf (132031 chars)\n",
      "[✓] Loaded: JADENU_SPRINKLE_DEFERASIROX_GRANULE_ORAL_207968_NOVARTIS_07-23-2020.pdf (132031 chars)\n",
      "[✓] Loaded: JANUMET_METFORMIN_HYDROCHLORIDE__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_22044_MERCK_SHARP_DOHME_06-21-2022.pdf (117402 chars)\n",
      "[✓] Loaded: JANUMET_XR_METFORMIN_HYDROCHLORIDE__SITAGLIPTIN_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_202270_MERCK_SHARP_DOHME_06-21-2022.pdf (125792 chars)\n",
      "[✓] Loaded: JANUVIA_SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_21995_MERCK_SHARP_DOHME_06-21-2022.pdf (91864 chars)\n",
      "[✓] Loaded: JARDIANCE_EMPAGLIFLOZIN_TABLET_ORAL_204629_BOEHRINGER_INGELHEIM_09-21-2023.pdf (141166 chars)\n",
      "[✓] Loaded: JEMPERLI_DOSTARLIMAB-GXLY_INJECTABLE_INJECTION_761174_GLAXOSMITHKLINE_08-01-2024.pdf (91567 chars)\n",
      "[✓] Loaded: JEMPERLI_DOSTARLIMAB-GXLY_INJECTABLE_INJECTION_761223_GLAXOSMITHKLINE_LLC_08-17-2021.pdf (70808 chars)\n",
      "[✓] Loaded: JENTADUETO_LINAGLIPTIN__METFORMIN_HYDROCHLORIDE_TABLET_ORAL_201281_BOEHRINGER_INGELHEIM_06-20-2023.pdf (108525 chars)\n",
      "[✓] Loaded: JENTADUETO_XR_LINAGLIPTIN__METFORMIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_208026_BOEHRINGER_INGELHEIM_06-20-2023.pdf (126033 chars)\n",
      "[✓] Loaded: JESDUVROQ_DAPRODUSTAT_TABLET_ORAL_216951_GLAXOSMITHKLINE_02-01-2023.pdf (62269 chars)\n",
      "[✓] Loaded: JEUVEAU_PRABOTULINUMTOXINA-XVFS_INJECTABLE_INJECTION_761085_EVOLUS_INC_07-12-2019.pdf (45061 chars)\n",
      "[✓] Loaded: JORNAY_PM_METHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_209311_IRONSHORE_PHARMS_10-13-2023.pdf (73930 chars)\n",
      "[✓] Loaded: JUXTAPID_LOMITAPIDE_MESYLATE_CAPSULE_ORAL_203858_AMRYT_05-27-2021.pdf (88441 chars)\n",
      "[✓] Loaded: JYNARQUE_TOLVAPTAN_TABLET_ORAL_204441_OTSUKA_11-25-2020.pdf (60593 chars)\n",
      "[✓] Loaded: KADIAN_MORPHINE_SULFATE_CAPSULE,_EXTENDED_RELEASE_ORAL_20616_ALLERGAN_03-04-2021.pdf (117394 chars)\n",
      "[✓] Loaded: KALBITOR_ECALLANTIDE_INJECTABLE__INJECTION_125277_DYAX_CORP._12-28-2020.pdf (38792 chars)\n",
      "[✓] Loaded: KALETRA_LOPINAVIR__RITONAVIR_CAPSULE_ORAL_21226_ABBVIE_10-21-2020.pdf (142226 chars)\n",
      "[✓] Loaded: KALETRA_LOPINAVIR__RITONAVIR_SOLUTION_ORAL_21251_ABBVIE_10-21-2020.pdf (160202 chars)\n",
      "[✓] Loaded: KALETRA_LOPINAVIR__RITONAVIR_TABLET_ORAL_21906_ABBVIE_10-21-2020.pdf (160202 chars)\n",
      "[✓] Loaded: KAZANO_ALOGLIPTIN_BENZOATE__METFORMIN_HYDROCHLORIDE_TABLET_ORAL_203414_TAKEDA_PHARMS_USA_07-27-2023.pdf (103131 chars)\n",
      "[✓] Loaded: KEPPRA_LEVETIRACETAM_SOLUTION_ORAL_21505_UCB_INC_03-12-2024.pdf (100244 chars)\n",
      "[✓] Loaded: KEPPRA_LEVETIRACETAM_TABLET_ORAL_21035_UCB_INC_03-12-2024.pdf (100244 chars)\n",
      "[✓] Loaded: KEPPRA_XR_LEVETIRACETAM_TABLET,_EXTENDED_RELEASE_ORAL_22285_UCB_INC_03-12-2024.pdf (89765 chars)\n",
      "[✓] Loaded: KESIMPTA_OFATUMUMAB_SOLUTION_SUBCUTANEOUS_125326_NOVARTIS_04-12-2024.pdf (73370 chars)\n",
      "[✓] Loaded: KETEK_TELITHROMYCIN_TABLET_ORAL_21144_SANOFI_AVENTIS_US_11-04-2015.pdf (79644 chars)\n",
      "[✓] Loaded: KEVZARA_SARILUMAB_INJECTABLE_INJECTION_761037_SANOFI_SYNTHELABO_06-10-2024.pdf (93373 chars)\n",
      "[✓] Loaded: KEYTRUDA_PEMBROLIZUMAB_SOLUTION_INTRAVENOUS_125514_MERCK_SHARP_DOHME_01-28-2025.pdf (470156 chars)\n",
      "[✓] Loaded: KHEDEZLA_DESVENLAFAXINE_TABLET,_EXTENDED_RELEASE_ORAL_204683_OSMOTICA_PHARM_CORP_09-20-2021.pdf (99585 chars)\n",
      "[✓] Loaded: KLONOPIN_CLONAZEPAM_TABLET_ORAL_17533_CHEPLAPHARM_01-13-2023.pdf (77420 chars)\n",
      "[✓] Loaded: KOMBIGLYZE_XR_METFORMIN_HYDROCHLORIDE__SAXAGLIPTIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_200678_ASTRAZENECA_AB_07-01-2019.pdf (149433 chars)\n",
      "[✓] Loaded: KONVOMEP_OMEPRAZOLE__SODIUM_BICARBONATE_SUSPENSION_ORAL_213593_AZURITY_08-30-2022.pdf (96794 chars)\n",
      "[✓] Loaded: KORLYM_MIFEPRISTONE_TABLET_ORAL_202107_CORCEPT_THERAP_11-05-2019.pdf (64731 chars)\n",
      "[✓] Loaded: KRYSTEXXA_PEGLOTICASE_INJECTABLE__INJECTION_125293_HORIZON_PHARMA_07-07-2022.pdf (69908 chars)\n",
      "[✓] Loaded: LACOSAMIDE_LACOSAMIDE_SOLUTION_ORAL_204839_AMNEAL_PHARMS_10-27-2017.pdf (11140 chars)\n",
      "[✓] Loaded: LACOSAMIDE_LACOSAMIDE_TABLET_ORAL_204855_ACTAVIS_LABS_FL_INC_10-27-2017.pdf (11746 chars)\n",
      "[✓] Loaded: LACOSAMIDE_LACOSAMIDE_TABLET_ORAL_204857_AMNEAL_PHARMS_NY_08-10-2021.pdf (10293 chars)\n",
      "[✓] Loaded: LAMICTAL_CD_LAMOTRIGINE_TABLET,_FOR_SUSPENSION_ORAL_20764_GLAXOSMITHKLINE_LLC_03-31-2021.pdf (196922 chars)\n",
      "[✓] Loaded: LAMICTAL_LAMOTRIGINE_TABLET_ORAL_20241_GLAXOSMITHKLINE_LLC_03-31-2021.pdf (196922 chars)\n",
      "[✓] Loaded: LAMICTAL_ODT_LAMOTRIGINE_TABLET,_ORALLY_DISINTEGRATING_ORAL_22251_GLAXOSMITHKLINE_LLC_03-31-2021.pdf (196922 chars)\n",
      "[✓] Loaded: LAMICTAL_XR_LAMOTRIGINE_TABLET,_EXTENDED_RELEASE_ORAL_22115_GLAXOSMITHKLINE_LLC_03-31-2021.pdf (159888 chars)\n",
      "[✓] Loaded: LAMICTAL_XR_LAMOTRIGINE_TABLET,_EXTENDED_RELEASE__ORAL_22509_SMITHKLINE_BEECHAM_01-29-2010.pdf (129920 chars)\n",
      "[✓] Loaded: LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf (89459 chars)\n",
      "[✓] Loaded: LAMISIL_TERBINAFINE_HYDROCHLORIDE_TABLET_ORAL_20539_NOVARTIS_03-29-2019.pdf (45554 chars)\n",
      "[✓] Loaded: LAMIVUDINE,_NEVIRAPINE_AND_ZIDOVUDINE_LAMIVUDINE__NEVIRAPINE__ZIDOVUDINE_TABLET_ORAL_205626_MICRO_LABS_08-13-2018.pdf (165630 chars)\n",
      "[✓] Loaded: LARIAM_MEFLOQUINE_HYDROCHLORIDE_TABLET_ORAL_19591_ROCHE_04-29-2011.pdf (65664 chars)\n",
      "[✓] Loaded: LATUDA_LURASIDONE_HYDROCHLORIDE_TABLET_ORAL_200603_SUNOVION_PHARMS_INC_01-22-2025.pdf (160759 chars)\n",
      "[✓] Loaded: LAZANDA_FENTANYL_CITRATE_SPRAY,_METERED_NASAL_22569_BTCP_PHARMA_12-03-2021.pdf (134202 chars)\n",
      "[✓] Loaded: LEMTRADA_ALEMTUZUMAB_INJECTABLE_INJECTION_103948_GENZYME_05-20-2024.pdf (107009 chars)\n",
      "[✓] Loaded: LEQEMBI_ECANEMAB-IRMB_INJECTABLE_INTRAVENOUS_761269_EISAI_INC_01-24-2025.pdf (68719 chars)\n",
      "[✓] Loaded: LETAIRIS_AMBRISENTAN_TABLET_ORAL_22081_GILEAD_06-08-2021.pdf (66148 chars)\n",
      "[✓] Loaded: LEVAQUIN_LEVOFLOXACIN_INJECTABLE_INJECTION_20635_JANSSEN_PHARMS_02-08-2017.pdf (166924 chars)\n",
      "[✓] Loaded: LEVAQUIN_LEVOFLOXACIN_SOLUTION_ORAL_21721_JANSSEN_PHARMS_02-08-2017.pdf (166924 chars)\n",
      "[✓] Loaded: LEVAQUIN_LEVOFLOXACIN_TABLET_ORAL_20634_JANSSEN_PHARMS_02-08-2017.pdf (157004 chars)\n",
      "[✓] Loaded: LEXAPRO_ESCITALOPRAM_OXALATE_SOLUTION_ORAL_21365_ALLERGAN_04-19-2024.pdf (109933 chars)\n",
      "[✓] Loaded: LEXAPRO_ESCITALOPRAM_OXALATE_TABLET_ORAL_21323_ALLERGAN_04-19-2024.pdf (109933 chars)\n",
      "[✓] Loaded: LIBRAX_CHLORDIAZEPOXIDE_HYDROCHLORIDE__CLIDINIUM_BROMIDE_CAPSULE_ORAL_12750_BAUSCH_01-13-2023.pdf (45925 chars)\n",
      "[✓] Loaded: LIBRIUM_CHLORDIAZEPOXIDE_HYDROCHLORIDE_CAPSULE_ORAL_12249_VALEANT_PHARM_INTL_12-16-2016.pdf (24770 chars)\n",
      "[✓] Loaded: LIBTAYO_CEMIPLIMAB-RWLC_INJECTABLE_INTRAVENOUS_761097_REGENERON_PHARMACEUTICALS_04-05-2024.pdf (100730 chars)\n",
      "[✓] Loaded: LICART_DICLOFENAC_EPOLAMINE_SYSTEM_TOPICAL_206976_IBSA_INST_BIO_11-21-2024.pdf (78953 chars)\n",
      "[✓] Loaded: LIMBITROL_AMITRIPTYLINE_HYDROCHLORIDE__CHLORDIAZEPOXIDE_TABLET_ORAL_16949_HERITAGE_PHARMS_INC_02-05-2021.pdf (53996 chars)\n",
      "[✓] Loaded: LIMBITROL_DS_AMITRIPTYLINE_HYDROCHLORIDE__CHLORDIAZEPOXIDE_TABLET_ORAL_16949_HERITAGE_PHARMS_INC_02-05-2021.pdf (53996 chars)\n",
      "[✓] Loaded: LINDANE_LINDANE_LOTION_TOPICAL_87313_OLTA_PHARMS_09-04-2001.pdf (13232 chars)\n",
      "[✓] Loaded: LINDANE_LINDANE_SHAMPOO_TOPICAL_87266_OLTA_PHARMS_04-05-2004.pdf (15751 chars)\n",
      "[✓] Loaded: LINZESS_LINACLOTIDE_CAPSULE_ORAL_202811_ALLERGAN_06-12-2023.pdf (68546 chars)\n",
      "[✓] Loaded: LITHIUM_CARBONATE_LITHIUM_CARBONATE_CAPSULE_ORAL_17812_HIKMA_10-13-2022.pdf (68237 chars)\n",
      "[✓] Loaded: LITHIUM_CARBONATE_LITHIUM_CARBONATE_TABLET_ORAL_18558_HIKMA_10-13-2022.pdf (68237 chars)\n",
      "[✓] Loaded: LITHIUM_CITRATE_LITHIUM_CITRATE_SYRUP_ORAL_18421_HIKMA_10-13-2022.pdf (68237 chars)\n",
      "[✓] Loaded: LOQTORZI_TORIPALIMAB-TPZI_INJECTABLE_INTRAVENOUS_761240_COHERUS_BIOSCIENCES_INC_04-22-2024.pdf (81103 chars)\n",
      "[✓] Loaded: LOREEV_XR_LORAZEPAM_CAPSULE,_EXTENDED_RELEASE_ORAL_214826_Almatica_Pharma_01-13-2023.pdf (66637 chars)\n",
      "[✓] Loaded: LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf (70863 chars)\n",
      "[✓] Loaded: LUNESTA_ESZOPICLONE_TABLET_ORAL_21476_SUNOVION_PHARMS_INC_08-18-2019.pdf (75165 chars)\n",
      "[✓] Loaded: LUNSUMIO_MOSUNETUZUMAB-AXGB_INJECTABLE_INTRAVENOUS_761263_GENENTECH,_INC_11-22-2024.pdf (68388 chars)\n",
      "[✓] Loaded: LUPANETA_PACK_leuprolide_acetate_for_depot_suspension,_norethindrone_acetate_USP_INJECTABLE_INTRAMUSCULAR__TABLET_ORAL_203696_GLENMARK_PHARMACEUTICALS_08-09-2023.pdf (137210 chars)\n",
      "[✓] Loaded: LUPKYNIS_VOCLOSPORIN_CAPSULE_ORAL_213716_AURINIA_04-29-2024.pdf (73271 chars)\n",
      "[✓] Loaded: LUPRON_DEPOT-PED_KIT_LEUPROLIDE_ACETATE_POWDER_INTRAMUSCULAR_20263_ABBVIE_ENDOCRINE_INC_04-14-2023.pdf (69408 chars)\n",
      "[✓] Loaded: LUPRON_LEUPROLIDE_ACETATE_INJECTABLE_INJECTION_19010_ABBVIE_ENDOCRINE_INC_12-10-2018.pdf (68115 chars)\n",
      "[✓] Loaded: LUVOX_CR_FLUVOXAMINE_MALEATE_CAPSULE,_EXTENDED_RELEASE_ORAL_22033_JAZZ_PHARMS_01-04-2017.pdf (135085 chars)\n",
      "[✓] Loaded: LUVOX_FLUVOXAMINE_MALEATE_TABLET_ORAL_21519_ANI_PHARMS_08-18-2023.pdf (121898 chars)\n",
      "[✓] Loaded: LYBALVI_OLANZAPINE__SAMIDORPHAN_L-MALATE_TABLET_ORAL_213378_ALKERMES_INC_02-28-2025.pdf (119978 chars)\n",
      "[✓] Loaded: LYNPARZA_OLAPARIB_CAPSULE_ORAL_206162_ASTRAZENECA_09-27-2018.pdf (48654 chars)\n",
      "[✓] Loaded: LYNPARZA_OLAPARIB_TABLET_ORAL_208558_ASTRAZENECA_11-06-2023.pdf (138443 chars)\n",
      "[✓] Loaded: LYRICA_CR_PREGABALIN_TABLET,_EXTENDED_RELEASE_ORAL_209501_UPJOHN_12-13-2023.pdf (105227 chars)\n",
      "[✓] Loaded: LYRICA_PREGABALIN_CAPSULE_ORAL_21446_UPJOHN_12-15-2023.pdf (160353 chars)\n",
      "[✓] Loaded: LYRICA_PREGABALIN_SOLUTION_ORAL_22488_UPJOHN_12-13-2023.pdf (160353 chars)\n",
      "[✓] Loaded: MAGNEVIST_GADOPENTETATE_DIMEGLUMINE_INJECTABLE_INJECTION_19596_BAYER_HLTHCARE_07-25-2018.pdf (44325 chars)\n",
      "[✓] Loaded: MAGNEVIST_GADOPENTETATE_DIMEGLUMINE_INJECTABLE_INJECTION_21037_BAYER_HLTHCARE_07-25-2018.pdf (47269 chars)\n",
      "[✓] Loaded: MARPLAN_ISOCARBOXAZID_TABLET_ORAL_11961_VALIDUS_PHARMS_INC_11-08-2018.pdf (51473 chars)\n",
      "[✓] Loaded: MAVENCLAD_CLADRIBINE_TABLET_ORAL_22561_EMD_SERONO_INC_09-19-2022.pdf (85895 chars)\n",
      "[✓] Loaded: MAYZENT_SIPONIMOD_FUMARIC_ACID_TABLET_ORAL_209884_NOVARTIS_06-05-2024.pdf (109812 chars)\n",
      "[✓] Loaded: MEKTOV_BINIMETINIB_TABLET_ORAL_210498_ARRAY_BIOPHARMA_INC_09-12-2024.pdf (73832 chars)\n",
      "[✓] Loaded: MERIDIA_SIBUTRAMINE_HYDROCHLORIDE_CAPSULE_ORAL_20632_ABBOTT_08-04-2010.pdf (9291 chars)\n",
      "[✓] Loaded: METADATE_CD_METHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_21259_LANNETT_CO_INC_10-13-2023.pdf (66745 chars)\n",
      "[✓] Loaded: METHYLIN_METHYLPHENIDATE_HYDROCHLORIDE_SOLUTION_ORAL_21419_SPECGX_LLC_10-13-2023.pdf (56886 chars)\n",
      "[✓] Loaded: METHYLIN_METHYLPHENIDATE_HYDROCHLORIDE_TABLET,_CHEWABLE_ORAL_21475_SPECGX_LLC_01-08-2025.pdf (65282 chars)\n",
      "[✓] Loaded: METOZOLV_ODT_METOCLOPRAMIDE_HYDROCHLORIDE_TABLET,_ORALLY_DISINTEGRATING_ORAL_22246_SALIX_PHARMS_02-28-2019.pdf (67124 chars)\n",
      "[✓] Loaded: MIFEPREX_MIFEPRISTONE_TABLET__ORAL_20687_DANCO_LABS_LLC_03-23-2023.pdf (53282 chars)\n",
      "[✓] Loaded: MIRCERA_METHOXY_POLYETHYLENE_GLYCOL-EPOETIN_BETA_INJECTABLE__SUBCUTANEOUS_126164_Vifor_International_Inc_04-13-2023.pdf (119792 chars)\n",
      "[✓] Loaded: MIRCERA_METHOXY_POLYETHYLENE_GLYCOL-EPOETIN_BETA_SOLUTION__INJECTION_125164_HOFFMAN-LA_ROCHE_06-04-2024.pdf (109111 chars)\n",
      "[✓] Loaded: MITIGARE_COLCHICINE_CAPSULE_ORAL_204820_HIKMA_AMERICAS_09-26-2014.pdf (39748 chars)\n",
      "[✓] Loaded: MOBIC_MELOXICAM_SUSPENSION_ORAL_21530_AVONDALE_PHARMS_11-21-2024.pdf (93333 chars)\n",
      "[✓] Loaded: MOBIC_MELOXICAM_TABLET_ORAL_20938_BOEHRINGER_INGELHEIM_11-21-2024.pdf (92317 chars)\n",
      "[✓] Loaded: MORPHABOND_ER_MORPHINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_206544_DAIICHI_SANKYO_INC_10-07-2019.pdf (107854 chars)\n",
      "[✓] Loaded: MORPHINE_SULFATE_MORPHINE_SULFATE_SOLUTION_ORAL_201517_LANNETT_CO_INC_12-15-2023.pdf (119062 chars)\n",
      "[✓] Loaded: MORPHINE_SULFATE_MORPHINE_SULFATE_SOLUTION_ORAL_22195_HIKMA_12-15-2023.pdf (132929 chars)\n",
      "[✓] Loaded: MORPHINE_SULFATE_MORPHINE_SULFATE_TABLET_ORAL_22207_HIKMA_12-15-2023.pdf (113723 chars)\n",
      "[✓] Loaded: MOTPOLY_XR_LACOSAMIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_216185_Aucta_Pharmaceuticals_06-07-2024.pdf (82824 chars)\n",
      "[✓] Loaded: MOTRIN_IBUPROFEN_TABLET_ORAL_17463_MCNEIL_CONSUMER_09-10-2007.pdf (43224 chars)\n",
      "[✓] Loaded: MOUNJARO_TIRZEPATIDE_INJECTABLE__SUBCUTANEOUS_215866_ELI_LILLY_AND_COMPANY_07-28-2023.pdf (105364 chars)\n",
      "[✓] Loaded: MOVANTIK_NALOXEGOL_OXALATE_TABLET_ORAL_204760_REDHILL_04-13-2020.pdf (59262 chars)\n",
      "[✓] Loaded: MOVIPREP_ASCORBIC_ACID__POLYETHYLENE_GLYCOL_3350__POTASSIUM_CHLORIDE__SODIUM_ASCORBATE__SODIUM_CHLORIDE__SODIUM_SULFATE_FOR_SOLUTION_ORAL_21881_SALIX_PHARMS_05-14-2021.pdf (60323 chars)\n",
      "[✓] Loaded: MOXIFLOXACIN_HYDROCHLORIDE_MOXIFLOXACIN_HYDROCHLORIDE_SOLUTION_INTRAVENOUS_205572_FRESENIUS_KABI_USA_07-26-2016.pdf (135699 chars)\n",
      "[✓] Loaded: MS_CONTIN_MORPHINE_SULFATE_TABLET,_EXTENDED_RELEASE_ORAL_19516_PURDUE_PHARMA_LP_12-15-2023.pdf (108792 chars)\n",
      "[✓] Loaded: MULTAQ_DRONEDARONE_HYDROCHLORIDE_TABLET_ORAL_22425_SANOFI_AVENTIS_US_10-23-2023.pdf (67437 chars)\n",
      "[✓] Loaded: MULTIHANCE_GADOBENATE_DIMEGLUMINE_INJECTABLE_INTRAVENOUS_21357_BRACCO_03-05-2025.pdf (69719 chars)\n",
      "[✓] Loaded: MULTIHANCE_MULTIPACK_GADOBENATE_DIMEGLUMINE_INJECTABLE_INTRAVENOUS_21358_BRACCO_03-05-2025.pdf (71438 chars)\n",
      "[✓] Loaded: MYALEPT_METRELEPTIN_INJECTABLE_INJECTION_125390_AEGERION_02-28-2022.pdf (93860 chars)\n",
      "[✓] Loaded: MYDAYIS_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_CAPSULE,_EXTENDED_RELEASE_ORAL_22063_TAKEDA_PHARMS_USA_10-13-2023.pdf (85017 chars)\n",
      "[✓] Loaded: MYFORTIC_MYCOPHENOLIC_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_50791_NOVARTIS_03-15-2022.pdf (101836 chars)\n",
      "[✓] Loaded: MYOBLOC_Botulinum_Toxin_Type_B_VIAL_103846_ELAN_PHARM_03-10-2021.pdf (63210 chars)\n",
      "[✓] Loaded: MYSOLINE_PRIMIDONE_TABLET_ORAL_9170_VALEANT_06-10-2020.pdf (22952 chars)\n",
      "[✓] Loaded: NALFON_FENOPROFEN_CALCIUM_CAPSULE_ORAL_17604_XSPIRE_PHARMA_11-21-2024.pdf (82269 chars)\n",
      "[✓] Loaded: NAPRELAN_NAPROXEN_SODIUM_TABLET,_EXTENDED_RELEASE_ORAL_20353_ALMATICA_11-21-2024.pdf (83171 chars)\n",
      "[✓] Loaded: NAPROSYN_NAPROXEN_SUSPENSION_ORAL_18965_ATNAHS_PHARMA_US_11-21-2024.pdf (88707 chars)\n",
      "[✓] Loaded: NAPROSYN_NAPROXEN_TABLET_ORAL_17581_ATNAHS_PHARMA_US_11-21-2024.pdf (106262 chars)\n",
      "[✓] Loaded: NATPARA_PARATHYROID_HORMONE_INJECTABLE_INJECTION_125511_NPS_PHARMS_INC_07-01-2020.pdf (93528 chars)\n",
      "[✓] Loaded: NAYZILAM_MIDAZOLAM_SPRAY_NASAL_211321_UCB_INC_01-13-2023.pdf (92622 chars)\n",
      "[✓] Loaded: NESINA_ALOGLIPTIN_BENZOATE_TABLET_ORAL_22271_TAKEDA_PHARMS_USA_07-27-2023.pdf (86418 chars)\n",
      "[✓] Loaded: NEURONTIN_GABAPENTIN_CAPSULE_ORAL_20235_UPJOHN_12-16-2020.pdf (91641 chars)\n",
      "[✓] Loaded: NEURONTIN_GABAPENTIN_SOLUTION_ORAL_21129_UPJOHN_12-16-2020.pdf (91641 chars)\n",
      "[✓] Loaded: NEURONTIN_GABAPENTIN_TABLET_ORAL_20882_UPJOHN_12-16-2020.pdf (91641 chars)\n",
      "[✓] Loaded: NEXIUM_ESOMEPRAZOLE_MAGNESIUM_CAPSULE,_DELAYED_REL_PELLETS_ORAL_21153_ASTRAZENECA_07-18-2023.pdf (143196 chars)\n",
      "[✓] Loaded: NEXIUM_ESOMEPRAZOLE_MAGNESIUM_FOR_SUSPENSION,_DELAYED_RELEASE_ORAL_21957_ASTRAZENECA_07-18-2023.pdf (143196 chars)\n",
      "[✓] Loaded: NEXIUM_ESOMEPRAZOLE_MAGNESIUM_FOR_SUSPENSION,_DELAYED_RELEASE_ORAL_22101_ASTRAZENECA_07-18-2023.pdf (143196 chars)\n",
      "[✓] Loaded: NILOTINIB_NILOTINIB_D-TARTRATE_CAPSULE_ORAL_218922_CIPLA_USA,_INC_02-19-2025.pdf (134007 chars)\n",
      "[✓] Loaded: NIZORAL_KETOCONAZOLE_TABLET_ORAL_18533_JANSSEN_PHARMS_07-30-2013.pdf (44625 chars)\n",
      "[✓] Loaded: NOCDURNA_DESMOPRESSIN_ACETATE_TABLET_SUBLINGUAL_22517_FERRING_PHARMS_INC_06-21-2018.pdf (45149 chars)\n",
      "[✓] Loaded: NOCTIVA_DESMOPRESSIN_ACETATE_SPRAY,_METERED_NASAL_201656_SERENITY_PHARMS_LLC_03-03-2017.pdf (57131 chars)\n",
      "[✓] Loaded: NORCO_ACETAMINOPHEN__HYDROCODONE_BITARTRATE_TABLET_ORAL_40099_APIL_03-04-2021.pdf (80145 chars)\n",
      "[✓] Loaded: NORPRAMIN_DESIPRAMINE_HYDROCHLORIDE_TABLET_ORAL_14399_VALIDUS_PHARMS_11-09-2018.pdf (5066 chars)\n",
      "[✓] Loaded: NOVANTRONE_MITOXANTRONE_HYDROCHLORIDE_INJECTABLE_INJECTION_19297_EMD_SERONO_03-23-2012.pdf (8837 chars)\n",
      "[✓] Loaded: NPLATE_ROMIPLOSTIM_INJECTABLE__SUBCUTANEOUS_125268_AMGEN_02-21-2025.pdf (76008 chars)\n",
      "[✓] Loaded: NUCYNTA_ER_TAPENTADOL_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_200533_COLLEGIUM_PHARM_INC_06-14-2024.pdf (122899 chars)\n",
      "[✓] Loaded: NUCYNTA_TAPENTADOL_HYDROCHLORIDE_SOLUTION_ORAL_203794_COLLEGIUM_PHARM_INC_06-14-2024.pdf (153322 chars)\n",
      "[✓] Loaded: NUCYNTA_TAPENTADOL_HYDROCHLORIDE_TABLET_ORAL_22304_COLLEGIUM_PHARM_INC_06-14-2024.pdf (126316 chars)\n",
      "[✓] Loaded: NULOJIX_BELATACEPT_INJECTABLE__INJECTION_125288_BRISTOL_MYERS_SQUIBB_07-28-2021.pdf (125379 chars)\n",
      "[✓] Loaded: NUVIGIL_ARMODAFINIL_TABLET_ORAL_21875_CEPHALON_02-07-2017.pdf (78223 chars)\n",
      "[✓] Loaded: OBREDON_GUAIFENESIN__HYDROCODONE_BITARTRATE_SOLUTION_ORAL_205474_SOVEREIGN_PHARMS_12-15-2023.pdf (92439 chars)\n",
      "[✓] Loaded: OCALIVA_OBETICHOLIC_ACID_TABLET_ORAL_207999_INTERCEPT_PHARMS_INC_05-26-2021.pdf (65538 chars)\n",
      "[✓] Loaded: OCREVUS_OCRELIZUMAB_INJECTABLE_INJECTION_761053_GENENTECH_INC_06-21-2024.pdf (72322 chars)\n",
      "[✓] Loaded: OCREVUS_ZUNOVO_OCRELIZUMAB_AND_HYALURONIDAZSE-OCSQ_INJECTABLE_SUBCUTANEOUS_761371_GENETECH,_INC._09-13-2024.pdf (82816 chars)\n",
      "[✓] Loaded: ODOMZO_SONIDEGIB_PHOSPHATE_CAPSULE_ORAL_205266_SUN_PHARMA_GLOBAL_08-22-2023.pdf (46241 chars)\n",
      "[✓] Loaded: OLUMIANT_BARICITINIB_TABLET_ORAL_207924_ELI_LILLY_AND_CO_05-10-2022.pdf (102660 chars)\n",
      "[✓] Loaded: OMNISCAN_GADODIAMIDE_INJECTABLE_INJECTION_20123_GE_HEALTHCARE_03-05-2025.pdf (104853 chars)\n",
      "[✓] Loaded: OMNISCAN_GADODIAMIDE_INJECTABLE_INJECTION_22066_GE_HEALTHCARE_03-05-2025.pdf (104853 chars)\n",
      "[✓] Loaded: OMONTYS_PEGINESATIDE_ACETATE_SOLUTION_INTRAVENOUS,_SUBCUTANEOUS_202799_TAKEDA_PHARMS_USA_12-04-2012.pdf (55067 chars)\n",
      "[✓] Loaded: OMVOH_MIRIKIZUMAB-MRKZ_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_761279_ELI_LILLY_AND_COMPANY_01-15-2025.pdf (116530 chars)\n",
      "[✓] Loaded: ONFI_CLOBAZAM_SUSPENSION_ORAL_203993_LUNDBECK_PHARMS_LLC_03-12-2024.pdf (100184 chars)\n",
      "[✓] Loaded: ONFI_CLOBAZAM_TABLET_ORAL_202067_LUNDBECK_PHARMS_LLC_03-12-2024.pdf (100184 chars)\n",
      "[✓] Loaded: ONGLYZA_SAXAGLIPTIN_HYDROCHLORIDE_TABLET_ORAL_22350_ASTRAZENECA_AB_07-01-2019.pdf (111594 chars)\n",
      "[✓] Loaded: ONSOLIS_FENTANYL_CITRATE_FILM_BUCCAL_22266_BDSI_12-03-2021.pdf (122028 chars)\n",
      "[✓] Loaded: OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf (117806 chars)\n",
      "[✓] Loaded: OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21610_ENDO_PHARMS_12-15-2023.pdf (127918 chars)\n",
      "[✓] Loaded: OPANA_OXYMORPHONE_HYDROCHLORIDE_TABLET_ORAL_21611_ENDO_PHARMS_10-25-2019.pdf (98842 chars)\n",
      "[✓] Loaded: OPDIVO_NIVOLUMAB_INJECTABLE_INJECTION_125554_BRISTOL_MYERS_SQUIBB_10-03-2024.pdf (418180 chars)\n",
      "[✓] Loaded: OPDIVO_QVANTIG_NIVOLUMAB_AND_HYALURONIDASE-NVHY_INJECTABLE_SUBCUTANEOUS_761381_BRISTOL-MYERS_SQUIBB_COMPANY_12-27-2024.pdf (335833 chars)\n",
      "[✓] Loaded: OPDIVO_QVANTIG_NIVOLUMAB_AND_HYALURONIDASE-NVHY_INJECTABLE_SUBCUTANEOUS_761429_BRISTOL-MYERS_SQUIBB_COMPANY_12-27-2024.pdf (335833 chars)\n",
      "[✓] Loaded: OPSUMIT_MACITENTAN_TABLET_ORAL_204410_ACTELION_02-28-2025.pdf (58919 chars)\n",
      "[✓] Loaded: OPTIMARK_GADOVERSETAMIDE_INJECTABLE_INJECTION_20937_LIEBEL-FLARSHEIM_11-02-2018.pdf (140925 chars)\n",
      "[✓] Loaded: OPTIMARK_GADOVERSETAMIDE_INJECTABLE_INJECTION_20975_LIEBEL-FLARSHEIM_11-02-2018.pdf (50789 chars)\n",
      "[✓] Loaded: OPTIMARK_IN_PLASTIC_CONTAINER_GADOVERSETAMIDE_INJECTABLE_INJECTION_20976_LIEBEL-FLARSHEIM_11-02-2018.pdf (50401 chars)\n",
      "[✓] Loaded: OPZELURA_RUXOLITINIB_PHOSPHATE_CREAM_TOPICAL_215309_INCYTE_CORP_03-13-2023.pdf (59511 chars)\n",
      "[✓] Loaded: ORIAHNN_(COPACKAGED)_ELAGOLIX_SODIUM,ESTRADIOL,NORETHINDRONE_ACETATE__ELAGOLIX_SODIUM_CAPSULE_ORAL_213388_ABBVIE_INC_05-29-2023.pdf (89860 chars)\n",
      "[✓] Loaded: ORILISSA_ELAGOLIX_SODIUM_TABLET_ORAL_210450_ABBVIE_INC_06-05-2023.pdf (78545 chars)\n",
      "[✓] Loaded: OSENI_ALOGLIPTIN_BENZOATE__PIOGLITAZONE_HYDROCHLORIDE_TABLET_ORAL_22426_TAKEDA_PHARMS_USA_06-28-2024.pdf (137702 chars)\n",
      "[✓] Loaded: OSMOPREP_SODIUM_PHOSPHATE,_DIBASIC,_ANHYDROUS__SODIUM_PHOSPHATE,_MONOBASIC,_MONOHYDRATE_TABLET_ORAL_21892_SALIX_PHARMS_11-29-2018.pdf (52705 chars)\n",
      "[✓] Loaded: OSPOMYV_DENOSUMAB-DSSB_INJECTABLE_SUBCUTANEOUS_761392_SAMSUNG_BIOPES_CO.,_LTD_02-13-2025.pdf (331904 chars)\n",
      "[✓] Loaded: OTULFI_USTEKINUMAB-AAUZ_INJECTABLE_INTRAVENOUS_761379_FRESENIUS_KABI_USA_02-19-2025.pdf (122538 chars)\n",
      "[✓] Loaded: OXAYDO_OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_202080_ZYLA_04-19-2024.pdf (103099 chars)\n",
      "[✓] Loaded: OXTELLAR_XR_OXCARBAZEPINE_TABLET,_EXTENDED_RELEASE_ORAL_202810_SUPERNUS_PHARMS_08-14-2024.pdf (80411 chars)\n",
      "[✓] Loaded: Oxycodone_Hydrochloride_Capsules_OXYCODONE_HYDROCHLORIDE_CAPSULE_ORAL_200534_GENUS_LIFESCIENCES_04-19-2024.pdf (104420 chars)\n",
      "[✓] Loaded: OXYCODONE_HYDROCHLORIDE_OXYCODONE_HYDROCHLORIDE_SOLUTION_ORAL_200535_GENUS_LIFESCIENCES_04-19-2024.pdf (114761 chars)\n",
      "[✓] Loaded: OXYCODONE_HYDROCHLORIDE_OXYCODONE_HYDROCHLORIDE_SOLUTION_ORAL_201194_VISTAPHARM_04-19-2024.pdf (110491 chars)\n",
      "[✓] Loaded: OXYCONTIN_OXYCODONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_22272_PURDUE_PHARMA_LP_12-15-2023.pdf (140770 chars)\n",
      "[✓] Loaded: OXYMORPHONE_HYDROCHLORIDE_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_79046_ACTAVIS_ELIZABETH_03-04-2021.pdf (4583 chars)\n",
      "[✓] Loaded: OZEMPIC_SEMAGLUTIDE_SOLUTION_SUBCUTANEOUS_209637_NOVO_01-28-2025.pdf (101354 chars)\n",
      "[✓] Loaded: PALYNZIQ_PEGVALIASE-PQPZ_INJECTABLE_INJECTION_761079_BIOMARIN_PHARM_11-20-2020.pdf (104283 chars)\n",
      "[✓] Loaded: PAMELOR_NORTRIPTYLINE_HYDROCHLORIDE_CAPSULE_ORAL_18013_SPECGX_LLC_04-09-2019.pdf (45043 chars)\n",
      "[✓] Loaded: PANCREAZE_PANCRELIPASE_(AMYLASE_LIPASE_PROTEASE)_CAPSULE,_DELAYED_RELEASE_ORAL_22523_VIVUS_INC_02-28-2024.pdf (55269 chars)\n",
      "[✓] Loaded: PARNATE_TRANYLCYPROMINE_SULFATE_TABLET_ORAL_12342_CONCORDIA_01-04-2018.pdf (69494 chars)\n",
      "[✓] Loaded: PAXIL_CR_PAROXETINE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_20936_APOTEX_TECHNOLOGIES_02-23-2024.pdf (90618 chars)\n",
      "[✓] Loaded: PAXIL_PAROXETINE_HYDROCHLORIDE_SUSPENSION_ORAL_20710_APOTEX_TECHNOLOGIES_11-26-2024.pdf (102447 chars)\n",
      "[✓] Loaded: PAXIL_PAROXETINE_HYDROCHLORIDE_TABLET_ORAL_20031_APOTEX_TECHNOLOGIES_11-26-2024.pdf (102447 chars)\n",
      "[✓] Loaded: PEGANONE_ETHOTOIN_TABLET_ORAL_10841_RECORDATI_RARE_02-27-2017.pdf (8595 chars)\n",
      "[✓] Loaded: PEGASYS_PEGINTERFERON_ALFA-2A_SYRINGE_103964_HOFFMAN-LA_ROCHE_12-11-2023.pdf (163857 chars)\n",
      "[✓] Loaded: PEGASYS_PEGINTERFERON_ALFA-2A_VIAL__SUBCUTANEOUS_103964_HOFFMAN-LA_ROCHE_12-11-2023.pdf (163857 chars)\n",
      "[✓] Loaded: PEGINTRON_PEGINTERFERON_ALFA-2B_SYRINGE_103949_SCHERING_12-21-2018.pdf (175668 chars)\n",
      "[✓] Loaded: PENNSAID_DICLOFENAC_SODIUM_SOLUTION_TOPICAL_204623_HORIZON_11-21-2024.pdf (87299 chars)\n",
      "[✓] Loaded: PERCOCET_ACETAMINOPHEN__OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_40330_VINTAGE_PHARMS_LLC_03-04-2021.pdf (84404 chars)\n",
      "[✓] Loaded: PERCODAN_ASPIRIN__OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_7337_ENDO_PHARMS_04-19-2024.pdf (106401 chars)\n",
      "[✓] Loaded: PERCODAN_ASPIRIN__OXYCODONE_HYDROCHLORIDE__OXYCODONE_TEREPHTHALATE_TABLET_ORAL_7337_ENDO_PHARMS_11-21-2024.pdf (102468 chars)\n",
      "[✓] Loaded: PERFOROMIST_FORMOTEROL_FUMARATE_SOLUTION_INHALATION_22007_MYLAN_SPECLT_05-29-2019.pdf (68160 chars)\n",
      "[✓] Loaded: PERTZYE_PANCRELIPASE_(AMYLASE_LIPASE_PROTEASE)_CAPSULE,_DELAYED_RELEASE_ORAL_22175_DIGESTIVE_CARE_INC_02-28-2024.pdf (60753 chars)\n",
      "[✓] Loaded: PEXEVA_PAROXETINE_MESYLATE_TABLET_ORAL_21299_SEBELA_IRELAND_LTD_08-18-2023.pdf (97297 chars)\n",
      "[✓] Loaded: PHENERGAN_VC_W-_CODEINE_CODEINE_PHOSPHATE__PHENYLEPHRINE_HYDROCHLORIDE__PROMETHAZINE_HYDROCHLORIDE_SYRUP_ORAL_8306_ANI_PHARMS_12-15-2023.pdf (293836 chars)\n",
      "[✓] Loaded: PHENERGAN_W-_CODEINE_CODEINE_PHOSPHATE__PROMETHAZINE_HYDROCHLORIDE_SYRUP_ORAL_8306_ANI_PHARMS_12-15-2023.pdf (293836 chars)\n",
      "[✓] Loaded: PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf (64422 chars)\n",
      "[✓] Loaded: PLEGRIDY_PEGINTERFERON_BETA-1A_INJECTABLE_INJECTION_125499_BIOGEN_IDEC_INC_07-28-2023.pdf (133991 chars)\n",
      "[✓] Loaded: PLENVU_ASCORBIC_ACID__POLYETHYLENE_GLYCOL_3350__POTASSIUM_CHLORIDE__SODIUM_ASCORBATE__SODIUM_CHLORIDE__SODIUM_SULFATE_FOR_SOLUTION_ORAL_209381_SALIX_09-08-2023.pdf (70870 chars)\n",
      "[✓] Loaded: POMALYST_POMALIDOMIDE_CAPSULE_ORAL_204026_CELGENE_02-26-2025.pdf (105388 chars)\n",
      "[✓] Loaded: PONSTEL_MEFENAMIC_ACID_CAPSULE_ORAL_15034_AVION_PHARMS_11-21-2024.pdf (61407 chars)\n",
      "[✓] Loaded: PONVORY_PONESIMOD_TABLET_ORAL_213498_JANSSEN_PHARMS_06-05-2024.pdf (96005 chars)\n",
      "[✓] Loaded: PRADAXA_DABIGATRAN_ETEXILATE_MESYLATE_CAPSULE_ORAL_22512_BOEHRINGER_INGELHEIM_11-17-2023.pdf (140554 chars)\n",
      "[✓] Loaded: PRADAXA_DABIGATRAN_ETEXILATE_MESYLATE_PELLETS_ORAL_214358_BOEHRINGER_INGELHEIM_11-14-2023.pdf (89763 chars)\n",
      "[✓] Loaded: PREPOPIK_CITRIC_ACID__MAGNESIUM_OXIDE__SODIUM_PICOSULFATE_FOR_SOLUTION_ORAL_202535_FERRING_PHARMS_INC_08-29-2023.pdf (74630 chars)\n",
      "[✓] Loaded: PRETOMANID_PRETOMANID_TABLET_ORAL_212862_MYLAN_IRELAND_LTD_11-22-2024.pdf (90876 chars)\n",
      "[✓] Loaded: PREVACID_LANSOPRAZOLE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_20406_TAKEDA_PHARMS_USA_08-08-2023.pdf (144984 chars)\n",
      "[✓] Loaded: PREVACID_LANSOPRAZOLE_TABLET,_ORALLY_DISINTEGRATING,_DELAYED_RELEASE_ORAL_21428_TAKEDA_PHARMS_USA_08-08-2023.pdf (144984 chars)\n",
      "[✓] Loaded: PRIFTIN_RIFAPENTINE_TABLET_ORAL_21024_SANOFI_AVENTIS_US_07-01-2015.pdf (92631 chars)\n",
      "[✓] Loaded: PRILOSEC_OMEPRAZOLE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_19810_ASTRAZENECA_12-19-2016.pdf (137139 chars)\n",
      "[✓] Loaded: PRILOSEC_OMEPRAZOLE_MAGNESIUM_FOR_SUSPENSION,_DELAYED_RELEASE_ORAL_22056_COVIS_07-18-2023.pdf (134622 chars)\n",
      "[✓] Loaded: PRISTIQ_DESVENLAFAXINE_SUCCINATE_TABLET,_EXTENDED_RELEASE_ORAL_21992_PF_PRISM_CV_11-10-2021.pdf (96534 chars)\n",
      "[✓] Loaded: PROBUPHINE_BUPRENORPHINE_HYDROCHLORIDE_IMPLANT_IMPLANTATION_204442_TITAN_PHARMS_12-15-2023.pdf (151366 chars)\n",
      "[✓] Loaded: PROHANCE_GADOTERIDOL_INJECTABLE_INJECTION_20131_BRACCO_08-14-2024.pdf (107564 chars)\n",
      "[✓] Loaded: PROHANCE_MULTIPACK_GADOTERIDOL_INJECTABLE_INJECTION_21489_BRACCO_08-14-2024.pdf (107564 chars)\n",
      "[✓] Loaded: PROLIA_DENOSUMAB_INJECTABLE__SUBCUTANEOUS_125320_AMGEN_01-03-2023.pdf (96264 chars)\n",
      "[✓] Loaded: PROMACTA_ELTROMBOPAG_OLAMINE_TABLET_ORAL_22291_NOVARTIS_03-09-2023.pdf (141157 chars)\n",
      "[✓] Loaded: PROMACTA_KIT_ELTROMBOPAG_OLAMINE_FOR_SUSPENSION_ORAL_207027_NOVARTIS_03-09-2023.pdf (141157 chars)\n",
      "[✓] Loaded: PROPULSID_CISAPRIDE_MONOHYDRATE_TABLET_ORAL_20210_JANSSEN_PHARMS_03-06-2000.pdf (13579 chars)\n",
      "[✓] Loaded: PROPYLTHIOURACIL_PROPYLTHIOURACIL_TABLET_ORAL_6188_DAVA_PHARMS_INC_09-19-2018.pdf (26743 chars)\n",
      "[✓] Loaded: PROQUIN_XR_CIPROFLOXACIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21744_DEPOMED_INC_08-15-2011.pdf (19336 chars)\n",
      "[✓] Loaded: PROTONIX_PANTOPRAZOLE_SODIUM_FOR_SUSPENSION,_DELAYED_RELEASE_ORAL_22020_WYETH_PHARMS_07-18-2023.pdf (102772 chars)\n",
      "[✓] Loaded: PROTONIX_PANTOPRAZOLE_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_20987_WYETH_PHARMS_07-18-2023.pdf (102772 chars)\n",
      "[✓] Loaded: PROVIGIL_MODAFINIL_TABLET_ORAL_20717_CEPHALON_01-15-2015.pdf (11354 chars)\n",
      "[✓] Loaded: PROZAC_FLUOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_18936_ELI_LILLY_AND_CO_08-18-2023.pdf (144836 chars)\n",
      "[✓] Loaded: PROZAC_WEEKLY_FLUOXETINE_HYDROCHLORIDE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_21235_LILLY_03-24-2017.pdf (160231 chars)\n",
      "[✓] Loaded: QDOLO_TRAMADOL_HYDROCHLORIDE_SOLUTION_ORAL_214044_ATHENA_12-15-2023.pdf (160918 chars)\n",
      "[✓] Loaded: QELBREE_VILOXAZINE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_211964_SUPERNUS_PHARMS_01-23-2025.pdf (65889 chars)\n",
      "[✓] Loaded: QMIIZ_ODT_MELOXICAM_TABLET,_ORALLY_DISINTEGRATING_ORAL_211210_TERSERA_04-28-2021.pdf (99215 chars)\n",
      "[✓] Loaded: QSYMIA_PHENTERMINE_HYDROCHLORIDE__TOPIRAMATE_CAPSULE,_EXTENDED_RELEASE_ORAL_22580_VIVUS_09-13-2024.pdf (140906 chars)\n",
      "[✓] Loaded: QTERNMET_XR_DAPAGLIFLOZIN__METFORMIN_HYDROCHLORIDE__SAXAGLIPTIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_210874_ASTRAZENECA_AB_01-24-2020.pdf (152187 chars)\n",
      "[✓] Loaded: QTERN_DAPAGLIFLOZIN__SAXAGLIPTIN_HYDROCHLORIDE_TABLET_ORAL_209091_ASTRAZENECA_AB_09-12-2023.pdf (105554 chars)\n",
      "[✓] Loaded: QUALAQUIN_QUININE_SULFATE_CAPSULE_ORAL_21799_SUN_PHARM_INDUSTRIES_06-19-2019.pdf (84939 chars)\n",
      "[✓] Loaded: QUDEXY_XR_TOPIRAMATE_CAPSULE,_EXTENDED_RELEASE_ORAL_205122_UPSHER_SMITH_LABS_03-28-2024.pdf (170166 chars)\n",
      "[✓] Loaded: QUILLICHEW_ER_METHYLPHENIDATE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE,_CHEWABLE_ORAL_207960_NEXTWAVE_PHARMS_06-25-2021.pdf (64204 chars)\n",
      "[✓] Loaded: QUILLIVANT_XR_METHYLPHENIDATE_HYDROCHLORIDE_FOR_SUSPENSION,_EXTENDED_RELEASE_ORAL_202100_NEXTWAVE_06-25-2021.pdf (67859 chars)\n",
      "[✓] Loaded: QUVIVIQ_DARIDOREXANT_TABLET__ORAL_214985_IDORSIA_PHARMACEUTICALS_LTD._09-30-2024.pdf (63585 chars)\n",
      "[✓] Loaded: RALDESY_TRAZODONE_HYDROCHLORIDE,_USP_SOLUTION_ORAL_218637_VALIDUS_PHARMACEUTICALS_LLC_11-26-2024.pdf (60231 chars)\n",
      "[✓] Loaded: RAPAMUNE_SIROLIMUS_SOLUTION_ORAL_21083_PF_PRISM_CV_01-02-2020.pdf (155891 chars)\n",
      "[✓] Loaded: RAPAMUNE_SIROLIMUS_TABLET_ORAL_21110_PF_PRISM_CV_08-09-2021.pdf (154762 chars)\n",
      "[✓] Loaded: RAVICTI_GLYCEROL_PHENYLBUTYRATE_LIQUID_ORAL_203284_HORIZON_THERAP_09-03-2021.pdf (85642 chars)\n",
      "[✓] Loaded: REBETOL_RIBAVIRIN_CAPSULE_ORAL_20903_MERCK_SHARP_DOHME_03-16-2022.pdf (126278 chars)\n",
      "[✓] Loaded: REBETOL_RIBAVIRIN_SOLUTION_ORAL_21546_SCHERING_03-16-2022.pdf (126278 chars)\n",
      "[✓] Loaded: REBIF_INTERFERON_BETA-1A_SYRINGE_103780_SERONO_INC_07-28-2023.pdf (74785 chars)\n",
      "[✓] Loaded: RECLAST_ZOLEDRONIC_ACID_INJECTABLE_INTRAVENOUS_21817_NOVARTIS_04-29-2020.pdf (108958 chars)\n",
      "[✓] Loaded: RECORLEV_LEVOKETOCONAZOLE_TABLET_ORAL_214133_STRONGBRIDGE_08-16-2023.pdf (86023 chars)\n",
      "[✓] Loaded: REGLAN_METOCLOPRAMIDE_HYDROCHLORIDE_INJECTABLE_INJECTION_17862_HIKMA_11-18-2010.pdf (9544 chars)\n",
      "[✓] Loaded: REGLAN_ODT_METOCLOPRAMIDE_HYDROCHLORIDE_TABLET,_ORALLY_DISINTEGRATING_ORAL_21793_MEDA_PHARMS_11-30-2011.pdf (10357 chars)\n",
      "[✓] Loaded: REGRANEX_BECAPLERMIN_GEL__TOPICAL_103691_SMITH_AND_NEPHEW_08-26-2019.pdf (34248 chars)\n",
      "[✓] Loaded: RELEXXII_METHYLPHENIDATE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_216117_VERTICAL_PHARMACEUTICALS_10-13-2023.pdf (88783 chars)\n",
      "[✓] Loaded: RELISTOR_METHYLNALTREXONE_BROMIDE_SOLUTION_SUBCUTANEOUS_21964_SALIX_PHARMS_03-14-2018.pdf (115953 chars)\n",
      "[✓] Loaded: RELISTOR_METHYLNALTREXONE_BROMIDE_TABLET_ORAL_208271_SALIX_03-14-2018.pdf (115953 chars)\n",
      "[✓] Loaded: REMERON_MIRTAZAPINE_TABLET_ORAL_20415_ORGANON_USA_INC_11-18-2021.pdf (88067 chars)\n",
      "[✓] Loaded: REMERON_SOLTAB_MIRTAZAPINE_TABLET,_ORALLY_DISINTEGRATING_ORAL_21208_ORGANON_USA_INC_11-18-2021.pdf (88067 chars)\n",
      "[✓] Loaded: REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf (168211 chars)\n",
      "[✓] Loaded: RENFLEXIS_INFLIXIMAB-ABDA_INJECTABLE_INJECTION_761054_SAMSUNG_BIOEPIS_CO_LTD_12-26-2023.pdf (179579 chars)\n",
      "[✓] Loaded: RESTORIL_TEMAZEPAM_CAPSULE_ORAL_18163_SPECGX_LLC_01-13-2023.pdf (56395 chars)\n",
      "[✓] Loaded: RETACRIT_EPOETIN_ALFA-EPBX_INJECTABLE_INJECTION_125545_HOSPIRA_INC_06-04-2024.pdf (135797 chars)\n",
      "[✓] Loaded: REVLIMID_LENALIDOMIDE_CAPSULE_ORAL_21880_CELGENE_03-24-2023.pdf (213547 chars)\n",
      "[✓] Loaded: REXULTI_BREXPIPRAZOLE_TABLET_ORAL_205422_OTSUKA_05-07-2024.pdf (121458 chars)\n",
      "[✓] Loaded: REYVOW_LASMIDITAN_SUCCINATE_TABLET_ORAL_211280_ELI_LILLY_AND_CO_09-15-2022.pdf (47354 chars)\n",
      "[✓] Loaded: REZIRA_HYDROCODONE_BITARTRATE__PSEUDOEPHEDRINE_HYDROCHLORIDE_SOLUTION_ORAL_22442_PERSION_06-28-2018.pdf (106270 chars)\n",
      "[✓] Loaded: RIABNI_RITUXIMAB-ARRX_INJECTABLE_INJECTION_761140_AMGEN_INC_06-03-2022.pdf (135668 chars)\n",
      "[✓] Loaded: RINVOQ_UPADACITINIB_TABLET,_EXTENDED_RELEASE_ORAL_211675_ABBVIE_INC_04-26-2024.pdf (211204 chars)\n",
      "[✓] Loaded: RITALIN-SR_METHYLPHENIDATE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_18029_NOVARTIS_11-19-2019.pdf (65169 chars)\n",
      "[✓] Loaded: RITALIN_LA_METHYLPHENIDATE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_21284_NOVARTIS_10-13-2023.pdf (70827 chars)\n",
      "[✓] Loaded: RITALIN_METHYLPHENIDATE_HYDROCHLORIDE_TABLET_ORAL_10187_NOVARTIS_02-04-2025.pdf (57043 chars)\n",
      "[✓] Loaded: RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf (95971 chars)\n",
      "[✓] Loaded: RITUXAN_RITUXIMAB_SOLUTION_INTRAVENOUS_103705_GENENTECH_12-17-2021.pdf (193294 chars)\n",
      "[✓] Loaded: ROMVIMZA_VIMSELTINIB_CAPSULE_ORAL_219304_DECIPHERA_PHARMACEUTICALS_LTD_02-14-2025.pdf (53269 chars)\n",
      "[✓] Loaded: ROXICODONE_OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_21011_SPECGX_LLC_04-19-2024.pdf (103430 chars)\n",
      "[✓] Loaded: ROXYBOND_OXYCODONE_HYDROCHLORIDE_TABLET_ORAL_209777_OHEMO_LIFE_04-19-2024.pdf (112827 chars)\n",
      "[✓] Loaded: ROZEREM_RAMELTEON_TABLET_ORAL_21782_TAKEDA_PHARMS_USA_11-03-2021.pdf (61272 chars)\n",
      "[✓] Loaded: RUXIENCE_RITUXIMAB-PVVR_INJECTABLE_INJECTION_761103_PFIZER_INC_10-16-2023.pdf (135756 chars)\n",
      "[✓] Loaded: RUZURGI_AMIFAMPRIDINE_TABLET_ORAL_209321_JACOBUS_PHARM_CO_INC_08-21-2020.pdf (46443 chars)\n",
      "[✓] Loaded: RYBELSUS_SEMAGLUTIDE_TABLET_ORAL_213051_NOVO_01-24-2024.pdf (85949 chars)\n",
      "[✓] Loaded: RYBELSUS_SEMAGLUTIDE_TABLET_ORAL_213182_NOVO_NORDISK_INC_01-16-2020.pdf (79966 chars)\n",
      "[✓] Loaded: SABRIL_VIGABATRIN_FOR_SOLUTION_ORAL_22006_LUNDBECK_PHARMS_LLC_10-20-2021.pdf (124935 chars)\n",
      "[✓] Loaded: SABRIL_VIGABATRIN_TABLET_ORAL_20427_LUNDBECK_PHARMS_LLC_10-20-2021.pdf (124935 chars)\n",
      "[✓] Loaded: SAMSCA_TOLVAPTAN_TABLET_ORAL_22275_OTSUKA_04-22-2021.pdf (63596 chars)\n",
      "[✓] Loaded: SARAFEM_FLUOXETINE_HYDROCHLORIDE_TABLET_ORAL_21860_APIL_09-20-2021.pdf (122714 chars)\n",
      "[✓] Loaded: SAVAYSA_EDOXABAN_TOSYLATE_TABLET_ORAL_206316_DAIICHI_SANKYO_INC_10-18-2023.pdf (97949 chars)\n",
      "[✓] Loaded: SAVELLA_MILNACIPRAN_HYDROCHLORIDE_TABLET_ORAL_22256_ALLERGAN_05-22-2024.pdf (97947 chars)\n",
      "[✓] Loaded: SAXENDA_LIRAGLUTIDE_RECOMBINANT_SOLUTION_SUBCUTANEOUS_206321_NOVO_04-20-2023.pdf (129364 chars)\n",
      "[✓] Loaded: SEGLENTIS_CELECOXIB__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_213426_KOWA_PHARMS_11-21-2024.pdf (195756 chars)\n",
      "[✓] Loaded: SEGLUROMET_ERTUGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET_ORAL_209806_MERCK_SHARP_DOHME_12-20-2024.pdf (136885 chars)\n",
      "[✓] Loaded: SELZENTRY_MARAVIROC_SOLUTION_ORAL_208984_VIIV_HLTHCARE_10-30-2020.pdf (137016 chars)\n",
      "[✓] Loaded: SELZENTRY_MARAVIROC_TABLET_ORAL_22128_VIIV_HLTHCARE_10-30-2020.pdf (137016 chars)\n",
      "[✓] Loaded: SEREVENT_SALMETEROL_XINAFOATE_POWDER_INHALATION_20692_GLAXOSMITHKLINE_07-22-2019.pdf (109304 chars)\n",
      "[✓] Loaded: SEROQUEL_QUETIAPINE_FUMARATE_TABLET_ORAL_20639_ASTRAZENECA_01-22-2025.pdf (169133 chars)\n",
      "[✓] Loaded: SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf (183047 chars)\n",
      "[✓] Loaded: SERTRALINE_SERTRALINE_HYDROCHLORIDE_CAPSULE_ORAL_215133_ALMATICA_PHARMA_08-18-2023.pdf (101528 chars)\n",
      "[✓] Loaded: SIGNIFOR_PASIREOTIDE_DIASPARTATE_SOLUTION_SUBCUTANEOUS_200677_RECORDATI_RARE_01-15-2020.pdf (68934 chars)\n",
      "[✓] Loaded: SIKLOS_HYDROXYUREA_TABLET_ORAL_208843_ADDMEDICA_SAS_11-28-2023.pdf (74709 chars)\n",
      "[✓] Loaded: SILENOR_DOXEPIN_HYDROCHLORIDE_TABLET_ORAL_22036_CURRAX_10-29-2020.pdf (60786 chars)\n",
      "[✓] Loaded: SILIQ_BRODALUMAB_INJECTABLE_INJECTION_761032_VALEANT_LUXEMBOURG_08-12-2024.pdf (59071 chars)\n",
      "[✓] Loaded: SIMPONI_ARIA_GOLIMUMAB_INJECTABLE__INJECTION_125433_JANSSEN_BIOTECH_02-01-2021.pdf (97057 chars)\n",
      "[✓] Loaded: SIMPONI_GOLIMUMAB_INJECTABLE__INJECTION_125289_CENTOCOR_ORTHO_BIOTECH_INC_09-24-2019.pdf (122472 chars)\n",
      "[✓] Loaded: SINGULAIR_MONTELUKAST_SODIUM_GRANULE_ORAL_21409_MERCK_02-22-2021.pdf (98693 chars)\n",
      "[✓] Loaded: SINGULAIR_MONTELUKAST_SODIUM_TABLET,_CHEWABLE_ORAL_20830_MSD_MERCK_CO_02-22-2021.pdf (98693 chars)\n",
      "[✓] Loaded: SINGULAIR_MONTELUKAST_SODIUM_TABLET_ORAL_20829_MSD_MERCK_CO_02-22-2021.pdf (98693 chars)\n",
      "[✓] Loaded: SIRTURO_BEDAQUILINE_FUMARATE_TABLET_ORAL_204384_JANSSEN_THERAP_06-21-2024.pdf (80957 chars)\n",
      "[✓] Loaded: SKYRIZI_RISANKIZUMAB-RZAA_INJECTABLE_INJECTION_761105_ABBVIE_INC_06-18-2024.pdf (133659 chars)\n",
      "[✓] Loaded: SKYRIZI_RISANKIZUMAB-RZAA_INJECTABLE_SUBCUTANEOUS_761262_ABBVIE_INC_06-18-2024.pdf (133659 chars)\n",
      "[✓] Loaded: SODIUM_OXYBATE_SODIUM_OXYBATE_SOLUTION_ORAL_202090_HIKMA_01-03-2022.pdf (82512 chars)\n",
      "[✓] Loaded: SOHONOS_PALOVEROTENE_CAPSULE_ORAL_215559_IPSEN_BIOPHARMACEUTICALS_08-16-2023.pdf (73008 chars)\n",
      "[✓] Loaded: Solaraze_Diclofenac_Sodium_GEL_TOPICAL_21005_FOUGERA_PHARMS_11-14-2022.pdf (79948 chars)\n",
      "[✓] Loaded: SOLIQUA_100-33_INSULIN_GLARGINE__LIXISENATIDE_SOLUTION_SUBCUTANEOUS_208673_SANOFI-AVENTIS_US_09-28-2023.pdf (114188 chars)\n",
      "[✓] Loaded: SOLIRIS_ECULIZUMAB_INJECTABLE__IV_(INFUSION)_125166_ALEXION_PHARM_02-28-2025.pdf (111039 chars)\n",
      "[✓] Loaded: SOLTAMOX_TAMOXIFEN_CITRATE_SOLUTION_ORAL_21807_MAYNE_PHARMA_INC_04-08-2019.pdf (106028 chars)\n",
      "[✓] Loaded: SONATA_ZALEPLON_CAPSULE_ORAL_20859_PFIZER_08-18-2019.pdf (71338 chars)\n",
      "[✓] Loaded: SORIATANE_ACITRETIN_CAPSULE_ORAL_19821_STIEFEL_LABS_INC_02-22-2023.pdf (168212 chars)\n",
      "[✓] Loaded: SOTRET_ISOTRETINOIN_CAPSULE_ORAL_76041_SUN_PHARM_INDS_LTD_04-12-2012.pdf (22517 chars)\n",
      "[✓] Loaded: SOTYKTU_DEUCRAVACITINIB_TABLET_ORAL_214958_BRISTOL_MYERS_SQUIBB_09-09-2022.pdf (56414 chars)\n",
      "[✓] Loaded: SPEVIGO_SPESOLIMAB-SBZO_INJECTABLE_INTRAVENOUS_761244_Boehringer_Ingelheim_Pharmaceuticals,_Inc_03-18-2024.pdf (36801 chars)\n",
      "[✓] Loaded: SPRAVATO_ESKETAMINE_HYDROCHLORIDE_SPRAY_NASAL_211243_JANSSEN_PHARMS_01-17-2025.pdf (120158 chars)\n",
      "[✓] Loaded: SPRITAM_LEVETIRACETAM_TABLET,_FOR_SUSPENSION_ORAL_207958_APRECIA_PHARMS_06-14-2024.pdf (97921 chars)\n",
      "[✓] Loaded: SPRIX_KETOROLAC_TROMETHAMINE_SPRAY,_METERED_NASAL_22382_ZYLA_11-21-2024.pdf (103520 chars)\n",
      "[✓] Loaded: STAVZOR_VALPROIC_ACID_CAPSULE,_DELAYED_RELEASE_ORAL_22152_BIONPHARMA_INC_11-30-2021.pdf (150470 chars)\n",
      "[✓] Loaded: STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf (129365 chars)\n",
      "[✓] Loaded: STELARA_USTEKINUMAB_INJECTABLE_INJECTION_761044_JANSSEN_BIOTECH_03-18-2024.pdf (107091 chars)\n",
      "[✓] Loaded: STELARA_USTEKINUMAB_INJECTABLE__INJECTION_125261_CENTOCOR_ORTHO_BIOTECH_INC_03-18-2024.pdf (113407 chars)\n",
      "[✓] Loaded: STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf (108096 chars)\n",
      "[✓] Loaded: STRIVERDI_RESPIMAT_OLODATEROL_HYDROCHLORIDE_SPRAY,_METERED_INHALATION_203108_BOEHRINGER_INGELHEIM_05-29-2019.pdf (8082 chars)\n",
      "[✓] Loaded: SUBLOCADE_BUPRENORPHINE_SOLUTION,_EXTENDED_RELEASE_SUBCUTANEOUS_209819_INDIVIOR_INC_02-21-2025.pdf (141824 chars)\n",
      "[✓] Loaded: SUBOXONE_BUPRENORPHINE_HYDROCHLORIDE__NALOXONE_HYDROCHLORIDE_FILM_BUCCAL,_SUBLINGUAL_22410_INDIVIOR_INC_06-17-2022.pdf (129190 chars)\n",
      "[✓] Loaded: SUBOXONE_BUPRENORPHINE_HYDROCHLORIDE__NALOXONE_HYDROCHLORIDE_TABLET_SUBLINGUAL_20733_INDIVIOR_INC_06-17-2022.pdf (120848 chars)\n",
      "[✓] Loaded: SUBSYS_FENTANYL_SPRAY_SUBLINGUAL_202788_BTCP_PHARMA_12-03-2021.pdf (140001 chars)\n",
      "[✓] Loaded: SUBUTEX_BUPRENORPHINE_HYDROCHLORIDE_TABLET_SUBLINGUAL_20732_INDIVIOR_INC_06-17-2022.pdf (112071 chars)\n",
      "[✓] Loaded: SUFLAVE_POLYETHYLENE_GLYCOL_3350__SODIUM_SULFATE__POTASSIUM_CHLORIDE__MAGNESIUM_SULFATE__SODIUM_CHLORIDE_SOLUTION_ORAL_215344_BRAINTREE_LABORATORIES_06-15-2023.pdf (50623 chars)\n",
      "[✓] Loaded: SUNOSI_SOLRIAMFETOL_HYDROCHLORIDE_TABLET_ORAL_211230_JAZZ_06-28-2023.pdf (69068 chars)\n",
      "[✓] Loaded: SUPPRELIN_LA_HISTRELIN_ACETATE_IMPLANT_SUBCUTANEOUS_22058_ENDO_PHARM_04-22-2022.pdf (55271 chars)\n",
      "[✓] Loaded: SUPREP_BOWEL_PREP_KIT_MAGNESIUM_SULFATE__POTASSIUM_SULFATE__SODIUM_SULFATE_SOLUTION_ORAL_22372_BRAINTREE_LABS_08-05-2020.pdf (55245 chars)\n",
      "[✓] Loaded: SURMONTIL_TRIMIPRAMINE_MALEATE_CAPSULE_ORAL_16792_ODYSSEY_PHARMS_09-30-2014.pdf (44772 chars)\n",
      "[✓] Loaded: SUSTOL_GRANISETRON_INJECTION,_EXTENDED_RELEASE_SUBCUTANEOUS_22445_HERON_THERAPS_INC_05-25-2023.pdf (63861 chars)\n",
      "[✓] Loaded: SUTAB_MAGNESIUM_SULFATE__POTASSIUM_CHLORIDE__SODIUM_SULFATE_TABLET_ORAL_213135_BRAINTREE_LABS_10-24-2023.pdf (54082 chars)\n",
      "[✓] Loaded: SUTENT_SUNITINIB_MALATE_CAPSULE_ORAL_21938_CPPI_CV_08-30-2021.pdf (128374 chars)\n",
      "[✓] Loaded: SYLATRON_PEGINTERFERON_ALFA-2B_VIAL_103949_SCHERING_12-21-2018.pdf (47537 chars)\n",
      "[✓] Loaded: SYMBRAVO_MELOXICAM,_RIZATRIPTAN_TABLET_ORAL_215431_AXSOME_THERAPEUTICS,_INC_01-30-2025.pdf (127664 chars)\n",
      "[✓] Loaded: SYMBYAX_FLUOXETINE_HYDROCHLORIDE__OLANZAPINE_CAPSULE_ORAL_21520_LILLY_01-22-2025.pdf (248658 chars)\n",
      "[✓] Loaded: SYMPAZAN_CLOBAZAM_FILM_ORAL_210833_AQUESTIVE_03-12-2024.pdf (93794 chars)\n",
      "[✓] Loaded: SYMPROIC_NALDEMEDINE_TOSYLATE_TABLET_ORAL_208854_BDSI_01-24-2018.pdf (43867 chars)\n",
      "[✓] Loaded: SYNALGOS-DC_ASPIRIN__CAFFEINE__DIHYDROCODEINE_BITARTRATE_CAPSULE_ORAL_11483_SUN_PHARM_INDUSTRIES_11-21-2024.pdf (154798 chars)\n",
      "[✓] Loaded: SYNAREL_NAFARELIN_ACETATE_SPRAY,_METERED_NASAL_19886_PFIZER_01-31-2023.pdf (84218 chars)\n",
      "[✓] Loaded: SYNJARDY_EMPAGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET_ORAL_206111_BOEHRINGER_INGELHEIM_10-30-2023.pdf (159146 chars)\n",
      "[✓] Loaded: SYNJARDY_XR_EMPAGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_208658_BOEHRINGER_INGELHEIM_10-30-2023.pdf (159146 chars)\n",
      "[✓] Loaded: SYNRIBO_OMACETAXINE_MEPESUCCINATE_POWDER_SUBCUTANEOUS_203585_TEVA_PHARMS_INTL_05-12-2021.pdf (68320 chars)\n",
      "[✓] Loaded: TAFINLAR_DABRAFENIB_MESYLATE_CAPSULE_ORAL_202806_NOVARTIS_01-30-2025.pdf (161154 chars)\n",
      "[✓] Loaded: TAFINLAR_DABRAFENIB_TABLET_ORAL_217514_NOVARTIS_PHARMACEUTICALS_01-30-2025.pdf (161154 chars)\n",
      "[✓] Loaded: TALTZ_IXEKIZUMAB_INJECTABLE_INJECTION_125521_ELI_LILLY_AND_CO_07-27-2022.pdf (83423 chars)\n",
      "[✓] Loaded: TALVEY_TALQUETAMAB-TGVS_INJECTABLE__SUBCUTANEOUS_761342_JANSSEN_BIOTECH_08-09-2023.pdf (101077 chars)\n",
      "[✓] Loaded: TANZEUM_ALBIGLUTIDE_INJECTABLE_INJECTION_125431_GLAXOSMITHKLINE_LLC_12-20-2017.pdf (136006 chars)\n",
      "[✓] Loaded: TARGINIQ_NALOXONE_HYDROCHLORIDE__OXYCODONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_205777_PURDUE_PHARMA_LP_09-18-2018.pdf (134167 chars)\n",
      "[✓] Loaded: TASCENSO_ODT_FINGOLIMOD_LAURYL_SULFATE_TABLET,_ORALLY_DISINTEGRATING_ORAL_214962_HANDA_NEUROSCIENCE,_LTD_01-28-2025.pdf (144052 chars)\n",
      "[✓] Loaded: TASIGNA_NILOTINIB_HYDROCHLORIDE_CAPSULE_ORAL_22068_NOVARTIS_02-08-2024.pdf (134845 chars)\n",
      "[✓] Loaded: TAVNEOS_AVACOPAN_CAPSULE_ORAL_214487_CHEMOCENTRYX_06-03-2024.pdf (50221 chars)\n",
      "[✓] Loaded: TAZVERIK_TAZEMETOSTAT_HYDROBROMIDE_TABLET_ORAL_211723_EPIZYME_INC_11-16-2023.pdf (51559 chars)\n",
      "[✓] Loaded: TAZVERIK_TAZEMETOSTAT_HYDROBROMIDE_TABLET_ORAL_213400_EPIZYME_INC_06-18-2020.pdf (61503 chars)\n",
      "[✓] Loaded: TECENTRIQ_ATEZOLIZUMAB_INJECTABLE_INJECTION_761034_GENENTECH_INC_04-22-2024.pdf (178535 chars)\n",
      "[✓] Loaded: TECENTRIQ_ATEZOLIZUMAB_INJECTABLE__INJECTION_761041_GENENTECH_INC_10-18-2016.pdf (72672 chars)\n",
      "[✓] Loaded: TECHNIVIE_OMBITASVIR__PARITAPREVIR__RITONAVIR_TABLET_ORAL_207931_ABBVIE_INC_12-06-2019.pdf (116961 chars)\n",
      "[✓] Loaded: TECVAYLI_TECLISTAMAB-CQYV_INJECTABLE__SUBCUTANEOUS_761291_JANSSEN_BIOTECH_11-22-2024.pdf (87047 chars)\n",
      "[✓] Loaded: TEGRETOL-XR_CARBAMAZEPINE_TABLET,_EXTENDED_RELEASE_ORAL_20234_NOVARTIS_09-13-2023.pdf (81768 chars)\n",
      "[✓] Loaded: TEGRETOL_CARBAMAZEPINE_SUSPENSION_ORAL_18927_NOVARTIS_09-13-2023.pdf (81768 chars)\n",
      "[✓] Loaded: TEGRETOL_CARBAMAZEPINE_TABLET,_CHEWABLE_ORAL_18281_NOVARTIS_03-20-2018.pdf (90423 chars)\n",
      "[✓] Loaded: TEGRETOL_CARBAMAZEPINE_TABLET_ORAL_16608_NOVARTIS_09-13-2023.pdf (81768 chars)\n",
      "[✓] Loaded: TEGSEDI_INOTERSEN_SODIUM_SOLUTION_SUBCUTANEOUS_211172_AKCEA_THERAPS_01-12-2024.pdf (79394 chars)\n",
      "[✓] Loaded: TESTIM_TESTOSTERONE_GEL_TRANSDERMAL_21454_AUXILIUM_PHARMS_LLC_08-20-2021.pdf (65657 chars)\n",
      "[✓] Loaded: TESTOSTERONE_CYPIONATE_INJECTION_TESTOSTERONE_CYPIONATE_INJECTABLE_INTRAMUSCULAR_216318_SLAYBACK_PHARMA_LLC_02-01-2024.pdf (52273 chars)\n",
      "[✓] Loaded: TESTOSTERONE_TESTOSTERONE_GEL_TRANSDERMAL_202763_ANI_PHARMS_10-25-2016.pdf (11592 chars)\n",
      "[✓] Loaded: TEVIMBRA_TISLELIZUMAB-JSGR_INJECTABLE_INTRAVENOUS_761380_BEIGENE,_LTD_03-03-2025.pdf (88881 chars)\n",
      "[✓] Loaded: TEVIMBRA_TISLELIZUMAB-JSGR_INJECTABLE_INTRAVENOUS_761417_BEIGENE,_LTD_12-26-2024.pdf (77032 chars)\n",
      "[✓] Loaded: THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf (110187 chars)\n",
      "[✓] Loaded: TIBSOVO_IVOSIDENIB_TABLET_ORAL_211192_SERVIER_10-24-2023.pdf (104372 chars)\n",
      "[✓] Loaded: TIKOSYN_DOFETILIDE_CAPSULE_ORAL_20931_PFIZER_08-08-2019.pdf (75453 chars)\n",
      "[✓] Loaded: TIVDAK_TISOTUMAB_VEDOTIN-TFTV_INJECTABLE_INJECTION_761208_SEAGEN_04-29-2024.pdf (60822 chars)\n",
      "[✓] Loaded: TIVORBEX_INDOMETHACIN_CAPSULE_ORAL_204768_GENUS_04-28-2021.pdf (81604 chars)\n",
      "[✓] Loaded: TOFIDENCE_TOCILIZUMAB-BAVI_INJECTABLE_INTRAVENOUS_761354_BIOGEN_MA_12-03-2024.pdf (161111 chars)\n",
      "[✓] Loaded: TOFRANIL_IMIPRAMINE_HYDROCHLORIDE_TABLET_ORAL_87846_SPECGX_LLC_06-29-2017.pdf (48972 chars)\n",
      "[✓] Loaded: TOPAMAX_SPRINKLE_TOPIRAMATE_CAPSULE_ORAL_20844_JANSSEN_PHARMS_05-03-2023.pdf (175178 chars)\n",
      "[✓] Loaded: TOPAMAX_TOPIRAMATE_CAPSULE_ORAL_20844_JANSSEN_PHARMS_05-03-2023.pdf (175178 chars)\n",
      "[✓] Loaded: TOPAMAX_TOPIRAMATE_TABLET_ORAL_20505_JANSSEN_PHARMS_05-03-2023.pdf (175178 chars)\n",
      "[✓] Loaded: TORADOL_KETOROLAC_TROMETHAMINE_TABLET_ORAL_19645_ROCHE_PALO_03-26-2013.pdf (63876 chars)\n",
      "[✓] Loaded: TRACLEER_BOSENTAN_TABLET,_FOR_SUSPENSION_ORAL_209279_ACTELION_02-08-2024.pdf (91465 chars)\n",
      "[✓] Loaded: TRACLEER_BOSENTAN_TABLET_ORAL_21290_ACTELION_02-08-2024.pdf (91465 chars)\n",
      "[✓] Loaded: TRADJENTA_LINAGLIPTIN_TABLET_ORAL_201280_BOEHRINGER_INGELHEIM_06-20-2023.pdf (88893 chars)\n",
      "[✓] Loaded: TRANXENE_CLORAZEPATE_DIPOTASSIUM_CAPSULE_ORAL_17105_RECORDATI_RARE_01-13-2023.pdf (51508 chars)\n",
      "[✓] Loaded: TRANXENE_CLORAZEPATE_DIPOTASSIUM_TABLET_ORAL_17105_RECORDATI_RARE_01-13-2023.pdf (51508 chars)\n",
      "[✓] Loaded: TRANXENE_SD_CLORAZEPATE_DIPOTASSIUM_TABLET_ORAL_17105_RECORDATI_RARE_01-13-2023.pdf (51508 chars)\n",
      "[✓] Loaded: TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf (84161 chars)\n",
      "[✓] Loaded: TRELEGY_ELLIPTA_FLUTICASONE_FUROATE__UMECLIDINIUM_BROMIDE__VILANTEROL_TRIFENATATE_POWDER_INHALATION_209482_GLAXOSMITHKLINE_06-02-2023.pdf (111653 chars)\n",
      "[✓] Loaded: TREMFYA_GUSELKUMAB_INJECTABLE_INJECTION_761061_JANSSEN_BIOTECH_06-29-2023.pdf (44641 chars)\n",
      "[✓] Loaded: TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf (138532 chars)\n",
      "[✓] Loaded: TRIJARDY_XR_EMPAGLIFLOZIN__LINAGLIPTIN__METFORMIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_212614_BOEHRINGER_INGELHEIM_10-30-2023.pdf (149285 chars)\n",
      "[✓] Loaded: TRILEPTAL_OXCARBAZEPINE_SUSPENSION_ORAL_21285_NOVARTIS_01-04-2019.pdf (107563 chars)\n",
      "[✓] Loaded: TRILEPTAL_OXCARBAZEPINE_TABLET_ORAL_21014_NOVARTIS_01-04-2019.pdf (107563 chars)\n",
      "[✓] Loaded: TRINTELLIX_VORTIOXETINE_HYDROBROMIDE_TABLET_ORAL_204447_TAKEDA_PHARMS_USA_08-23-2023.pdf (99039 chars)\n",
      "[✓] Loaded: TRIPTODUR_KIT_TRIPTORELIN_PAMOATE_FOR_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_208956_ARBOR_PHARMS_LLC_12-07-2022.pdf (39414 chars)\n",
      "[✓] Loaded: TRIUMEQ_ABACAVIR_SULFATE__DOLUTEGRAVIR_SODIUM__LAMIVUDINE_TABLET_ORAL_205551_VIIV_HLTHCARE_04-18-2024.pdf (179110 chars)\n",
      "[✓] Loaded: TRIUMEQ_PD_ABACAVIR_SULFATE__DOLUTEGRAVIR_SODIUM__LAMIVUDINE_SUSPENSION_ORAL_215413_VIIV_HLTHCARE_04-18-2024.pdf (179110 chars)\n",
      "[✓] Loaded: TRIZIVIR_ABACAVIR_SULFATE__LAMIVUDINE__ZIDOVUDINE_TABLET_ORAL_21205_VIIV_HLTHCARE_02-17-2021.pdf (110546 chars)\n",
      "[✓] Loaded: TROKENDI_XR_TOPIRAMATE_CAPSULE,_EXTENDED_RELEASE_ORAL_201635_SUPERNUS_PHARMS_01-04-2024.pdf (174905 chars)\n",
      "[✓] Loaded: TROXYCA_ER_NALTREXONE_HYDROCHLORIDE__OXYCODONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_207621_PFIZER_05-26-2017.pdf (140814 chars)\n",
      "[✓] Loaded: TRUDHESA_DIHYDROERGOTAMINE_MESYLATE_SPRAY,_METERED_NASAL_213436_IMPEL_NEUROPHARMA_09-02-2021.pdf (62830 chars)\n",
      "[✓] Loaded: TRULANCE_PLECANATIDE_TABLET_ORAL_208745_SALIX_04-13-2021.pdf (49549 chars)\n",
      "[✓] Loaded: TRULICITY_DULAGLUTIDE_INJECTABLE_INJECTION_125469_ELI_LILLY_AND_CO_11-17-2022.pdf (140130 chars)\n",
      "[✓] Loaded: TRUVADA_EMTRICITABINE__TENOFOVIR_DISOPROXIL_FUMARATE_TABLET_ORAL_21752_GILEAD_04-29-2024.pdf (114692 chars)\n",
      "[✓] Loaded: TRUXIMA_RITUXIMAB-ABBS_INJECTABLE_INJECTION_761088_CELLTRION_INC_02-04-2022.pdf (157299 chars)\n",
      "[✓] Loaded: TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf (67322 chars)\n",
      "[✓] Loaded: TUSSIONEX_PENNKINETIC_CHLORPHENIRAMINE_POLISTIREX__HYDROCODONE_POLISTIREX_SUSPENSION,_EXTENDED_RELEASE_ORAL_19111_UCB_INC_06-28-2018.pdf (100079 chars)\n",
      "[✓] Loaded: TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf (118594 chars)\n",
      "[✓] Loaded: TUZISTRA_XR_CHLORPHENIRAMINE_POLISTIREX__CODEINE_POLISTIREX_SUSPENSION,_EXTENDED_RELEASE_ORAL_207768_AYTU_12-15-2023.pdf (114464 chars)\n",
      "[✓] Loaded: TYENNE_TOCILIZUMAB--AAZG_INJECTABLE_SUBCUTANEOUS_761275_FRESENIUS_KABI_USA_LLC_02-28-2025.pdf (234579 chars)\n",
      "[✓] Loaded: TYMLOS_ABALOPARATIDE_SOLUTION_SUBCUTANEOUS_208743_RADIUS_HEALTH_INC_12-21-2023.pdf (67459 chars)\n",
      "[✓] Loaded: TYSABRI_NATALIZUMAB_VIAL__SINGLE-USE_125104_BIOGEN_IDEC_10-30-2023.pdf (101424 chars)\n",
      "[✓] Loaded: TYZEKA_TELBIVUDINE_SOLUTION_ORAL_22154_NOVARTIS_12-27-2018.pdf (74036 chars)\n",
      "[✓] Loaded: TYZEKA_TELBIVUDINE_TABLET_ORAL_22011_NOVARTIS_12-27-2018.pdf (74036 chars)\n",
      "[✓] Loaded: UKONIQ_UMBRALISIB_TOSYLATE_TABLET_ORAL_213176_TG_THERAPS_02-05-2021.pdf (55390 chars)\n",
      "[✓] Loaded: ULORIC_FEBUXOSTAT_TABLET_ORAL_21856_TAKEDA_PHARMS_USA_04-17-2023.pdf (72122 chars)\n",
      "[✓] Loaded: ULTOMIRIS_RAVULIZUMAB-CWVZ_INJECTABLE_INJECTION_761108_ALEXION_PHARM_07-01-2024.pdf (126703 chars)\n",
      "[✓] Loaded: ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf (152483 chars)\n",
      "[✓] Loaded: ULTRAM_ER_TRAMADOL_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21692_VALEANT_PHARMS_08-29-2017.pdf (124806 chars)\n",
      "[✓] Loaded: ULTRAM_TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_20281_JANSSEN_PHARMS_02-13-2023.pdf (136303 chars)\n",
      "[✓] Loaded: UPLIZNA_INEBILIZUMAB-CDON_INJECTABLE_INJECTION_761142_VIELA_BIO_06-11-2020.pdf (49197 chars)\n",
      "[✓] Loaded: VALCHLOR_MECHLORETHAMINE_HYDROCHLORIDE_GEL_TOPICAL_202317_HELSINN_05-01-2020.pdf (46795 chars)\n",
      "[✓] Loaded: VALIUM_DIAZEPAM_TABLET_ORAL_13263_ROCHE_03-19-2024.pdf (52693 chars)\n",
      "[✓] Loaded: VALTOCO_DIAZEPAM_SPRAY_NASAL_211635_NEURELIS_INC_01-13-2023.pdf (86641 chars)\n",
      "[✓] Loaded: VANFLYTA_QUIZARTINIB_TABLET_ORAL_216993_DAIICHI_SANKYO_06-25-2024.pdf (64926 chars)\n",
      "[✓] Loaded: VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf (114154 chars)\n",
      "[✓] Loaded: VELSIPITY_ETRASIMOD_ARGANINE_TABLET_ORAL_216956_PFIZER_LABS_06-05-2024.pdf (81538 chars)\n",
      "[✓] Loaded: VENBYSI_XR_VENLAFAXINE_BESYLATE_TABLET,_EXTENDED_RELEASE__ORAL_215429_ALMATICA_08-18-2023.pdf (111628 chars)\n",
      "[✓] Loaded: VENCLEXTA_VENETOCLAX_TABLET_ORAL_208573_ABBVIE_INC_06-15-2022.pdf (152098 chars)\n",
      "[✓] Loaded: VENLAFAXINE_HYDROCHLORIDE_VENLAFAXINE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_22104_OSMOTICA_PHARM_08-18-2023.pdf (140439 chars)\n",
      "[✓] Loaded: VEOPOZ_POZELIMAB-BBFG_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_761339_REGENERON_PHARMACEUTICALS_08-18-2023.pdf (45508 chars)\n",
      "[✓] Loaded: VERQUVO_VERICIGUAT_TABLET_ORAL_214377_Bayer_AG_05-10-2023.pdf (50076 chars)\n",
      "[✓] Loaded: VIBERZI_ELUXADOLINE_TABLET_ORAL_206940_ALLERGAN_HOLDINGS_06-17-2020.pdf (56755 chars)\n",
      "[✓] Loaded: VICOPROFEN_HYDROCODONE_BITARTRATE__IBUPROFEN_TABLET_ORAL_20716_ABBVIE_12-16-2016.pdf (111755 chars)\n",
      "[✓] Loaded: VICTOZA_LIRAGLUTIDE_RECOMBINANT_SOLUTION_SUBCUTANEOUS_22341_NOVO_NORDISK_INC_02-12-2025.pdf (132619 chars)\n",
      "[✓] Loaded: VICTRELIS_BOCEPREVIR_CAPSULE_ORAL_202258_MERCK_SHARP_DOHME_01-30-2017.pdf (125275 chars)\n",
      "[✓] Loaded: VIDEX_DIDANOSINE_FOR_SOLUTION_ORAL_20156_BRISTOL-MYERS_SQUIBB_12-17-2018.pdf (82571 chars)\n",
      "[✓] Loaded: VIDEX_EC_DIDANOSINE_CAPSULE,_DELAYED_REL_PELLETS_ORAL_21183_BRISTOL_MYERS_SQUIBB_12-17-2018.pdf (78249 chars)\n",
      "[✓] Loaded: VIEKIRA_PAK_(COPACKAGED)_DASABUVIR_SODIUM__OMBITASVIR,_PARITAPREVIR,_RITONAVIR_TABLET_ORAL_206619_ABBVIE_INC_12-06-2019.pdf (145869 chars)\n",
      "[✓] Loaded: VIEKIRA_XR_DASABUVIR_SODIUM__OMBITASVIR__PARITAPREVIR__RITONAVIR_TABLET,_EXTENDED_RELEASE_ORAL_208624_ABBVIE_INC_12-06-2019.pdf (146095 chars)\n",
      "[✓] Loaded: VIIBRYD_VILAZODONE_HYDROCHLORIDE_TABLET_ORAL_22567_ALLERGAN_04-19-2024.pdf (71919 chars)\n",
      "[✓] Loaded: VIMOVO_ESOMEPRAZOLE_MAGNESIUM__NAPROXEN_TABLET,_DELAYED_RELEASE_ORAL_22511_HORIZON_11-21-2024.pdf (173181 chars)\n",
      "[✓] Loaded: VIMPAT_LACOSAMIDE_SOLUTION_INTRAVENOUS_22254_UCB_INC_10-16-2023.pdf (99875 chars)\n",
      "[✓] Loaded: VIMPAT_LACOSAMIDE_SOLUTION_ORAL_22255_UCB_INC_10-16-2023.pdf (99875 chars)\n",
      "[✓] Loaded: VIMPAT_LACOSAMIDE_TABLET_ORAL_22253_UCB_INC_10-16-2023.pdf (99875 chars)\n",
      "[✓] Loaded: VIOKACE_PANCRELIPASE_(AMYLASE_LIPASE_PROTEASE)_TABLET_ORAL_22542_VIOKACE_02-28-2024.pdf (38570 chars)\n",
      "[✓] Loaded: VIRAMUNE_NEVIRAPINE_SUSPENSION_ORAL_20933_BOEHRINGER_INGELHEIM_06-10-2022.pdf (106667 chars)\n",
      "[✓] Loaded: VIRAMUNE_NEVIRAPINE_TABLET_ORAL_20636_BOEHRINGER_INGELHEIM_06-10-2022.pdf (106667 chars)\n",
      "[✓] Loaded: VIRAMUNE_XR_NEVIRAPINE_TABLET,_EXTENDED_RELEASE_ORAL_201152_BOEHRINGER_INGELHEIM_06-10-2022.pdf (108625 chars)\n",
      "[✓] Loaded: VISICOL_SODIUM_PHOSPHATE,_DIBASIC_ANHYDROUS__SODIUM_PHOSPHATE,_MONOBASIC,_MONOHYDRATE_TABLET_ORAL_21097_SALIX_PHARMS_03-07-2013.pdf (37350 chars)\n",
      "[✓] Loaded: VITUZ_CHLORPHENIRAMINE_MALEATE__HYDROCODONE_BITARTRATE_SOLUTION_ORAL_204307_PERSION_06-28-2018.pdf (103798 chars)\n",
      "[✓] Loaded: VIVACTIL_PROTRIPTYLINE_HYDROCHLORIDE_TABLET_ORAL_16012_TEVA_WOMENS_07-17-2014.pdf (7989 chars)\n",
      "[✓] Loaded: VIVITROL_NALTREXONE_FOR_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_21897_ALKERMES_09-30-2022.pdf (100108 chars)\n",
      "[✓] Loaded: VIVLODEX_MELOXICAM_CAPSULE_ORAL_207233_ZYLA_11-21-2024.pdf (81406 chars)\n",
      "[✓] Loaded: VOGELXO_TESTOSTERONE_GEL,_METERED_TRANSDERMAL_204399_UPSHER_SMITH_LABS_04-30-2020.pdf (71792 chars)\n",
      "[✓] Loaded: VOGELXO_TESTOSTERONE_GEL_TRANSDERMAL_204399_UPSHER_SMITH_LABS_04-30-2020.pdf (71792 chars)\n",
      "[✓] Loaded: VOLTAREN-XR_DICLOFENAC_SODIUM_TABLET,_EXTENDED_RELEASE_ORAL_20254_NOVARTIS_04-28-2021.pdf (65216 chars)\n",
      "[✓] Loaded: VOLTAREN_ARTHRITIS_PAIN_DICLOFENAC_SODIUM_GEL_TOPICAL_22122_GLAXOSMITHKLINE_CONS_11-29-2023.pdf (77910 chars)\n",
      "[✓] Loaded: VOLTAREN_DICLOFENAC_SODIUM_TABLET,_DELAYED_RELEASE_ORAL_19201_NOVARTIS_04-28-2021.pdf (62714 chars)\n",
      "[✓] Loaded: VOTRIENT_PAZOPANIB_HYDROCHLORIDE_TABLET_ORAL_22465_NOVARTIS_01-25-2024.pdf (106062 chars)\n",
      "[✓] Loaded: VRAYLAR_CARIPRAZINE_HYDROCHLORIDE_CAPSULE_ORAL_204370_ALLERGAN_11-22-2024.pdf (129841 chars)\n",
      "[✓] Loaded: VYVANSE_LISDEXAMFETAMINE_DIMESYLATE_CAPSULE_ORAL_21977_TAKEDA_PHARMS_USA_10-13-2023.pdf (105890 chars)\n",
      "[✓] Loaded: VYVANSE_LISDEXAMFETAMINE_DIMESYLATE_TABLET,_CHEWABLE_ORAL_208510_TAKEDA_PHARMS_USA_10-13-2023.pdf (105890 chars)\n",
      "[✓] Loaded: WEGOVY_SEMAGLUTIDE_SOLUTION_SUBCUTANEOUS_215256_NOVO_11-27-2024.pdf (139231 chars)\n",
      "[✓] Loaded: WELIREG_BELZUTIFAN_TABLET_ORAL_215383_MERCK_SHARP_DOHME_02-26-2024.pdf (62922 chars)\n",
      "[✓] Loaded: WELLBUTRIN_BUPROPION_HYDROCHLORIDE_TABLET_ORAL_18644_GLAXOSMITHKLINE_05-07-2024.pdf (111442 chars)\n",
      "[✓] Loaded: WELLBUTRIN_SR_BUPROPION_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_20358_GLAXOSMITHKLINE_05-07-2024.pdf (118625 chars)\n",
      "[✓] Loaded: WELLBUTRIN_XL_BUPROPION_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_21515_BAUSCH_05-07-2024.pdf (116546 chars)\n",
      "[✓] Loaded: WEZLANA_USTEKINUMAB-AUUB_INJECTABLE_SUBCUTANEOUS,_INTRAVENOUS_761285_AMGEN_INC_12-26-2024.pdf (130575 chars)\n",
      "[✓] Loaded: WEZLANA_USTEKINUMAB-AUUB_INJECTABLE_SUBCUTANEOUS,_INTRAVENOUS_761331_AMGEN_INC_12-26-2024.pdf (130575 chars)\n",
      "[✓] Loaded: XALKORI_CRIZOTINIB_CAPSULE_ORAL_202570_PF_PRISM_CV_09-07-2023.pdf (133592 chars)\n",
      "[✓] Loaded: XANAX_ALPRAZOLAM_TABLET_ORAL_18276_UPJOHN_01-13-2023.pdf (149196 chars)\n",
      "[✓] Loaded: XANAX_XR_ALPRAZOLAM_TABLET,_EXTENDED_RELEASE_ORAL_21434_UPJOHN_01-13-2023.pdf (149196 chars)\n",
      "[✓] Loaded: XARELTO_RIVAROXABAN_FOR_SUSPENSION_ORAL_215859_JANSSEN_PHARMS_02-08-2023.pdf (209212 chars)\n",
      "[✓] Loaded: XARELTO_RIVAROXABAN_TABLET_ORAL_202439_JANSSEN_PHARMS_03-01-2022.pdf (201652 chars)\n",
      "[✓] Loaded: XARELTO_RIVAROXABAN_TABLET_ORAL_22406_JANSSEN_PHARMS_02-08-2023.pdf (201652 chars)\n",
      "[✓] Loaded: XARTEMIS_XR_ACETAMINOPHEN__OXYCODONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_204031_MALLINCKRODT_INC_09-18-2018.pdf (107607 chars)\n",
      "[✓] Loaded: XCOPRI_CENOBAMATE_TABLET_ORAL_212839_SK_LIFE_04-05-2024.pdf (69802 chars)\n",
      "[✓] Loaded: XELJANZ_TOFACITINIB_CITRATE_SOLUTION_ORAL_213082_PFIZER_02-21-2025.pdf (183574 chars)\n",
      "[✓] Loaded: XELJANZ_TOFACITINIB_CITRATE_TABLET_ORAL_203214_PF_PRISM_CV_02-21-2025.pdf (183574 chars)\n",
      "[✓] Loaded: XELJANZ_XR_TOFACITINIB_CITRATE_TABLET,_EXTENDED_RELEASE_ORAL_208246_PFIZER_02-21-2025.pdf (183574 chars)\n",
      "[✓] Loaded: XELSTRYM_DEXTROAMPHETAMINE_SYSTEM_TRANSDERMAL_215401_NOVEN_PHARMACEUTICALS_INC_10-13-2023.pdf (101262 chars)\n",
      "[✓] Loaded: XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf (77548 chars)\n",
      "[✓] Loaded: Xeomin_incobotulinumtoxinA_INJECTABLE_INJECTION_125360_MERZ_PHARMS_09-08-2023.pdf (107269 chars)\n",
      "[✓] Loaded: XIAFLEX_COLLAGENASE_CLOSTRIDIUM_HISTOLYTICUM_SOLUTION__INJECTION_125338_AUXILIUM_PHARMS_07-12-2023.pdf (115671 chars)\n",
      "[✓] Loaded: XIGDUO_XR_DAPAGLIFLOZIN__METFORMIN_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_205649_ASTRAZENECA_AB_06-12-2024.pdf (164280 chars)\n",
      "[✓] Loaded: XOLAIR_OMALIZUMAB_VIAL_103976_GENENTECH_02-16-2024.pdf (159629 chars)\n",
      "[✓] Loaded: XOSPATA_GILTERITINIB_FUMARATE_TABLET_ORAL_211349_ASTELLAS_01-12-2022.pdf (61320 chars)\n",
      "[✓] Loaded: XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf (96517 chars)\n",
      "[✓] Loaded: XROMI_HYDROXYUREA_SOLUTION-ORAL_216593_RARE_DISEASE_THERAPEUTICS,_INC_12-23-2024.pdf (65535 chars)\n",
      "[✓] Loaded: XTAMPZA_ER_OXYCODONE_CAPSULE,_EXTENDED_RELEASE_ORAL_208090_COLLEGIUM_PHARM_INC_12-15-2023.pdf (138382 chars)\n",
      "[✓] Loaded: XTRELUS_HYDROCODONE_BITARTRATE_GUAIFENESIN_TABLET_ORAL_208085_ECI_PHARMACEUTICALS_12-15-2023.pdf (100371 chars)\n",
      "[✓] Loaded: XULTOPHY_100-3.6_INSULIN_DEGLUDEC__LIRAGLUTIDE_SOLUTION_SUBCUTANEOUS_208583_NOVO_07-10-2023.pdf (149722 chars)\n",
      "[✓] Loaded: XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf (59912 chars)\n",
      "[✓] Loaded: XYREM_SODIUM_OXYBATE_SOLUTION_ORAL_21196_JAZZ_PHARMS_05-22-2024.pdf (105177 chars)\n",
      "[✓] Loaded: XYWAV_CALCIUM_OXYBATE__MAGNESIUM_OXYBATE__POTASSIUM_OXYBATE__SODIUM_OXYBATE_SOLUTION_ORAL_212690_JAZZ_05-22-2024.pdf (122904 chars)\n",
      "[✓] Loaded: YERVOY_IPILIMUMAB_INJECTABLE__INJECTION_125377_BRISTOL_MYERS_SQUIBB_01-28-2025.pdf (179724 chars)\n",
      "[✓] Loaded: YESINTEK_USTEKINUMAB-KFCE_INJECTABLE_INTRAVENOUS,_SUBCUTANEOUS_761406_BIOCON_BIOLOGICS_INC_nan.pdf (122911 chars)\n",
      "[✓] Loaded: YOSPRALA_ASPIRIN__OMEPRAZOLE_TABLET,_DELAYED_RELEASE_ORAL_205103_GENUS_LIFESCIENCES_11-21-2024.pdf (127391 chars)\n",
      "[✓] Loaded: YUFLYMA_ADALIMUMAB-AATY_INJECTABLE_SUBCUTANEOUS_761219_CELLTRION_12-23-2024.pdf (223651 chars)\n",
      "[✓] Loaded: YUSIMRY_ADALIMUMAB-AQVH_INJECTABLE_INJECTION_761216_COHERUS_BIOSCIENCES_INC_09-13-2023.pdf (163821 chars)\n",
      "[✓] Loaded: ZARONTIN_ETHOSUXIMIDE_CAPSULE_ORAL_12380_PARKE_DAVIS_10-28-2021.pdf (9936 chars)\n",
      "[✓] Loaded: ZEGERID_OMEPRAZOLE__SODIUM_BICARBONATE_CAPSULE_ORAL_21849_SALIX_07-18-2023.pdf (111585 chars)\n",
      "[✓] Loaded: ZEGERID_OMEPRAZOLE__SODIUM_BICARBONATE_FOR_SUSPENSION_ORAL_21636_SALIX_07-18-2023.pdf (111585 chars)\n",
      "[✓] Loaded: ZELBORAF_VEMURAFENIB_TABLET_ORAL_202429_HOFFMANN_LA_ROCHE_05-18-2020.pdf (72154 chars)\n",
      "[✓] Loaded: ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf (53400 chars)\n",
      "[✓] Loaded: ZEPOSIA_OZANIMOD_HYDROCHLORIDE_CAPSULE_ORAL_209899_CELGENE_INTL_06-05-2024.pdf (109746 chars)\n",
      "[✓] Loaded: ZERIT_STAVUDINE_FOR_SOLUTION_ORAL_20413_BRISTOL-MYERS_SQUIBB_12-17-2018.pdf (71702 chars)\n",
      "[✓] Loaded: ZIAGEN_ABACAVIR_SULFATE_SOLUTION_ORAL_20978_VIIV_HLTHCARE_11-24-2020.pdf (89836 chars)\n",
      "[✓] Loaded: ZILBRYSQ_ZILUCOPLAN_INJECTABLE_SUBCUTANEOUS_216834_UCB_INC_04-26-2024.pdf (65867 chars)\n",
      "[✓] Loaded: ZINBRYTA_DACLIZUMAB_INJECTABLE_INJECTION_761029_BIOGEN_11-01-2017.pdf (95821 chars)\n",
      "[✓] Loaded: ZIPSOR_DICLOFENAC_POTASSIUM_CAPSULE_ORAL_22202_ASSERTIO_11-21-2024.pdf (88600 chars)\n",
      "[✓] Loaded: ZITUVIMET_SITAGLIPTIN,_METFORMIN_HYDROCHLORIDE_TABLET_ORAL_216743_ZYDUS_PHARMACEUTICALS_11-03-2023.pdf (131799 chars)\n",
      "[✓] Loaded: ZITUVIO_SITAGLIPTIN_TABLET_ORAL_211566_ZYDUS_PHARMACEUTICALS_INC_10-18-2023.pdf (92683 chars)\n",
      "[✓] Loaded: ZOHYDRO_ER_HYDROCODONE_BITARTRATE_CAPSULE,_EXTENDED_RELEASE_ORAL_202880_RECRO_GAINESVILLE_03-04-2021.pdf (115726 chars)\n",
      "[✓] Loaded: ZOLOFT_SERTRALINE_HYDROCHLORIDE_CONCENTRATE_ORAL_20990_UPJOHN_08-18-2023.pdf (114107 chars)\n",
      "[✓] Loaded: ZOLOFT_SERTRALINE_HYDROCHLORIDE_TABLET_ORAL_19839_UPJOHN_08-18-2023.pdf (114107 chars)\n",
      "[✓] Loaded: ZOLPIDEM_TARTRATE_CAPSULES_ZOLPIDEM_TARTRATE_CAPSULE_ORAL_215721_Almatica_Pharma_05-09-2023.pdf (82839 chars)\n",
      "[✓] Loaded: ZOLPIDEM_TARTRATE_ZOLPIDEM_TARTRATE_TABLET_ORAL_76062_STRIDES_PHARMA_03-07-2023.pdf (9712 chars)\n",
      "[✓] Loaded: ZOLPIMIST_ZOLPIDEM_TARTRATE_SPRAY,_METERED_ORAL_22196_AYTU_08-18-2019.pdf (80210 chars)\n",
      "[✓] Loaded: ZONEGRAN_ZONISAMIDE_CAPSULE_ORAL_20789_CONCORDIA_04-13-2020.pdf (86433 chars)\n",
      "[✓] Loaded: ZONISADE_ZONISAMIDE_SUSPENSION_ORAL_214273_AZURITY_07-15-2022.pdf (97360 chars)\n",
      "[✓] Loaded: ZORTRESS_EVEROLIMUS_TABLET_ORAL_21560_NOVARTIS_02-28-2024.pdf (135691 chars)\n",
      "[✓] Loaded: ZORVOLEX_DICLOFENAC_CAPSULE_ORAL_204592_ZYLA_11-21-2024.pdf (80875 chars)\n",
      "[✓] Loaded: ZTALMY_GANAXOLONE_SUSPENSION_ORAL_215904_MARINUS_PHARMACEUTICALS_06-21-2023.pdf (56604 chars)\n",
      "[✓] Loaded: ZUBSOLV_BUPRENORPHINE_HYDROCHLORIDE__NALOXONE_HYDROCHLORIDE_TABLET_SUBLINGUAL_204242_OREXO_US_INC_03-20-2024.pdf (123887 chars)\n",
      "[✓] Loaded: ZULRESSO_BREXANOLONE_SOLUTION_INTRAVENOUS_211371_SAGE_THERAP_10-17-2023.pdf (51663 chars)\n",
      "[✓] Loaded: ZURAMPIC_LESINURAD_TABLET_ORAL_207988_IRONWOOD_PHARMS_INC_08-04-2016.pdf (53606 chars)\n",
      "[✓] Loaded: ZURZUVAE_ZURANOLONE_CAPSULE_ORAL_217369_BIOGEN_INC_08-04-2023.pdf (60761 chars)\n",
      "[✓] Loaded: ZUTRIPRO_CHLORPHENIRAMINE_MALEATE__HYDROCODONE_BITARTRATE__PSEUDOEPHEDRINE_HYDROCHLORIDE_SOLUTION_ORAL_22439_PERSION_06-28-2018.pdf (109445 chars)\n",
      "[✓] Loaded: ZYBAN_BUPROPION_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_20711_GLAXOSMITHKLINE_03-09-2021.pdf (123339 chars)\n",
      "[✓] Loaded: ZYDELIG_IDELALISIB_TABLET_ORAL_205858_GILEAD_SCIENCES_INC_07-06-2022.pdf (71573 chars)\n",
      "[✓] Loaded: ZYMFENTRA_INFLIXIMAB-DYYB_INJECTABLE_SUBCUTANEOUS_761358_CELLTRION_USA_02-22-2024.pdf (127798 chars)\n",
      "[✓] Loaded: ZYNYZ_RETIFANLIMAB-DLWR_INJECTABLE_INTRAVENOUS_761334_INCYTE_04-22-2024.pdf (56341 chars)\n",
      "[✓] Loaded: ZYPREXA_OLANZAPINE_INJECTABLE_INTRAMUSCULAR_21253_LILLY_01-22-2025.pdf (209507 chars)\n",
      "[✓] Loaded: ZYPREXA_OLANZAPINE_TABLET_ORAL_20592_LILLY_01-22-2025.pdf (209507 chars)\n",
      "[✓] Loaded: ZYPREXA_RELPREVV_OLANZAPINE_PAMOATE_SUSPENSION,_EXTENDED_RELEASE_INTRAMUSCULAR_22173_ELI_LILLY_CO_01-22-2025.pdf (141118 chars)\n",
      "[✓] Loaded: ZYPREXA_ZYDIS_OLANZAPINE_TABLET,_ORALLY_DISINTEGRATING_ORAL_21086_LILLY_01-22-2025.pdf (209507 chars)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "import fitz  # PyMuPDF\n",
    "import os\n",
    "\n",
    "PDF_DIR = r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\MedicationGuides_2025_05_19\"\n",
    "\n",
    "def extract_pdf_text_pymupdf(pdf_path):\n",
    "    doc = fitz.open(pdf_path)\n",
    "    full_text = \"\"\n",
    "    for page in doc:\n",
    "        full_text += page.get_text()\n",
    "    return full_text.strip()\n",
    "\n",
    "# Parse all PDFs\n",
    "pdf_texts = []\n",
    "pdf_paths = []\n",
    "for filename in os.listdir(PDF_DIR):\n",
    "    if filename.endswith(\".pdf\"):\n",
    "        path = os.path.join(PDF_DIR, filename)\n",
    "        text = extract_pdf_text_pymupdf(path)\n",
    "        if text:\n",
    "            pdf_texts.append(text)\n",
    "            pdf_paths.append(path)\n",
    "            print(f\"[✓] Loaded: {filename} ({len(text)} chars)\")\n",
    "        else:\n",
    "            print(f\"[!] Skipped empty: {filename}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5392283e",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[94m2025-05-19 17:43:50 - pipmaster.package_manager - INFO - Targeting pip associated with Python: c:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\.venv\\Scripts\\python.exe | Command base: c:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\.venv\\Scripts\\python.exe -m pip\u001b[0m\n",
      "INFO: Process 25796 Shared-Data created for Single Process\n",
      "INFO: Loaded graph from ./my_rag_project\\graph_chunk_entity_relation.graphml with 4715 nodes, 7590 edges\n",
      "INFO:nano-vectordb:Load (4661, 1536) data\n",
      "INFO:nano-vectordb:Init {'embedding_dim': 1536, 'metric': 'cosine', 'storage_file': './my_rag_project\\\\vdb_entities.json'} 4661 data\n",
      "INFO:nano-vectordb:Load (7590, 1536) data\n",
      "INFO:nano-vectordb:Init {'embedding_dim': 1536, 'metric': 'cosine', 'storage_file': './my_rag_project\\\\vdb_relationships.json'} 7590 data\n",
      "INFO:nano-vectordb:Load (940, 1536) data\n",
      "INFO:nano-vectordb:Init {'embedding_dim': 1536, 'metric': 'cosine', 'storage_file': './my_rag_project\\\\vdb_chunks.json'} 940 data\n",
      "INFO: Process 25796 initialized updated flags for namespace: [full_docs]\n",
      "INFO: Process 25796 ready to initialize storage namespace: [full_docs]\n",
      "INFO: Process 25796 KV load full_docs with 43 records\n",
      "INFO: Process 25796 initialized updated flags for namespace: [text_chunks]\n",
      "INFO: Process 25796 ready to initialize storage namespace: [text_chunks]\n",
      "INFO: Process 25796 KV load text_chunks with 943 records\n",
      "INFO: Process 25796 initialized updated flags for namespace: [entities]\n",
      "INFO: Process 25796 initialized updated flags for namespace: [relationships]\n",
      "INFO: Process 25796 initialized updated flags for namespace: [chunks]\n",
      "INFO: Process 25796 initialized updated flags for namespace: [chunk_entity_relation]\n",
      "INFO: Process 25796 initialized updated flags for namespace: [llm_response_cache]\n",
      "INFO: Process 25796 ready to initialize storage namespace: [llm_response_cache]\n",
      "INFO: Process 25796 KV load llm_response_cache with 2468 records\n",
      "INFO: Process 25796 initialized updated flags for namespace: [doc_status]\n",
      "INFO: Process 25796 ready to initialize storage namespace: [doc_status]\n",
      "INFO: Process 25796 doc status load doc_status with 809 records\n",
      "INFO: Process 25796 storage namespace already initialized: [full_docs]\n",
      "INFO: Process 25796 storage namespace already initialized: [text_chunks]\n",
      "INFO: Process 25796 storage namespace already initialized: [llm_response_cache]\n",
      "INFO: Process 25796 storage namespace already initialized: [doc_status]\n",
      "INFO: Process 25796 Pipeline namespace initialized\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO: Storage Initialization completed!\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from lightrag import LightRAG, QueryParam\n",
    "from lightrag.llm.openai import gpt_4o_mini_complete, openai_embed\n",
    "from lightrag.kg.shared_storage import initialize_pipeline_status\n",
    "from lightrag.utils import setup_logger\n",
    "import asyncio\n",
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "\n",
    "# Setup\n",
    "setup_logger(\"lightrag\", level=\"INFO\")\n",
    "\n",
    "WORKING_DIR = \"./my_rag_project\"\n",
    "os.makedirs(WORKING_DIR, exist_ok=True)\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "async def init_rag():\n",
    "    rag = LightRAG(\n",
    "        working_dir=\"./my_rag_project\",\n",
    "        embedding_func=openai_embed,\n",
    "        llm_model_func=gpt_4o_mini_complete\n",
    "    )\n",
    "    await rag.initialize_storages()\n",
    "    await initialize_pipeline_status()\n",
    "    return rag\n",
    "\n",
    "# This now works safely in Jupyter\n",
    "rag = await init_rag()\n",
    "\n",
    "#rag.insert(pdf_texts, file_paths=pdf_paths)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a65d3472",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import networkx as nx\n",
    "from pyvis.network import Network\n",
    "import random\n",
    "from IPython.display import display, HTML\n",
    "\n",
    "graph_path = \"./my_rag_project/graph_chunk_entity_relation.graphml\"\n",
    "G = nx.read_graphml(graph_path)\n",
    "\n",
    "net = Network(height=\"750px\", width=\"100%\", notebook=True, directed=True, cdn_resources=\"in_line\")\n",
    "net.from_nx(G)\n",
    "\n",
    "for node in net.nodes:\n",
    "    node['color'] = \"#{:06x}\".format(random.randint(0, 0xFFFFFF))\n",
    "\n",
    "with open(\"knowledge_graph.html\", \"w\", encoding=\"utf-8\") as f:\n",
    "    f.write(net.generate_html())\n",
    "\n",
    "import webbrowser\n",
    "webbrowser.open(\"knowledge_graph.html\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "3138bdda",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:  == LLM cache == saving hybrid: 6c64b614a258f5595a97a0e24dd95865\n",
      "INFO: Process 25796 building query context...\n",
      "INFO: Query nodes: Irritable Bowel Syndrome, Dosage instructions, Prescription, Side effects, top_k: 60, cosine: 0.2\n",
      "INFO: Local query uses 52 entites, 143 relations, 3 chunks\n",
      "INFO: Query edges: IBSRELA, Standard dosage, Medication, top_k: 60, cosine: 0.2\n",
      "INFO: Global query uses 15 entites, 60 relations, 3 chunks\n",
      "INFO: Process 25796 building query context...\n",
      "INFO: Query nodes: Irritable Bowel Syndrome, Dosage instructions, Prescription, Side effects, top_k: 60, cosine: 0.2\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "📄 Retrieved Context:\n",
      "-----Entities(KG)-----\n",
      "\n",
      "```json\n",
      "[{\"id\": \"1\", \"entity\": \"Inflammatory Bowel Disease Questionnaire (IBDQ)\", \"type\": \"event\", \"description\": \"The Inflammatory Bowel Disease Questionnaire (IBDQ) is a tool used to assess the quality of life and symptoms in patients with inflammatory bowel diseases.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:43:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"2\", \"entity\": \"REMICADE\", \"type\": \"organization\", \"description\": \"REMICADE is a TNF blocker medication, specifically a chimeric IgG1κ monoclonal antibody known as infliximab, used for the treatment of a variety of autoimmune conditions. Approved in the U.S. in 1998, it is widely employed to treat diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease, ulcerative colitis (UC), psoriatic arthritis, and plaque psoriasis. REMICADE effectively inhibits tumor necrosis factor (TNF), contributing to its therapeutic action by reducing immune system damage and improving patient symptoms.\\n\\nThe medication is administered via intravenous infusion and has shown significant results in clinical studies, including improvements in physical function and inhibition of structural damage in conditions like RA and AS. It has also been used as a maintenance therapy for Crohn's disease, demonstrating efficacy in managing fistulas and enhancing clinical remission rates.\\n\\nHowever, the use of REMICADE comes with associated risks, including the potential for serious adverse reactions, such as infections, malignancies, and infusion reactions. Patients may experience the development of antibodies against the medication, and its use carries contraindications and warnings, especially concerning pregnancy and breastfeeding. REMICADE is typically used in conjunction with other treatments, such as methotrexate (MTX), to enhance its effectiveness in managing autoimmune diseases. \\n\\nOverall, while REMICADE has proven to be a valuable treatment option for many individuals suffering from challenging inflammatory conditions, its safety and efficacy continue to be evaluated in clinical studies, emphasizing the need for careful monitoring during treatment.<SEP>REMICADE is a medication (infliximab) that may pose risks if taken while using HULIO.\", \"rank\": 210, \"created_at\": \"2025-05-19 17:03:50\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"3\", \"entity\": \"5 mg/kg\", \"type\": \"category\", \"description\": \"5 mg/kg is a dosage level of REMICADE administered in clinical trials to evaluate its response in patients with Ulcerative Colitis.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:43:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"4\", \"entity\": \"FDA\", \"type\": \"organization\", \"description\": \"The FDA (Food and Drug Administration) is a federal agency of the United States government with a crucial mission to protect public health by regulating a diverse range of products, including food, drugs, cosmetics, and medical devices. This regulatory body is tasked with ensuring the safety, efficacy, and accurate labeling of these products through rigorous compliance standards, evaluations, and various regulatory activities.\\n\\nThe agency is well-known for its role in the approval and monitoring of numerous medications, which include widely recognized pharmaceuticals such as STRATTERA (atomoxetine), ASTAGRAF XL, BRIVIACT, VANTRELA ER, SEROQUEL XR, ROZEREM, Infliximab, BANZEL, HULIO, ULTRACET, and DIACOMIT. The FDA conducts thorough analyses of clinical trials, safety reports, and drug labeling, thereby ensuring that the information made available to the public is both current and accurate while complying with safety guidelines.\\n\\nTo uphold drug safety even after approval, the FDA employs monitoring systems like MedWatch, which tracks adverse reactions and fetal exposures. The agency also implements Risk Evaluation and Mitigation Strategies (REMS) to address potential issues related to medication addiction, abuse, and misuse. Furthermore, the FDA oversees regulations associated with medical devices, emphasizing safe disposal practices to help mitigate risks tied to medical waste.\\n\\nIn summary, the FDA serves as the principal regulatory authority in the United States, ensuring that food, drugs, and medical devices are safe, effective, and correctly labeled, thereby safeguarding public health.\", \"rank\": 139, \"created_at\": \"2025-05-19 17:17:57\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ROZEREM_RAMELTEON_TABLET_ORAL_21782_TAKEDA_PHARMS_USA_11-03-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET_ORAL_5378_RECORDATI_RARE_10-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ADDERALL_10_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf\"}, {\"id\": \"5\", \"entity\": \"IBSRELA\", \"type\": \"organization\", \"description\": \"IBSRELA is the brand name for a medication containing tenapanor hydrochloride, specifically designed for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults. It aims to alleviate symptoms such as abdominal pain and improve bowel movement frequencies by inhibiting sodium absorption in the intestines. IBSRELA has been evaluated in clinical settings and clinical trials for its efficacy in managing IBS-C, along with the potential for adverse reactions and drug interactions. As a prescription medication, it is crucial for patients to adhere to prescribed dosing instructions and be aware of any possible side effects. Additionally, specific storage instructions are advised to maintain the medication's efficacy. Overall, IBSRELA is positioned as a management option for individuals dealing with certain gastrointestinal conditions, particularly IBS.\", \"rank\": 42, \"created_at\": \"2025-05-19 16:04:49\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"6\", \"entity\": \"Adverse Reactions\", \"type\": \"category\", \"description\": \"Adverse Reactions refer to the negative side effects or unwanted responses that patients may experience while undergoing treatment with various medications. These reactions are especially critical in the context of clinical trials, where they require meticulous monitoring to ensure patient safety and guide ongoing treatment protocols. A broad range of medications has been examined for their potential adverse reactions, which can vary widely in nature and severity.\\n\\nOne notable medication is BANZEL, which has exhibited significant adverse effects during clinical trials. Similar vigilance is warranted for treatments like Ertugliflozin, used in diabetes management, and Infliximab (marketed as REMICADE), known for severe infections and infusion reactions, highlighting the necessity for attentive monitoring of these therapies.\\n\\nThe spectrum of adverse reactions includes a diverse array of side effects across different medications. For instance, ROZEREM may lead to somnolence and dizziness, while THALOMID can cause fatigue, hypocalcemia, and neuropathy, particularly when administered alongside dexamethasone. Other medications, such as TREXIMET, are associated with dizziness and nausea, whereas RITUXAN HYCELA requires careful oversight due to its potential adverse effects. EMBEDA raises concerns regarding addiction and respiratory depression, while TUXARIN ER may induce hypersensitivity and respiratory issues.\\n\\nSevere reactions have also been documented with drugs like Abacavir, recognized for causing significant hypersensitivity reactions, and SEROQUEL XR, which poses risks including somnolence, dizziness, increased mortality in elderly patients, and suicidal thoughts, alongside tachycardia and extrapyramidal effects. Furthermore, patients treated with TNF blockers like adalimumab and HULIO face risks of serious infections and site reactions.\\n\\nParticular mention is made of STRATTERA, where adverse reactions encompass nausea, fatigue, and headache, all of which are closely monitored during clinical trials. Similar careful observation is required for TURALIO, especially noted during both clinical trials and post-marketing experiences.\\n\\nIn summary, adverse reactions cover a wide range of undesirable effects linked to numerous medications, underscoring the importance of rigorous documentation, safety monitoring, and heightened patient awareness throughout clinical trials and real-world medical applications. The implications of these reactions extend beyond individual medications, raising broader health concerns, particularly in complex medical contexts like post-transplant care. It is essential that adverse reactions are acknowledged and addressed to mitigate risks and ensure patient safety.\", \"rank\": 120, \"created_at\": \"2025-05-19 17:18:49\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ROZEREM_RAMELTEON_TABLET_ORAL_21782_TAKEDA_PHARMS_USA_11-03-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET_ORAL_5378_RECORDATI_RARE_10-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf\"}, {\"id\": \"7\", \"entity\": \"Patients\", \"type\": \"person\", \"description\": \"Patients are a diverse group of individuals engaged in various clinical studies and receiving treatments for a wide range of health conditions, both physical and mental. This population typically consists of adults aged 18 to 74, but also includes children and adolescents. Notably, younger patients, aged 6 to 18, are involved in trials for medications such as STRATTERA to manage ADHD.\\n\\nWithin clinical trials, patients undergo evaluations to assess the safety and efficacy of numerous medications. Some of the notable treatments being studied include VANTRELA ER, with effects on both opioid-naïve and opioid-experienced individuals, and medications like Ertugliflozin and Sitagliptin for diabetes management. Patients facing various health challenges are prescribed specific therapies tailored to their conditions, emphasizing the need for personalized treatment plans and careful monitoring.\\n\\nFor those on pain management therapies, medications such as OPANA ER and EMBEDA are provided, while autoimmune disorder patients may receive BENLYSTA. Some adolescents suffering from severe migraines are treated with TREXIMET, which is prescribed with caution due to potential side effects and addiction risks. In the context of autoimmune diseases, patients receive REMICADE for rheumatoid arthritis and ulcerative colitis, and they are vigilantly monitored for potential side effects like hypersensitivity reactions and infections.\\n\\nPatients with cardiovascular issues benefit from medications like Plavix, aimed at reducing the likelihood of heart attacks and strokes. In the realm of mental health, individuals diagnosed with major depressive disorder, bipolar mania, and schizophrenia are prescribed antipsychotic medications such as SEROQUEL and SEROQUEL XR, necessitating close observation for adverse reactions.\\n\\nFor patients with inflammatory bowel diseases, treatments include ENTYVIO. Those suffering from fungal infections may utilize Lamisil Oral Granules, and patients with exocrine pancreatic insufficiency due to cystic fibrosis find ZENPEP crucial for effective management of their condition. Additionally, individuals on antiepileptic drugs (AEDs) like BANZEL and DIACOMIT must monitor for changes in mood and behavior, reflecting the complexities of managing conditions such as epilepsy and related psychiatric disorders.\\n\\nInclusively, patients are also involved in clinical trials assessing therapies for ulcerative colitis and psoriasis, with particular inclusion criteria based on weight and medical history. Furthermore, patients undergoing certain treatments, such as HULIO, are at a higher risk of developing infections or malignancies, underscoring the critical nature of supervision throughout their medical care.\", \"rank\": 133, \"created_at\": \"2025-05-19 17:19:07\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf\"}, {\"id\": \"8\", \"entity\": \"Trial 1\", \"type\": \"event\", \"description\": \"Trial 1 encompasses multiple clinical studies with distinct focuses. One aspect of Trial 1 is dedicated to comparing the efficacy of BAXDELA against vancomycin and aztreonam for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Additionally, Trial 1 evaluates the efficacy and safety of BENLYSTA in patients with systemic lupus erythematosus (SLE), enrolling a total of 449 patients and comparing various doses of the drug against a placebo. Furthermore, Trial 1 includes a study assessing the efficacy of IBSRELA in adults with irritable bowel syndrome with constipation (IBS-C), where it serves as one of two clinical trials involving 620 patients. This particular study evaluates IBSRELA's safety and efficacy over a 26-week period, with comparisons made against a placebo. Overall, Trial 1 represents a multifaceted clinical research initiative addressing various therapeutic agents for different medical conditions.\", \"rank\": 17, \"created_at\": \"2025-05-19 16:05:09\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"9\", \"entity\": \"Patient Counseling Information\", \"type\": \"category\", \"description\": \"Patient Counseling Information consists of guidance provided to patients regarding the usage and side effects of BRIVIACT.<SEP>Patient Counseling Information is a comprehensive resource that encompasses essential guidelines and advice aimed at ensuring the safe and effective use of various medications. It covers important aspects such as safe usage, potential side effects, necessary precautions, and monitoring recommendations, which are critical for patients undergoing treatment.\\n\\nFor instance, it provides detailed guidelines for medications such as VANTRELA ER and hydrocodone, emphasizing the importance of safe usage and the risks associated with misuse. Similarly, it includes specific instructions related to the usage and monitoring of XPOVIO, which focuses on potential side effects that patients should be aware of.\\n\\nIn addition to these medications, Patient Counseling Information offers guidance on DAYTRANA, outlining its safe use and the implications of treatment. Detailed information is also provided for OPANA ER, ensuring that healthcare providers can effectively communicate the associated risks and benefits to patients, thus keeping them well-informed.\\n\\nOther medications covered include EMBEDA, where guidelines emphasize proper storage and disposal methods along with potential risks, and LAMISIL Tablets, which highlight necessary precautions and the significance of health monitoring during LAMISIL therapy. Additionally, guidance is offered for ENTYVIO, focusing on proper use and possible side effects, as well as SEROQUEL XR, which includes important side effect information and monitoring recommendations.\\n\\nOverall, Patient Counseling Information is designed to enhance patient safety and understanding, summarizing necessary information about symptoms to monitor, drug interactions, and how patients should be informed about their treatment and potential reactions. It serves as a vital tool for both patients and healthcare providers in promoting safe medication practices.<SEP>Patient counseling information involves guidelines provided to patients regarding the use, benefits, and risks associated with medications.<SEP>Patient counseling information includes guidance for patients about the use of medications, their storage, risks, and disposal instructions.<SEP>Patient Counseling Information includes details necessary for safe and effective use of DIACOMIT, ensuring patients are well-informed about the medication.\", \"rank\": 18, \"created_at\": \"2025-05-19 17:18:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"10\", \"entity\": \"VANTRELA ER\", \"type\": \"organization\", \"description\": \"VANTRELA ER is an extended-release brand of hydrocodone bitartrate, specifically developed for the management of chronic pain. This medication is classified as a Schedule II controlled substance, reflecting its potential for abuse and dependency. VANTRELA ER is administered in tablet form, with dosing generally conducted every 12 hours. It is designed for use in both opioid-naïve and opioid-experienced patients, making it suitable for a wide range of individuals requiring long-term opioid treatment for severe pain.\\n\\nThe medication operates under stringent FDA regulations and guidelines, necessitating careful monitoring during therapy. It is important to follow specific dosage adjustments based on individual patient conditions and possible drug interactions, especially with other central nervous system (CNS) depressants. VANTRELA ER has a profile of pharmacokinetic properties that have been studied for their implications regarding abuse potential and opioid conversion.\\n\\nPatients using VANTRELA ER must be aware of its associated risks, which include side effects such as respiratory depression, adrenal insufficiency, QT interval prolongation, and other serious complications such as chest pain and confusion. Due to these risks, healthcare providers are advised to carefully monitor patients throughout the duration of their treatment with VANTRELA ER.\\n\\nThe medication is distributed by Teva Pharmaceuticals and is recognized as a strong prescription opioid analgesic intended to relieve severe pain that necessitates extended management strategies.\", \"rank\": 121, \"created_at\": \"2025-05-19 16:37:20\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"11\", \"entity\": \"Selective Serotonin Reuptake Inhibitors (SSRIs)\", \"type\": \"category\", \"description\": \"SSRIs are a class of drugs commonly used to treat depression by increasing serotonin levels in the brain.<SEP>SSRIs are a type of serotonergic drug used to treat depression and anxiety, which can interact with opioids.\", \"rank\": 1, \"created_at\": \"2025-05-19 17:15:32\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf\"}, {\"id\": \"12\", \"entity\": \"TREXIMET\", \"type\": \"organization\", \"description\": \"TREXIMET is a prescription medication that combines sumatriptan and naproxen sodium for the acute treatment of migraine headaches in adults and pediatric patients aged 12 years and older. This combination drug is used primarily to provide relief for established migraine headaches and demonstrates significant efficacy in clinical studies compared to placebo. However, TREXIMET is associated with various serious medical warnings, contraindications, and potential side effects, including risks of liver dysfunction, hypertension, cardiovascular events such as heart attack and stroke, as well as gastrointestinal issues.\\n\\nIt is indicated specifically for treating migraines but also helps prevent headache recurrence. Patients using TREXIMET should be aware of the potential for adverse effects such as hepatotoxicity, anaphylactic reactions, and fetal toxicity in pregnant patients. Due to its combination of naproxen and sumatriptan, healthcare professionals may consider specific patient groups and caution against its use in individuals with certain medical conditions. Overall, TREXIMET is an effective option for those seeking relief from acute migraine attacks while necessitating careful consideration of its associated risks.\", \"rank\": 136, \"created_at\": \"2025-05-19 16:12:40\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf\"}, {\"id\": \"13\", \"entity\": \"Initial Dosing\", \"type\": \"category\", \"description\": \"Initial Dosing outlines the recommended starting dosage for VANTRELA ER in both opioid-naïve and opioid-tolerant patients.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:38:55\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"14\", \"entity\": \"Clinical Trials\", \"type\": \"event\", \"description\": \"Clinical Trials are structured research studies designed to evaluate the efficacy and safety of various medications across diverse patient populations. They play a critical role in advancing medical knowledge and enhancing treatment protocols. Among the medications studied in Clinical Trials are ROZEREM, specifically evaluated for its effectiveness in treating insomnia, with a focus on sleep latency and overall efficacy.\\n\\nFurthermore, Clinical Trials extensively examined SEROQUEL and its extended-release formulation, SEROQUEL XR, aimed at treating mental health conditions such as bipolar mania, bipolar depression, schizophrenia, and major depressive disorder (MDD). These trials employ rigorous methodologies, including randomized double-blind and placebo-controlled designs, to ensure the reliability of results. They not only assess the therapeutic effectiveness of SEROQUEL and SEROQUEL XR but also monitor potential adverse reactions and side effects, particularly in pediatric psychiatric disorders.\\n\\nOther medications that have been evaluated in Clinical Trials include REMICADE, studied for its effectiveness and safety across various diseases, and BRIVIACT, which has been tested for its safety and efficacy in adult epilepsy patients, particularly focusing on adverse reactions including psychiatric symptoms and suicidal thoughts. Additionally, medications such as ertugliflozin and sitagliptin have undergone trials aimed at assessing their safety and effectiveness in improving patient health.\\n\\nSpecific to attention-deficit/hyperactivity disorder (ADHD), Clinical Trials have assessed the efficacy and safety of STRATTERA in both pediatric and adult populations. These studies revealed risks associated with its use, particularly emphasizing its effect on children and adolescents.\\n\\nFurthermore, BANZEL has also been evaluated in Clinical Trials, contributing valuable insights regarding its safety and therapeutic profile. Overall, Clinical Trials are a vital component of the medical research landscape, systematically evaluating the therapeutic benefits and safety profiles of a broad spectrum of medications. This comprehensive process ensures a thorough understanding of both the benefits and potential risks associated with new and existing treatments, ultimately aimed at improving healthcare approaches for various health conditions.<SEP>Clinical Trials involved assessments of ULTRACET's efficacy and adverse effects among subjects.<SEP>Clinical Trials are structured studies conducted to assess the safety and efficacy of new drugs, including AEDs, in various patient populations.<SEP>Clinical Trials provide data on the safety, effectiveness, and adverse reactions associated with DIACOMIT treatments.<SEP>Clinical trials are research studies performed on patients to evaluate a medical, surgical, or behavioral intervention, specifically for DIACOMIT's efficacy in treating seizures.\", \"rank\": 58, \"created_at\": \"2025-05-19 17:18:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ROZEREM_RAMELTEON_TABLET_ORAL_21782_TAKEDA_PHARMS_USA_11-03-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"15\", \"entity\": \"Renal Impairment\", \"type\": \"category\", \"description\": \"Renal Impairment assesses the effects and considerations for administering DIACOMIT in patients with kidney issues.<SEP>Renal Impairment describes a medical condition characterized by the decreased ability of the kidneys to function effectively. This impairment necessitates careful management, particularly regarding the dosing of various medications, including TURALIO. Affected patients often require dosage adjustments because renal impairment significantly alters the pharmacokinetics, metabolism, and clearance of numerous drugs. \\n\\nThe implications of renal impairment extend to many medications, highlighting its relevance in clinical care. For instance, patients treated with therapies like LUMOXITI can experience renal impairment, with approximately 1.6% presenting this condition. Other drugs that necessitate dosage modifications due to renal function decline include VANTRELA ER, OPANA ER, BAXDELA, morphine, Plavix, naproxen, TREXIMET, LAMISIL Tablets, and BENLYSTA. Additionally, specific medications, such as sitagliptin, ertugliflozin, and tacrolimus, are also influenced by renal function, affecting their dosing and overall effectiveness. Conversely, some medications like BRIVIACT and ROZEREM do not require dosage adjustments although caution is still advised due to potential safety concerns.\\n\\nThe management of medications in individuals with renal impairment is complex, as the effects vary widely among different drugs. For instance, while thalidomide shows minimal effects from renal impairment, drugs like trazodone and terbinafine still require further investigation regarding their efficacy in this population. \\n\\nIn summary, Renal Impairment is a condition that results in diminished kidney function, impacting not only the treatment strategies employed for various medications—such as adalimumab and tramadol—but also necessitating a personalized medical approach to optimize treatment outcomes while minimizing risks. Tailoring treatment strategies is essential for effective management of patients suffering from reduced kidney function, underscoring the role of healthcare providers in navigating the challenges associated with this condition.<SEP>Renal impairment is a condition that necessitates adjustments or considerations when prescribing DIACOMIT.\", \"rank\": 40, \"created_at\": \"2025-05-19 17:18:49\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STEGLUJAN_ERTUGLIFLOZIN__SITAGLIPTIN_PHOSPHATE_TABLET_ORAL_209805_MERCK_SHARP_DOHME_12-20-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ROZEREM_RAMELTEON_TABLET_ORAL_21782_TAKEDA_PHARMS_USA_11-03-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf\"}, {\"id\": \"16\", \"entity\": \"Prescription Instructions\", \"type\": \"category\", \"description\": \"Prescription instructions for LAMISIL Tablets include guidance on dosage and side effects to ensure safe usage.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"17\", \"entity\": \"10 mg Tablets\", \"type\": \"event\", \"description\": \"10 mg Tablets refer to the specific dosage form of IBSRELA used for treatment.\", \"rank\": 0, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"18\", \"entity\": \"Dosage Instructions\", \"type\": \"category\", \"description\": \"Dosage Instructions include specific guidelines on how to properly take BRIVIACT with food and liquid.<SEP>Dosage Instructions provide guidelines on how to properly take medications, which are critical for the safe use of medications like OPANA ER.<SEP>Dosage instructions provide guidance on how to take LAMISIL Tablets effectively for treating fungal infections, including the recommended frequency and duration of use.<SEP>Dosage instructions for ADDERALL vary based on the age and responsiveness of the patient.<SEP>Dosage instructions outline the amount and timing for taking BRIVIACT as directed by the healthcare provider.\", \"rank\": 5, \"created_at\": \"2025-05-19 16:47:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ADDERALL_10_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"19\", \"entity\": \"Treatment Guidelines\", \"type\": \"category\", \"description\": \"Treatment guidelines outline the recommended usage and precautions for prescribing IBSRELA to patients with IBS-C.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"20\", \"entity\": \"IBSRELA\", \"type\": \"organization\", \"description\": \"IBSRELA is the brand name for a medication containing tenapanor hydrochloride, specifically designed for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults. It aims to alleviate symptoms such as abdominal pain and improve bowel movement frequencies by inhibiting sodium absorption in the intestines. IBSRELA has been evaluated in clinical settings and clinical trials for its efficacy in managing IBS-C, along with the potential for adverse reactions and drug interactions. As a prescription medication, it is crucial for patients to adhere to prescribed dosing instructions and be aware of any possible side effects. Additionally, specific storage instructions are advised to maintain the medication's efficacy. Overall, IBSRELA is positioned as a management option for individuals dealing with certain gastrointestinal conditions, particularly IBS.\", \"rank\": 42, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"21\", \"entity\": \"Dosage and Administration Guidelines\", \"type\": \"category\", \"description\": \"Dosage and administration guidelines provide critical information on how to safely prescribe and dispense TUXARIN ER.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:24:02\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf\"}, {\"id\": \"22\", \"entity\": \"Instructions for Administration\", \"type\": \"category\", \"description\": \"Instructions for Administration provide vital information on how to properly take EMBEDA to avoid serious side effects and risks such as overdose or withdrawal.\", \"rank\": 1, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"23\", \"entity\": \"Dosage Changes\", \"type\": \"event\", \"description\": \"Dosage changes refer to adjustments in the amount of medication prescribed, which can influence the emergence of side effects or other symptoms in patients.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"24\", \"entity\": \"FDA-approved patient labeling\", \"type\": \"document\", \"description\": \"The FDA-approved patient labeling serves as a crucial resource for patients, containing important information about various medications. It encompasses details about each medication's uses, potential side effects, and instructions for proper administration. Specifically, the labeling includes guidelines for patients taking IBSRELA, ensuring they understand the medication's usage. Additionally, it provides essential information regarding the use, risks, and administration of XYOSTED, as well as ZENPEP, highlighting the necessity of following appropriate usage protocols. The labeling also includes critical information about TURALIO, detailing its usage, risks, and the requirements for patient monitoring. Overall, FDA-approved patient labeling is designed to enhance patient understanding and adherence to prescribed therapies by offering comprehensive insight into the medications they are using.\", \"rank\": 6, \"created_at\": \"2025-05-19 17:09:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf\"}, {\"id\": \"25\", \"entity\": \"IBS-C\", \"type\": \"category\", \"description\": \"IBS-C refers to Irritable Bowel Syndrome with Constipation, the condition for which IBSRELA is evaluated as a treatment.<SEP>IBS-C refers to irritable bowel syndrome with constipation, a condition for which IBSRELA is indicated for treatment.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"26\", \"entity\": \"Safety Instructions\", \"type\": \"category\", \"description\": \"Safety Instructions provide guidelines on what to do in case of overdose or side effects associated with STRATTERA.\", \"rank\": 1, \"created_at\": \"2025-05-19 17:07:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf\"}, {\"id\": \"27\", \"entity\": \"Diarrhea\", \"type\": \"category\", \"description\": \"Diarrhea is a common gastrointestinal symptom characterized by frequent and watery bowel movements, often indicating digestive issues.<SEP>Diarrhea is a condition characterized by frequent, watery bowel movements and is commonly associated with various gastrointestinal issues. It is recognized as a prevalent adverse reaction reported by patients using certain medications, particularly IBSRELA, where it is noted as the most common side effect. The severity of diarrhea can vary among patients and may lead to complications such as dehydration, especially when associated with overdose or in sensitive populations.\\n\\nIn addition to IBSRELA, diarrhea has been documented as a gastrointestinal side effect in clinical trials for several other medications. For instance, it has been reported as a common adverse reaction to XPOVIO, requiring interventions depending on the severity of the condition. Similarly, in trials for BENLYSTA and LAMISIL, diarrhea was frequently observed as an adverse event, indicating its significant impact on gastrointestinal health in those undergoing treatment.\\n\\nMoreover, the antibiotic BAXDELA has also been linked to diarrhea, which may persist even after the medication has been discontinued, highlighting the importance of monitoring this side effect in clinical settings. Overall, diarrhea is a notable concern in patient management and outcomes across various treatments, necessitating awareness and appropriate interventions by healthcare professionals.<SEP>Diarrhea is a condition characterized by frequent and watery bowel movements, which can result in dehydration and other health complications.<SEP>Diarrhea is one of the adverse reactions commonly experienced by patients taking ASTAGRAF XL, affecting a considerable percentage of patients as outlined in the study results.\", \"rank\": 9, \"created_at\": \"2025-05-19 16:53:00\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"28\", \"entity\": \"Irritable Bowel Syndrome with Constipation (IBS-C)\", \"type\": \"category\", \"description\": \"IBS-C is a gastrointestinal disorder characterized by constipation and is the primary condition treated by IBSRELA.<SEP>IBS-C is a medical condition characterized by chronic abdominal pain and constipation, which IBSRELA is designed to treat.<SEP>Irritable Bowel Syndrome with Constipation (IBS-C) is a medical condition characterized by chronic abdominal pain and constipation.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"29\", \"entity\": \"Flatulence\", \"type\": \"category\", \"description\": \"Flatulence is a reported side effect of IBSRELA usage, as part of the common adverse reactions.<SEP>Flatulence is the accumulation of gas in the digestive tract that leads to the expulsion of gas through the rectum.\", \"rank\": 2, \"created_at\": \"2025-05-19 16:20:28\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"30\", \"entity\": \"Severe Diarrhea\", \"type\": \"adverse reaction\", \"description\": \"Severe diarrhea was identified as an adverse reaction affecting a percentage of patients treated with IBSRELA.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"31\", \"entity\": \"Constipation\", \"type\": \"symptom\", \"description\": \"Constipation is a common digestive condition characterized by infrequent or difficult bowel movements. It may lead to serious complications, such as paralytic ileus or intestinal obstruction, particularly when associated with certain medications. Patients often experience constipation as a symptom related to gastrointestinal disorders, which can cause discomfort and pain. \\n\\nIn clinical settings, constipation has been noted as a side effect in patients treated with THALOMID, resulting in difficulties in achieving regular bowel movements. Similarly, constipation has been identified as a side effect of SEROQUEL XR, specifically reported in clinical trials at the 300 mg dosage. It is recognized as a frequently reported issue among individuals taking SEROQUEL XR treatment, highlighting the need for awareness and management of this condition.<SEP>Constipation is another adverse reaction reported in patients taking ASTAGRAF XL, showing significant rates in the context of the study.<SEP>Constipation is a frequently reported side effect in STRATTERA-treated patients, noted for its clinical relevance.\", \"rank\": 5, \"created_at\": \"2025-05-19 17:07:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf\"}, {\"id\": \"32\", \"entity\": \"Dosing Instructions\", \"type\": \"category\", \"description\": \"Dosing Instructions are guidelines provided to patients on how to correctly take BANZEL for optimal effectiveness and safety.<SEP>Dosing instructions provide detailed protocols on how to administer ZENPEP, including specific dosages for different age groups.\", \"rank\": 4, \"created_at\": \"2025-05-19 16:57:03\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"33\", \"entity\": \"Dosage and Administration\", \"type\": \"category\", \"description\": \"Dosage and Administration outlines recommended dosages for TURALIO, adjustments required for adverse reactions, and considerations regarding food intake.<SEP>The \\\"Dosage and Administration\\\" section provides a comprehensive overview of the recommended dosages and administration methods for a variety of medications, ensuring safe and effective usage tailored to specific patient needs. It includes detailed guidance for the administration of the drug HULIO for particular conditions, and also covers Rufinamide, emphasizing its absorption characteristics under various circumstances.\\n\\nAdditionally, the section elaborates on the administration protocols for VANTRELA ER, including dosing intervals and adjustment recommendations. For EPZICOM, it specifies that the medication is taken orally as a fixed-dose tablet once daily. The guidelines also detail the correct prescribing and administration techniques for TREXIMET, taking into account different patient groups and relevant factors.\\n\\nZENPEP's administration guidelines stress the importance of clinical assessments and individualized patient needs. RITUXAN HYCELA’s recommendations provide specific protocols for proper patient administration. FOSRENOL's guidelines recommend initial doses and titration based on serum phosphate levels, while DAYTRANA emphasizes the appropriate application and removal processes. Oxymorphone administration is governed by pharmaceutical guidelines that highlight patient evaluation and the understanding of risk factors to ensure safe use of EMBEDA.\\n\\nFurthermore, IBSRELA is to be taken at a dosage of 50 mg twice daily, and TUXARIN ER's guidelines ensure its correct usage based on outlined recommendations. Finally, the section also encompasses guidance for BANZEL, detailing indications for treatment and the importance of patient monitoring.\\n\\nOverall, the \\\"Dosage and Administration\\\" guidelines are crucial for achieving optimal therapeutic outcomes across these medications, providing detailed recommendations that help healthcare providers in their prescribing and administrative practices.<SEP>Dosage and administration provides guidelines on how to appropriately prescribe and use a medication like ALKINDI SPRINKLE.<SEP>Dosage and Administration refers to the guidelines provided to ensure safe and effective use of ULTRACET.<SEP>Dosage and Administration refers to the section in medication labeling that provides information on how a drug should be used, including dosing guidelines and related instructions.\", \"rank\": 16, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf\"}, {\"id\": \"34\", \"entity\": \"Weekly Treatment Regimen\", \"type\": \"category\", \"description\": \"Weekly treatment regimen refers to the schedule by which the IBSRELA medication is administered to patients in the trials.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"35\", \"entity\": \"dosage and administration\", \"type\": \"category\", \"description\": \"Dosage and administration refer to guidelines for using medications, highlighting the importance of individualized dosing based on patient needs.\", \"rank\": 0, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf\"}, {\"id\": \"36\", \"entity\": \"Prescription Information\", \"type\": \"category\", \"description\": \"Prescription Information includes guidelines on the safe usage of LAMISIL Tablets, including indications and contraindications.<SEP>Prescription information provides crucial guidelines for safely and effectively using ALKINDI SPRINKLE, including indications and dosage recommendations.\", \"rank\": 2, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"37\", \"entity\": \"Gastrointestinal Disorders\", \"type\": \"category\", \"description\": \"Gastrointestinal Disorders encompass a broad spectrum of conditions that impact the digestive system, including the stomach and intestines. These disorders can be aggravated by various factors, including the use of specific medications such as corticosteroids, LAMISIL, BAXDELA, OPANA ER, LUMOXITI, THALOMID, VANTRELA ER, and STRATTERA. Common symptoms associated with these disorders include abdominal pain, nausea, vomiting, constipation, diarrhea, dyspepsia, and dry mouth. Severe conditions such as gastrointestinal hemorrhage, pancreatitis, colitis, and other gastrointestinal issues are notable among these disorders and may arise as adverse effects linked to certain treatments. In particular, kidney transplant patients may experience gastrointestinal adverse reactions that require careful monitoring. Clinical trials have demonstrated that these disorders can significantly affect patient health and treatment outcomes, underscoring the importance of managing and understanding gastrointestinal health within the context of various therapeutic interventions. Overall, Gastrointestinal Disorders represent a complex interplay of symptoms and reactions that impair digestive health and necessitate vigilant observation during treatment.\", \"rank\": 13, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"38\", \"entity\": \"Rome III criteria\", \"type\": \"category\", \"description\": \"Rome III criteria are the guidelines used to diagnose Irritable Bowel Syndrome, applicable in the trials for IBSRELA.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"39\", \"entity\": \"Colloidal Silicon Dioxide\", \"type\": \"category\", \"description\": \"Colloidal Silicon Dioxide is an inactive ingredient included in the composition of IBSRELA to aid in its formulation.<SEP>Colloidal Silicon Dioxide is an inactive ingredient used in the formulation of XPOVIO tablets, contributing to the drug's stability and texture.<SEP>Colloidal silicon dioxide is an inactive ingredient used in the formulation of trazodone hydrochloride tablets that helps to keep the active ingredients stable and effective.\", \"rank\": 3, \"created_at\": \"2025-05-19 16:07:54\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"40\", \"entity\": \"Serious Dehydration Risk\", \"type\": \"category\", \"description\": \"Serious dehydration risk is a significant concern highlighted in the prescribing information regarding the use of IBSRELA in pediatric patients.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"41\", \"entity\": \"FDA Medication Guide\", \"type\": \"document\", \"description\": \"The FDA Medication Guide provides important information regarding the use and side effects of LAMISIL Oral Granules.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"42\", \"entity\": \"Dosage Modification Guidelines\", \"type\": \"category\", \"description\": \"Dosage Modification Guidelines are criteria established to adjust medication dosages based on patient reactions, crucial for safe administration of XPOVIO.\", \"rank\": 1, \"created_at\": \"2025-05-19 15:36:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"43\", \"entity\": \"Rome III Criteria for IBS-C\", \"type\": \"category\", \"description\": \"Rome III Criteria for IBS-C are guidelines defining diagnosis and inclusion criteria for patients in IBSRELA trials.\", \"rank\": 2, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"44\", \"entity\": \"Abdominal Distension\", \"type\": \"adverse_reaction\", \"description\": \"Abdominal distension is another adverse reaction associated with IBSRELA, which patients may experience during the treatment.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"45\", \"entity\": \"Table 13\", \"type\": \"event\", \"description\": \"Table 13 contains efficacy results from the BOSTON trial as assessed by the Independent Review Committee (IRC).<SEP>Table 13 summarizes adverse reactions during a different phase of trials focused on bipolar mania, noting incidence rates of side effects for SEROQUEL XR.<SEP>Table 13 details the maintenance of clinical remission outcomes for patients in Study CD-III comparing adalimumab and placebo.\", \"rank\": 4, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"46\", \"entity\": \"SSRIs\", \"type\": \"category\", \"description\": \"SSRIs are selective serotonin reuptake inhibitors, a class of drugs commonly prescribed for depression and anxiety disorders.<SEP>Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of antidepressants that can interact with Trazodone, potentially leading to Serotonin Syndrome.<SEP>Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants linked to various bleeding events and side effects.<SEP>Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that affect serotonin levels in the brain and can impact platelet activation when combined with clopidogrel.\", \"rank\": 3, \"created_at\": \"2025-05-19 16:28:12\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET_ORAL_5378_RECORDATI_RARE_10-13-2023.pdf\"}, {\"id\": \"47\", \"entity\": \"Ulcerative Colitis\", \"type\": \"category\", \"description\": \"Ulcerative Colitis (UC) is a chronic inflammatory bowel disease characterized by long-lasting inflammation and ulcers primarily in the colon and rectum. This condition significantly impacts patients' quality of life, often leading to severe symptoms such as diarrhea and abdominal pain. Ulcerative Colitis can affect both adult and pediatric populations, with specific dosing recommendations available for medications used in treatment.\\n\\nTreatment options include various therapies, notably medications such as REMICADE (an Infliximab-based medication), ENTYVIO, and HULIO, which is associated with a specific dosing regimen for adults. Additionally, other medications like adalimumab are also utilized in the management of this condition. It is crucial for healthcare providers to monitor patients receiving HULIO due to potential malignancy risks associated with the therapy.\\n\\nClinical trials have been conducted to examine the efficacy of these medications, including REMICADE, while also evaluating potential adverse reactions. Overall, managing Ulcerative Colitis presents significant challenges and requires careful treatment strategies to help alleviate its debilitating symptoms.\", \"rank\": 8, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"48\", \"entity\": \"Non-Psychotic Symptoms\", \"type\": \"category\", \"description\": \"Non-psychotic symptoms include irritability, anxiety, and mood swings, which were reported as adverse reactions during BRIVIACT clinical trials.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:47:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"49\", \"entity\": \"Storage and Disposal Instructions\", \"type\": \"category\", \"description\": \"Storage and disposal instructions provide guidance on how to properly store medications and dispose of them safely.\", \"rank\": 1, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"50\", \"entity\": \"MEDICATION GUIDE\", \"type\": \"event\", \"description\": \"The Medication Guide provides essential information regarding the use and risks associated with BAXDELA, including serious side effects and instructions for use.\", \"rank\": 2, \"created_at\": \"2025-05-19 15:17:31\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"51\", \"entity\": \"Table 12\", \"type\": \"event\", \"description\": \"Table 12 presents data on adverse reactions observed in patients during clinical trials for SEROQUEL XR, summarizing incidence rates of various side effects.<SEP>Table 12 provides outcomes by baseline pathogen in the CABP Trial 3, detailing early clinical responses and success rates.<SEP>Table 12 provides data on MMF dosages by time period and patient population in the context of ASTAGRAF XL treatment.<SEP>Table 12 summarizes the induction of clinical remission outcomes for Crohn’s Disease patients in Studies CD-I and CD-II.\", \"rank\": 6, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"52\", \"entity\": \"Selective Serotonin Reuptake Inhibitors (SSRIs)\", \"type\": \"category\", \"description\": \"SSRIs are a class of drugs commonly used to treat depression by increasing serotonin levels in the brain.<SEP>SSRIs are a type of serotonergic drug used to treat depression and anxiety, which can interact with opioids.\", \"rank\": 1, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf\"}, {\"id\": \"53\", \"entity\": \"Patient Counseling Information\", \"type\": \"category\", \"description\": \"Patient Counseling Information consists of guidance provided to patients regarding the usage and side effects of BRIVIACT.<SEP>Patient Counseling Information is a comprehensive resource that encompasses essential guidelines and advice aimed at ensuring the safe and effective use of various medications. It covers important aspects such as safe usage, potential side effects, necessary precautions, and monitoring recommendations, which are critical for patients undergoing treatment.\\n\\nFor instance, it provides detailed guidelines for medications such as VANTRELA ER and hydrocodone, emphasizing the importance of safe usage and the risks associated with misuse. Similarly, it includes specific instructions related to the usage and monitoring of XPOVIO, which focuses on potential side effects that patients should be aware of.\\n\\nIn addition to these medications, Patient Counseling Information offers guidance on DAYTRANA, outlining its safe use and the implications of treatment. Detailed information is also provided for OPANA ER, ensuring that healthcare providers can effectively communicate the associated risks and benefits to patients, thus keeping them well-informed.\\n\\nOther medications covered include EMBEDA, where guidelines emphasize proper storage and disposal methods along with potential risks, and LAMISIL Tablets, which highlight necessary precautions and the significance of health monitoring during LAMISIL therapy. Additionally, guidance is offered for ENTYVIO, focusing on proper use and possible side effects, as well as SEROQUEL XR, which includes important side effect information and monitoring recommendations.\\n\\nOverall, Patient Counseling Information is designed to enhance patient safety and understanding, summarizing necessary information about symptoms to monitor, drug interactions, and how patients should be informed about their treatment and potential reactions. It serves as a vital tool for both patients and healthcare providers in promoting safe medication practices.<SEP>Patient counseling information involves guidelines provided to patients regarding the use, benefits, and risks associated with medications.<SEP>Patient counseling information includes guidance for patients about the use of medications, their storage, risks, and disposal instructions.<SEP>Patient Counseling Information includes details necessary for safe and effective use of DIACOMIT, ensuring patients are well-informed about the medication.\", \"rank\": 18, \"created_at\": \"2025-05-19 17:19:59\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"54\", \"entity\": \"Serotonin Reuptake Inhibitors\", \"type\": \"category\", \"description\": \"Serotonin reuptake inhibitors (SSRIs) are a class of medications used primarily to treat depression and anxiety by increasing serotonin levels in the brain.\", \"rank\": 0, \"created_at\": \"2025-05-19 16:15:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf\"}, {\"id\": \"55\", \"entity\": \"dosage adjustments\", \"type\": \"category\", \"description\": \"Dosage adjustments are necessary in various medical situations, such as acute illnesses, to ensure safe and effective treatment.\", \"rank\": 2, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf\"}, {\"id\": \"56\", \"entity\": \"Dosage Guidelines\", \"type\": \"category\", \"description\": \"Dosage Guidelines refer to recommended practices for administering ULTRACET to minimize risks, particularly concerning respiratory depression and overdose.<SEP>Dosage guidelines for TUXARIN ER specify administration for adults only, highlighting the necessity for careful patient selection.<SEP>Dosage guidelines provide detailed instructions for the administration of Thalidomide, including capsule strengths and usage directions.\", \"rank\": 3, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf\"}, {\"id\": \"57\", \"entity\": \"Approved Recommended Dosage\", \"type\": \"category\", \"description\": \"The approved recommended dosage represents the officially sanctioned amount of LUMOXITI administered to patients for maximum efficacy.\", \"rank\": 0, \"created_at\": \"2025-05-19 15:43:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"58\", \"entity\": \"Stearic Acid\", \"type\": \"category\", \"description\": \"Stearic Acid is included in IBSRELA as an inactive ingredient, serving as a lubricant in tablet formulation.<SEP>Stearic acid is an inactive ingredient commonly used in pharmaceuticals as a lubricant or to maintain the consistency of the formulation.\", \"rank\": 2, \"created_at\": \"2025-05-19 16:28:12\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DESOXYN_METHAMPHETAMINE_HYDROCHLORIDE_TABLET_ORAL_5378_RECORDATI_RARE_10-13-2023.pdf\"}, {\"id\": \"59\", \"entity\": \"Agitation and Irritability Changes\", \"type\": \"category\", \"description\": \"Agitation and irritability are symptoms that may emerge in patients taking TRAZODONE, prompting monitoring by caregivers to ensure patient safety.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:07:54\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf\"}, {\"id\": \"60\", \"entity\": \"Recommended Dosage\", \"type\": \"category\", \"description\": \"Recommended Dosage specifies the optimal dosing regimen for TURALIO to enhance its effectiveness and reduce the risks of adverse reactions.<SEP>The recommended dosage for LUMOXITI is 0.04 mg/kg administered as an intravenous infusion over 30 minutes on specified days.\", \"rank\": 5, \"created_at\": \"2025-05-19 17:09:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"61\", \"entity\": \"Dosage Forms and Strengths\", \"type\": \"category\", \"description\": \"Dosage Forms and Strengths categorizes the various available strengths of Trazodone hydrochloride tablets which can be prescribed based on individual patient needs.<SEP>Dosage Forms and Strengths refer to the different available strengths of VANTRELA ER, including 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg extended-release tablets.<SEP>Dosage Forms and Strengths refer to the specifications regarding the form and amount of Infliximab administered to patients.<SEP>Dosage forms and strengths describe the available formulations of BRIVIACT, including tablets and injections in various dosages like 10 mg to 100 mg.<SEP>Refers to the specific preparations of HULIO that are available, including multiple strengths and forms for administration.\", \"rank\": 4, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"62\", \"entity\": \"IR Morphine Sulfate\", \"type\": \"organization\", \"description\": \"IR Morphine Sulfate refers to immediate-release morphine sulfate used as a comparison in studies for assessing drug liking and high scores.\", \"rank\": 2, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"63\", \"entity\": \"Low-Substituted Hydroxypropyl Cellulose\", \"type\": \"category\", \"description\": \"Low-Substituted Hydroxypropyl Cellulose is an inactive ingredient in IBSRELA, contributing to its stability and absorption.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"64\", \"entity\": \"Dosing Schedule\", \"type\": \"category\", \"description\": \"Dosing Schedule comprises the specific plan for medication administration which varies by patient needs and specific treatment protocols.<SEP>Dosing schedule refers to the specified timing and dosage of medications; in this case, LUMOXITI is administered on specific days of a cycle.\", \"rank\": 2, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"65\", \"entity\": \"Tartaric Acid\", \"type\": \"category\", \"description\": \"Tartaric Acid is also an inactive ingredient in IBSRELA that helps in the manufacturing process of the tablets.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"66\", \"entity\": \"ZICOM\", \"type\": \"category\", \"description\": \"ZICOM is a medication that the instructions recommend taking as prescribed by a healthcare provider to avoid complications related to dosing or missed doses.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:26:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf\"}, {\"id\": \"67\", \"entity\": \"Triacetin\", \"type\": \"category\", \"description\": \"Triacetin is an inactive ingredient in IBSRELA, which plays a role in the formulation and stability of the medication.\", \"rank\": 1, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}]\n",
      "```\n",
      "\n",
      "-----Relationships(KG)-----\n",
      "\n",
      "```json\n",
      "[{\"id\": \"1\", \"entity1\": \"Inflammatory Bowel Disease Questionnaire (IBDQ)\", \"entity2\": \"REMICADE\", \"description\": \"The IBDQ was used to assess the impact of REMICADE on quality of life and symptoms for patients with Crohn’s Disease.\", \"keywords\": \"patient assessment,treatment evaluation\", \"weight\": 9.0, \"rank\": 211, \"created_at\": \"2025-05-19 16:44:51\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"2\", \"entity1\": \"5 mg/kg\", \"entity2\": \"REMICADE\", \"description\": \"5 mg/kg is a specific dosage of REMICADE used in the study to assess its effects on UC patients.\", \"keywords\": \"dosage level,treatment assessment\", \"weight\": 8.0, \"rank\": 211, \"created_at\": \"2025-05-19 16:44:51\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"3\", \"entity1\": \"FDA\", \"entity2\": \"IBSRELA\", \"description\": \"The FDA is involved in the regulation of IBSRELA, ensuring its safety and overseeing reporting of side effects to protect patient health.<SEP>The FDA oversees the approval and regulation of IBSRELA to ensure safety and efficacy in treatment.\", \"keywords\": \"regulation,regulatory oversight,safety,safety oversight\", \"weight\": 18.0, \"rank\": 181, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"4\", \"entity1\": \"Adverse Reactions\", \"entity2\": \"IBSRELA\", \"description\": \"The occurrence of adverse reactions during IBSRELA treatment is monitored and reported, linking the medication to observed side effects.\", \"keywords\": \"effects,safety\", \"weight\": 8.0, \"rank\": 162, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"5\", \"entity1\": \"Patients\", \"entity2\": \"Trial 1\", \"description\": \"Patients in Trial 1 were assessed for their response to IBSRELA, indicating the study's focus on patient outcomes.\", \"keywords\": \"clinical trials,patient outcomes\", \"weight\": 8.0, \"rank\": 150, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"6\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"VANTRELA ER\", \"description\": \"Patient Counseling Information outlines instructions on the proper usage of VANTRELA ER, including dosage considerations.\", \"keywords\": \"patient safety,usage instructions\", \"weight\": 8.0, \"rank\": 139, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"7\", \"entity1\": \"Selective Serotonin Reuptake Inhibitors (SSRIs)\", \"entity2\": \"TREXIMET\", \"description\": \"TREXIMET should be discontinued if serotonin syndrome is suspected, particularly when combined with SSRIs.\", \"keywords\": \"drug safety,serotonin syndrome\", \"weight\": 10.0, \"rank\": 137, \"created_at\": \"2025-05-19 16:15:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TREXIMET_NAPROXEN_SODIUM__SUMATRIPTAN_SUCCINATE_TABLET_ORAL_21926_CURRAX_11-21-2024.pdf\"}, {\"id\": \"8\", \"entity1\": \"Initial Dosing\", \"entity2\": \"VANTRELA ER\", \"description\": \"Initial Dosing guidelines specify how to start treatment with VANTRELA ER for both opioid-naïve and opioid-tolerant patients.\", \"keywords\": \"dosing guidelines,treatment initiation\", \"weight\": 8.0, \"rank\": 122, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"9\", \"entity1\": \"Clinical Trials\", \"entity2\": \"IBSRELA\", \"description\": \"Clinical trials were conducted to demonstrate the safety and efficacy of IBSRELA in treating IBS-C.\", \"keywords\": \"drug evaluation,research study\", \"weight\": 8.0, \"rank\": 100, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"10\", \"entity1\": \"IBSRELA\", \"entity2\": \"Renal Impairment\", \"description\": \"The efficacy and safety of IBSRELA were analyzed in relation to patients with renal impairment during clinical trials.\", \"keywords\": \"clinical relevance,patient population\", \"weight\": 7.0, \"rank\": 82, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"11\", \"entity1\": \"Clinical Trials\", \"entity2\": \"Geriatric Use\", \"description\": \"Clinical trials are designed to assess the safety and effectiveness of IBSRELA, particularly considering the geriatric population of patients involved in these trials.<SEP>Clinical trials evaluated IBSRELA's effects specifically on elderly patients, highlighting geriatric safety and efficacy.\", \"keywords\": \"clinical evaluation,clinical research,elder considerations,elderly considerations\", \"weight\": 14.0, \"rank\": 79, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"12\", \"entity1\": \"IBSRELA\", \"entity2\": \"Medication Guide\", \"description\": \"The Medication Guide provides information on IBSRELA, including usage instructions and warnings, ensuring patient awareness.\", \"keywords\": \"health regulation,patient information\", \"weight\": 10.0, \"rank\": 78, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"13\", \"entity1\": \"IBSRELA\", \"entity2\": \"U.S. Food and Drug Administration\", \"description\": \"The U.S. Food and Drug Administration approved the Medication Guide for IBSRELA, ensuring its compliance with safety standards.\", \"keywords\": \"regulatory approval,safety compliance\", \"weight\": 8.0, \"rank\": 78, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"14\", \"entity1\": \"IBSRELA\", \"entity2\": \"Pediatric Patients\", \"description\": \"IBSRELA has specific contraindications regarding its use in pediatric patients under age 12 to prevent serious dehydration.<SEP>IBSRELA is contraindicated in pediatric patients under the age of 6, highlighting safety concerns for younger populations.\", \"keywords\": \"age restrictions,age-related precautions,safety,safety concerns\", \"weight\": 17.0, \"rank\": 74, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"15\", \"entity1\": \"IBSRELA\", \"entity2\": \"Warnings and Precautions\", \"description\": \"Warnings and Precautions inform clinicians about potential adverse reactions when prescribing IBSRELA.\", \"keywords\": \"clinical usage,safety guidelines\", \"weight\": 9.0, \"rank\": 74, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"16\", \"entity1\": \"Clinical Trials\", \"entity2\": \"Healthy Subjects\", \"description\": \"Healthy subjects were participants in the clinical studies designed to assess IBSRELA's efficacy, reflecting their health status in trials.\", \"keywords\": \"clinical assessment,trial participation\", \"weight\": 8.0, \"rank\": 69, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"17\", \"entity1\": \"Placebo\", \"entity2\": \"Trial 2\", \"description\": \"Placebo is utilized in Trial 2 to measure the difference in treatment impact between IBSRELA and a non-active treatment.<SEP>Placebo served as a control in Trial 2 to compare the effects of IBSRELA with those of an inactive intervention.\", \"keywords\": \"clinical comparison,clinical control,control group,trial methodology\", \"weight\": 14.0, \"rank\": 64, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"18\", \"entity1\": \"Placebo\", \"entity2\": \"Trial 1\", \"description\": \"Placebo serves as the control group in Trial 1 to compare the efficacy of IBSRELA against standard treatment for IBS-C.<SEP>Placebo was used as a control in Trial 1 to evaluate the efficacy of IBSRELA against natural recovery rates in patients.\", \"keywords\": \"clinical comparison,clinical control,control group,trial methodology\", \"weight\": 14.0, \"rank\": 62, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"19\", \"entity1\": \"IBSRELA\", \"entity2\": \"Trial 2\", \"description\": \"Trial 2 also evaluated IBSRELA's efficacy, indicating its relevance in both trials conducted.<SEP>Trial 2 similarly evaluates IBSRELA's effectiveness in improving symptoms of IBS-C, providing further data on its efficacy.<SEP>Trial 2 was conducted to further assess IBSRELA's safety and treatment outcomes over 12 weeks.\", \"keywords\": \"clinical evaluation,clinical study,clinical trial,continued evaluation,drug efficacy,medication assessment\", \"weight\": 26.0, \"rank\": 61, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"20\", \"entity1\": \"IBSRELA\", \"entity2\": \"Trial 1\", \"description\": \"The efficacy of IBSRELA was evaluated in Trial 1, focusing on responder rates in a double-blind study design.<SEP>Trial 1 assesses the efficacy of IBSRELA in treating IBS-C symptoms, including abdominal pain and bowel movement frequency.<SEP>Trial 1 evaluated the safety and efficacy of IBSRELA in treating patients over 26 weeks.\", \"keywords\": \"clinical evaluation,clinical study,clinical trial,drug efficacy,efficacy assessment,medication evaluation\", \"weight\": 27.0, \"rank\": 59, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"21\", \"entity1\": \"Clinical Trials\", \"entity2\": \"Placebo-Controlled Clinical Trials\", \"description\": \"The clinical trials for IBSRELA were conducted using a placebo-controlled methodology to accurately evaluate its effectiveness against IBS.\", \"keywords\": \"efficacy assessment,research methodology\", \"weight\": 8.0, \"rank\": 59, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"22\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"IBSRELA\", \"description\": \"The dosage and administration guidelines dictate how IBSRELA should be correctly used for optimal results.\", \"keywords\": \"guidelines,usage\", \"weight\": 8.0, \"rank\": 58, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"23\", \"entity1\": \"IBSRELA\", \"entity2\": \"Tenapanor\", \"description\": \"IBSRELA contains tenapanor as its active ingredient to treat irritable bowel syndrome.<SEP>IBSRELA is a medication that contains tenapanor as its active ingredient for treating IBS-C.<SEP>Tenapanor is the active ingredient in IBSRELA, which is crucial for its therapeutic effect on IBS-C.<SEP>Tenapanor is the active ingredient in IBSRELA, which is prescribed for managing irritable bowel syndrome symptoms.<SEP>Tenapanor is the active ingredient of IBSRELA and is responsible for its pharmacological effects.\", \"keywords\": \"active ingredient,medication,medication component,medication ingredient,therapy,treatment\", \"weight\": 47.0, \"rank\": 57, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"24\", \"entity1\": \"Dizziness\", \"entity2\": \"IBSRELA\", \"description\": \"Dizziness is identified as a common side effect of IBSRELA, affecting patient experience.\", \"keywords\": \"adverse effects,patient safety\", \"weight\": 7.0, \"rank\": 57, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"25\", \"entity1\": \"Contraindications\", \"entity2\": \"IBSRELA\", \"description\": \"There are specific contraindications for the use of IBSRELA, particularly regarding young patients and gastrointestinal issues.\", \"keywords\": \"guidelines,risk\", \"weight\": 9.0, \"rank\": 52, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"26\", \"entity1\": \"Diarrhea\", \"entity2\": \"IBSRELA\", \"description\": \"Diarrhea is a common side effect of IBSRELA, implying a direct medical concern related to the medication.<SEP>Diarrhea is a documented adverse reaction for patients using IBSRELA, highlighting treatment side effects.<SEP>Overdose of IBSRELA can lead to diarrhea, which is a significant adverse effect resulting from the pharmacological action of the drug.\", \"keywords\": \"adverse effects,health risk,overdose,patient safety,side effect\", \"weight\": 25.0, \"rank\": 51, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"27\", \"entity1\": \"FDA-approved patient labeling\", \"entity2\": \"IBSRELA\", \"description\": \"The FDA-approved patient labeling provides crucial information on the usage, benefits, and risks associated with taking IBSRELA.\", \"keywords\": \"patient information,regulatory compliance\", \"weight\": 9.0, \"rank\": 48, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"28\", \"entity1\": \"IBSRELA\", \"entity2\": \"pregnancy\", \"description\": \"The use of IBSRELA has implications for pregnant women, as safety during this condition needs to be assessed.\", \"keywords\": \"medical implications,pregnancy\", \"weight\": 8.0, \"rank\": 48, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"29\", \"entity1\": \"IBSRELA\", \"entity2\": \"United States\", \"description\": \"IBSRELA is relevant to the healthcare context of the United States, where it is prescribed for gastrointestinal conditions.\", \"keywords\": \"healthcare,pharmacology\", \"weight\": 8.0, \"rank\": 47, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"30\", \"entity1\": \"IBSRELA\", \"entity2\": \"Microcrystalline Cellulose\", \"description\": \"Microcrystalline Cellulose serves as a binder in IBSRELA's formulation, contributing to tablet integrity.\", \"keywords\": \"formulation,inactive ingredient\", \"weight\": 7.0, \"rank\": 46, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"31\", \"entity1\": \"IBSRELA\", \"entity2\": \"Titanium Dioxide\", \"description\": \"Titanium Dioxide provides color and coating for IBSRELA tablets, enhancing their appearance and marketability.\", \"keywords\": \"coating,inactive ingredient\", \"weight\": 6.0, \"rank\": 46, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"32\", \"entity1\": \"Hypromellose\", \"entity2\": \"IBSRELA\", \"description\": \"Hypromellose is included in IBSRELA for its role in formulation, ensuring proper tablet structure.\", \"keywords\": \"formulation,inactive ingredient\", \"weight\": 7.0, \"rank\": 45, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"33\", \"entity1\": \"Colloidal Silicon Dioxide\", \"entity2\": \"IBSRELA\", \"description\": \"Colloidal Silicon Dioxide is an inactive ingredient in IBSRELA, contributing to its stability and formulation.\", \"keywords\": \"formulation,inactive ingredient\", \"weight\": 7.0, \"rank\": 45, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"34\", \"entity1\": \"Ardelyx, Inc.\", \"entity2\": \"IBSRELA\", \"description\": \"IBSRELA is manufactured and distributed by Ardelyx, Inc., indicating a direct organizational responsibility for the product.<SEP>IBSRELA is produced and distributed by Ardelyx, Inc., indicating a direct manufacturing relationship.\", \"keywords\": \"distribution,manufacturing,product responsibility\", \"weight\": 18.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"35\", \"entity1\": \"IBSRELA\", \"entity2\": \"Rome III Criteria for IBS-C\", \"description\": \"The Rome III criteria were used to define eligibility for IBSRELA trials, establishing a standard for patient inclusion.\", \"keywords\": \"clinical trials,diagnostic criteria\", \"weight\": 9.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"36\", \"entity1\": \"IBSRELA\", \"entity2\": \"pediatric use\", \"description\": \"IBSRELA is contraindicated in children less than 6 years of age, indicating specific safety concerns in pediatric use.\", \"keywords\": \"medication standards,pediatric safety\", \"weight\": 7.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"37\", \"entity1\": \"Flatulence\", \"entity2\": \"IBSRELA\", \"description\": \"Flatulence is another common adverse reaction reported by patients using IBSRELA.\\\".\", \"keywords\": \"adverse effects,patient safety\", \"weight\": 7.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"38\", \"entity1\": \"IBSRELA\", \"entity2\": \"Propyl Gallate\", \"description\": \"Propyl Gallate acts as a preservative in IBSRELA, which is important for maintaining the medication's efficacy.\", \"keywords\": \"inactive ingredient,preservation\", \"weight\": 6.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"39\", \"entity1\": \"IBSRELA\", \"entity2\": \"Stearic Acid\", \"description\": \"Stearic Acid is included in IBSRELA to facilitate the manufacturing process of tablets.\", \"keywords\": \"inactive ingredient,manufacturing\", \"weight\": 6.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"40\", \"entity1\": \"IBSRELA\", \"entity2\": \"Irritable Bowel Syndrome with Constipation (IBS-C)\", \"description\": \"IBSRELA is indicated specifically for treating IBS-C, establishing a medical relationship between the drug and the condition.<SEP>IBSRELA is specifically indicated for the treatment of IBS-C in adults.<SEP>IBSRELA is specifically used as a treatment for Irritable Bowel Syndrome with Constipation (IBS-C).\", \"keywords\": \"indication,medical application,medical indication,treatment\", \"weight\": 30.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"41\", \"entity1\": \"IBS-C\", \"entity2\": \"IBSRELA\", \"description\": \"IBSRELA is evaluated specifically as a treatment for IBS-C, directly linking the drug to the condition being treated.<SEP>IBSRELA is specifically indicated for the treatment of IBS-C in adults, connecting the drug directly to the condition.\", \"keywords\": \"medical condition,medication use,treatment relationship\", \"weight\": 20.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"42\", \"entity1\": \"IBSRELA\", \"entity2\": \"Serious Dehydration Risk\", \"description\": \"There is a clearly stated risk of serious dehydration associated with the use of IBSRELA in pediatric patients.\", \"keywords\": \"contraindications,safety warnings\", \"weight\": 10.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"43\", \"entity1\": \"IBSRELA\", \"entity2\": \"Tenapanor Hydrochloride\", \"description\": \"Tenapanor Hydrochloride is the active ingredient in IBSRELA, which is essential for its function as a medication.\", \"keywords\": \"ingredient,therapeutic role\", \"weight\": 10.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"44\", \"entity1\": \"IBSRELA\", \"entity2\": \"Treatment Guidelines\", \"description\": \"Treatment guidelines provide essential information for prescribing IBSRELA, ensuring safe and effective use of the medication.\", \"keywords\": \"recommendations,treatment\", \"weight\": 9.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"45\", \"entity1\": \"IBSRELA\", \"entity2\": \"Severe Diarrhea\", \"description\": \"Severe diarrhea was reported as a common adverse reaction in IBSRELA clinical trials.\", \"keywords\": \"adverse reaction,clinical outcome\", \"weight\": 9.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"46\", \"entity1\": \"Ardelyx\", \"entity2\": \"IBSRELA\", \"description\": \"Ardelyx manufactures IBSRELA and is responsible for its market regulation and reporting of adverse effects.\", \"keywords\": \"manufacturing,regulatory responsibilities\", \"weight\": 9.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"47\", \"entity1\": \"IBSRELA\", \"entity2\": \"Severe Dehydration\", \"description\": \"Severe Dehydration can result from diarrhea caused by IBSRELA, highlighting the potential risk following its use.\", \"keywords\": \"health risk,side effect\", \"weight\": 8.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"48\", \"entity1\": \"Abdominal Distension\", \"entity2\": \"IBSRELA\", \"description\": \"Abdominal distension is noted as a side effect associated with the usage of IBSRELA.\", \"keywords\": \"adverse effects,patient safety\", \"weight\": 7.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"49\", \"entity1\": \"IBSRELA\", \"entity2\": \"Low-Substituted Hydroxypropyl Cellulose\", \"description\": \"Low-Substituted Hydroxypropyl Cellulose is used in IBSRELA to enhance its stability and absorption in the body.\", \"keywords\": \"inactive ingredient,stability\", \"weight\": 7.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"50\", \"entity1\": \"IBSRELA\", \"entity2\": \"Rome III criteria\", \"description\": \"The Rome III criteria were used to determine if patients were eligible for the IBSRELA trials.\", \"keywords\": \"clinical trials,diagnostic criteria\", \"weight\": 7.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"51\", \"entity1\": \"IBSRELA\", \"entity2\": \"Weekly Treatment Regimen\", \"description\": \"The weekly treatment regimen details the schedule for administering IBSRELA to patients during the clinical study periods.\", \"keywords\": \"patient care,treatment administration\", \"weight\": 6.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"52\", \"entity1\": \"IBSRELA\", \"entity2\": \"Tartaric Acid\", \"description\": \"Tartaric Acid is used in the production of IBSRELA to ensure quality control during formulation.\", \"keywords\": \"inactive ingredient,manufacturing\", \"weight\": 6.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"53\", \"entity1\": \"IBSRELA\", \"entity2\": \"Triacetin\", \"description\": \"Triacetin contributes to the formulation and stability of IBSRELA, playing a role in its overall effectiveness.\", \"keywords\": \"formulation,inactive ingredient\", \"weight\": 6.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"54\", \"entity1\": \"Abdominal Pain\", \"entity2\": \"Trial 2\", \"description\": \"Abdominal pain is assessed in Trial 2, tracking the impact of IBSRELA treatment on this symptom.\", \"keywords\": \"clinical measurement,primary endpoint\", \"weight\": 8.0, \"rank\": 27, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"55\", \"entity1\": \"Abdominal Pain\", \"entity2\": \"Trial 1\", \"description\": \"Abdominal pain is another primary endpoint measured in Trial 1 to determine the effectiveness of IBSRELA.\", \"keywords\": \"clinical measurement,primary endpoint\", \"weight\": 8.0, \"rank\": 25, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"56\", \"entity1\": \"Table 2\", \"entity2\": \"Trial 2\", \"description\": \"Table 2 similarly summarizes responder data for Trial 2, illustrating the efficacy of IBSRELA compared to placebo treatment.\", \"keywords\": \"data presentation,efficacy summary\", \"weight\": 7.0, \"rank\": 25, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"57\", \"entity1\": \"CSBM\", \"entity2\": \"Trial 2\", \"description\": \"CSBM is also a critical measure in Trial 2, helping evaluate the effectiveness of IBSRELA over placebo.\", \"keywords\": \"clinical measurement,primary endpoint\", \"weight\": 8.0, \"rank\": 21, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"58\", \"entity1\": \"CSBM\", \"entity2\": \"Trial 1\", \"description\": \"CSBM is a key endpoint in Trial 1 for measuring treatment response in participants taking IBSRELA.\", \"keywords\": \"clinical measurement,primary endpoint\", \"weight\": 8.0, \"rank\": 19, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"59\", \"entity1\": \"Healthy Subjects\", \"entity2\": \"Rome III Criteria for IBS-C\", \"description\": \"Healthy subjects must meet the Rome III criteria to qualify for participation in the IBSRELA clinical trials.\", \"keywords\": \"diagnostic standards,trial eligibility\", \"weight\": 7.0, \"rank\": 13, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"60\", \"entity1\": \"adult population\", \"entity2\": \"clinical trials\", \"description\": \"Clinical trials for IBSRELA involve the adult population to evaluate its safety and efficacy in treating gastrointestinal conditions.\", \"keywords\": \"adult health,research participation\", \"weight\": 9.0, \"rank\": 5, \"created_at\": \"2025-05-19 16:05:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"61\", \"entity1\": \"REMICADE\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"REMICADE is a biologic medication primarily indicated for the treatment of Ulcerative Colitis, an inflammatory bowel disease characterized by inflammation and ulcers in the gastrointestinal tract. It has been shown to be effective in both inducing and maintaining remission in patients, particularly in children, as evidenced by placebo-controlled studies aimed at symptom reduction. The treatment focuses on alleviating symptoms and promoting mucosal healing in affected patients. Clinical evaluations of REMICADE have documented positive treatment outcomes over multiple doses, further solidifying its role in managing the severe symptoms associated with Ulcerative Colitis. Additionally, adverse reactions have been noted in clinical trials, underscoring the importance of monitoring during treatment. Overall, REMICADE is recognized as a relevant therapeutic option for individuals suffering from Ulcerative Colitis and is part of the broader spectrum of treatments available for various inflammatory bowel diseases.\", \"keywords\": \"chronic condition,clinical focus,clinical therapy,clinical trials,inflammatory bowel disease,inflammatory disease,medication treatment,therapeutic use,treatment,treatment effectiveness,treatment indication\", \"weight\": 69.0, \"rank\": 218, \"created_at\": \"2025-05-19 16:43:57\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"62\", \"entity1\": \"10 mg/kg\", \"entity2\": \"REMICADE\", \"description\": \"10 mg/kg is another dosage level of REMICADE evaluated for its clinical response in patients.\", \"keywords\": \"dosage comparison,efficacy study\", \"weight\": 8.0, \"rank\": 211, \"created_at\": \"2025-05-19 16:44:51\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"63\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"SEROQUEL XR\", \"description\": \"Patient Counseling Information is provided to help patients understand the risks and benefits of taking SEROQUEL XR.\", \"keywords\": \"medication safety,patient guidance\", \"weight\": 9.0, \"rank\": 170, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"64\", \"entity1\": \"BAXDELA\", \"entity2\": \"Gastrointestinal Disorders\", \"description\": \"Gastrointestinal adverse reactions, such as abdominal pain and dyspepsia, have been noted in patients receiving BAXDELA.\", \"keywords\": \"adverse effects,drug safety\", \"weight\": 8.0, \"rank\": 160, \"created_at\": \"2025-05-19 15:17:31\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"65\", \"entity1\": \"Constipation\", \"entity2\": \"SEROQUEL XR\", \"description\": \"Constipation is a commonly reported side effect of SEROQUEL XR that can lead to more severe complications such as intestinal obstruction.<SEP>Constipation specifically at the 300 mg dosage of SEROQUEL XR shows a direct link between medication use and side effects.<SEP>Constipation was indicated as an adverse reaction for patients taking SEROQUEL XR.\", \"keywords\": \"adverse reaction,clinical findings,medication risk,side effects\", \"weight\": 21.0, \"rank\": 157, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"66\", \"entity1\": \"FDA\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information is approved and mandated by the FDA to ensure safety and efficacy communication to patients.\", \"keywords\": \"patient safety,regulatory compliance\", \"weight\": 8.0, \"rank\": 157, \"created_at\": \"2025-05-19 16:26:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf\"}, {\"id\": \"67\", \"entity1\": \"BAXDELA\", \"entity2\": \"Diarrhea\", \"description\": \"Diarrhea is listed as a significant adverse reaction for patients taking BAXDELA, indicating its impact on patient comfort and treatment compliance.<SEP>Diarrhea is noted as a common problem associated with BAXDELA, requiring patient awareness and management.\", \"keywords\": \"adverse effects,patient management,treatment outcomes\", \"weight\": 15.0, \"rank\": 156, \"created_at\": \"2025-05-19 15:17:31\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"68\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"THALOMID\", \"description\": \"Patient Counseling Information provides guidance on how patients should be informed about using THALOMID safely.\", \"keywords\": \"drug use,patient education\", \"weight\": 9.0, \"rank\": 156, \"created_at\": \"2025-05-19 16:20:28\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf\"}, {\"id\": \"69\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"THALOMID\", \"description\": \"Gastrointestinal disorders are among the adverse reactions noted in patients taking THALOMID during clinical trials.\", \"keywords\": \"adverse reactions,clinical findings\", \"weight\": 9.0, \"rank\": 151, \"created_at\": \"2025-05-19 16:20:28\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf\"}, {\"id\": \"70\", \"entity1\": \"BAXDELA\", \"entity2\": \"MEDICATION GUIDE\", \"description\": \"The MEDICATION GUIDE provides critical information about the use and risks of BAXDELA, informing users about serious side effects.\", \"keywords\": \"informational resource,safety guidelines\", \"weight\": 10.0, \"rank\": 149, \"created_at\": \"2025-05-19 15:17:31\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BAXDELA_DELAFLOXACIN_MEGLUMINE_POWDER_INTRAVENOUS_208611_MELINTA_12-01-2023.pdf\"}, {\"id\": \"71\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"HULIO\", \"description\": \"Dosage and Administration guidelines are necessary for proper and effective use of HULIO in treating conditions.\", \"keywords\": \"drug administration,treatment protocol\", \"weight\": 8.0, \"rank\": 148, \"created_at\": \"2025-05-19 17:04:14\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"72\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"XPOVIO\", \"description\": \"Patient Counseling Information provides guidance on the proper use and expected side effects of XPOVIO, ensuring safety in its administration.\", \"keywords\": \"patient education,treatment adherence\", \"weight\": 10.0, \"rank\": 147, \"created_at\": \"2025-05-19 15:36:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"73\", \"entity1\": \"HULIO\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"HULIO is indicated for the treatment of ulcerative colitis, providing relief to affected patients.<SEP>HULIO is specifically indicated for treating Ulcerative Colitis in adults.<SEP>HULIO is used as a treatment for Ulcerative Colitis, involving specific dosing guidelines for effective management.<SEP>HULIO's application in treating Ulcerative Colitis demonstrates its role in managing severe bowel diseases.<SEP>Patients with ulcerative colitis prescribed HULIO are monitored for risks of developing malignancies during treatment.\", \"keywords\": \"IBD treatment,dosing guidelines,inflammatory bowel disease,medical indication,patient care,therapeutic application,treatment,treatment indication,treatment safety\", \"weight\": 43.0, \"rank\": 140, \"created_at\": \"2025-05-19 17:04:10\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"74\", \"entity1\": \"Diarrhea\", \"entity2\": \"XPOVIO\", \"description\": \"Diarrhea can occur as an adverse reaction to XPOVIO, necessitating adjustments in dosage based on severity.<SEP>Diarrhea is noted as a potential side effect for patients using XPOVIO during their treatment.\", \"keywords\": \"dosage modification,drug safety,side effects,symptom management\", \"weight\": 16.0, \"rank\": 138, \"created_at\": \"2025-05-19 15:36:19\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"75\", \"entity1\": \"Dosage Forms and Strengths\", \"entity2\": \"HULIO\", \"description\": \"HULIO is available in various dosage forms and strengths, providing options for effective treatment.\", \"keywords\": \"medication forms,treatment options\", \"weight\": 9.0, \"rank\": 136, \"created_at\": \"2025-05-19 17:04:14\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"76\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"STRATTERA\", \"description\": \"STRATTERA is linked to gastrointestinal disorders, with high percentages of patients reporting reactions such as nausea and dry mouth during treatment.\", \"keywords\": \"digestive health,medication impact\", \"weight\": 8.0, \"rank\": 136, \"created_at\": \"2025-05-19 17:07:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf\"}, {\"id\": \"77\", \"entity1\": \"FDA Medication Guide\", \"entity2\": \"Patients\", \"description\": \"The FDA Medication Guide provides essential information about LAMISIL for patients, covering side effects and usage instructions.\", \"keywords\": \"medication instructions,patient information\", \"weight\": 10.0, \"rank\": 134, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"78\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"VANTRELA ER\", \"description\": \"Patients using VANTRELA ER may face gastrointestinal disorders, demonstrating a need for careful monitoring of side effects.\", \"keywords\": \"adverse reaction,monitoring\", \"weight\": 8.0, \"rank\": 134, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"79\", \"entity1\": \"Dosage Changes\", \"entity2\": \"Patients\", \"description\": \"Changes in dosage for patients prescribed medications can influence the emergence of symptoms, requiring careful management.\", \"keywords\": \"medication adjustments,patient safety\", \"weight\": 7.0, \"rank\": 134, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"80\", \"entity1\": \"Adverse Reactions\", \"entity2\": \"Gastrointestinal Disorders\", \"description\": \"Gastrointestinal Disorders such as constipation and nausea are classified as Adverse Reactions reported by patients during the study.<SEP>Various adverse reactions such as nausea and diarrhea are linked to gastrointestinal disorders experienced by patients in the study.\", \"keywords\": \"patient symptoms,symptom classification,treatment effects,treatment side effects\", \"weight\": 17.0, \"rank\": 133, \"created_at\": \"2025-05-19 16:20:28\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\THALOMID_THALIDOMIDE_CAPSULE_ORAL_20785_CELGENE_03-24-2023.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf\"}, {\"id\": \"81\", \"entity1\": \"EMBEDA\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information for EMBEDA emphasizes the importance of proper use, storage, and disposal of the medication.\", \"keywords\": \"proper usage,safety guidelines\", \"weight\": 8.0, \"rank\": 133, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"82\", \"entity1\": \"Colloidal Silicon Dioxide\", \"entity2\": \"XPOVIO\", \"description\": \"Colloidal Silicon Dioxide is one of the inactive ingredients in XPOVIO tablets, playing a role in the formulation of the drug.\", \"keywords\": \"formulation,pharmaceutical ingredients\", \"weight\": 8.0, \"rank\": 132, \"created_at\": \"2025-05-19 15:36:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"83\", \"entity1\": \"DAYTRANA\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information provides essential guidelines for the proper handling and use of DAYTRANA.\", \"keywords\": \"patient safety,usage guidelines\", \"weight\": 8.0, \"rank\": 132, \"created_at\": \"2025-05-19 15:11:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf\"}, {\"id\": \"84\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"EMBEDA\", \"description\": \"Dosage and Administration guidelines for EMBEDA provide essential information for healthcare providers on safe prescribing practices.\", \"keywords\": \"patient care,prescribing guidelines\", \"weight\": 8.0, \"rank\": 131, \"created_at\": \"2025-05-19 15:46:12\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"85\", \"entity1\": \"Administration Instructions\", \"entity2\": \"XPOVIO\", \"description\": \"Administration instructions provide essential guidance for the correct use of XPOVIO, ensuring patient safety and effectiveness.\", \"keywords\": \"dosage,treatment guidelines\", \"weight\": 8.0, \"rank\": 131, \"created_at\": \"2025-05-19 15:36:19\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"86\", \"entity1\": \"DAYTRANA\", \"entity2\": \"Dosage and Administration\", \"description\": \"The Dosage and Administration section provides guidelines on how to use DAYTRANA safely and effectively.\", \"keywords\": \"safety,usage instructions\", \"weight\": 9.0, \"rank\": 130, \"created_at\": \"2025-05-19 15:11:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf\"}, {\"id\": \"87\", \"entity1\": \"Dosage Modification Guidelines\", \"entity2\": \"XPOVIO\", \"description\": \"Dosage Modification Guidelines assist healthcare providers in adjusting the treatment plan based on patient responses while on XPOVIO.\", \"keywords\": \"safety management,treatment protocol\", \"weight\": 8.0, \"rank\": 130, \"created_at\": \"2025-05-19 15:36:19\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XPOVIO_SELINEXOR_TABLET_ORAL_212306_KARYOPHARM_THERAPS_07-15-2022.pdf\"}, {\"id\": \"88\", \"entity1\": \"Adverse Reactions\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"Adverse reactions were reported in pediatric patients with Ulcerative Colitis, highlighting the effects of treatment on this population.<SEP>Ulcerative Colitis is treated with TNF blockers, which can lead to adverse reactions including severe malignancies.\", \"keywords\": \"adverse outcomes,clinical trial,safety profile,treatment indication\", \"weight\": 17.0, \"rank\": 128, \"created_at\": \"2025-05-19 17:04:14\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf<SEP>C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"89\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"TUXARIN ER\", \"description\": \"The guidelines for dosage and administration of TUXARIN ER are critical for ensuring patient safety and therapeutic effectiveness.\", \"keywords\": \"dosage guidelines,patient safety\", \"weight\": 8.0, \"rank\": 128, \"created_at\": \"2025-05-19 16:24:02\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf\"}, {\"id\": \"90\", \"entity1\": \"DAYTRANA\", \"entity2\": \"Gastrointestinal Disorders\", \"description\": \"Gastrointestinal disorders like nausea and vomiting have been frequently mentioned as adverse reactions to DAYTRANA.\", \"keywords\": \"medication risks,side effects\", \"weight\": 8.0, \"rank\": 127, \"created_at\": \"2025-05-19 15:11:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf\"}, {\"id\": \"91\", \"entity1\": \"Adverse Reactions\", \"entity2\": \"Table 12\", \"description\": \"Table 12 enumerates the incidence of adverse reactions observed in patients during SEROQUEL XR trials, providing quantitative data on side effects.\", \"keywords\": \"clinical trials,data presentation\", \"weight\": 8.0, \"rank\": 126, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"92\", \"entity1\": \"BENLYSTA\", \"entity2\": \"Diarrhea\", \"description\": \"Diarrhea was frequently reported as an adverse event in patients treated with BENLYSTA, indicating its impact on gastrointestinal health.\", \"keywords\": \"patient responses,side effects\", \"weight\": 6.0, \"rank\": 126, \"created_at\": \"2025-05-19 15:26:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf\"}, {\"id\": \"93\", \"entity1\": \"Dosage Forms and Strengths\", \"entity2\": \"VANTRELA ER\", \"description\": \"VANTRELA ER is available in multiple dosage forms and strengths, ensuring proper dosing for patients.\", \"keywords\": \"dosing,medication formulation\", \"weight\": 9.0, \"rank\": 125, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"94\", \"entity1\": \"Adverse Reactions\", \"entity2\": \"Recommended Dosage\", \"description\": \"Adverse reactions necessitate dosage modifications as outlined in the dosage recommendations for TURALIO.\", \"keywords\": \"adaptation to side effects,medication adjustments\", \"weight\": 8.0, \"rank\": 125, \"created_at\": \"2025-05-19 17:09:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf\"}, {\"id\": \"95\", \"entity1\": \"STRATTERA\", \"entity2\": \"Safety Instructions\", \"description\": \"Safety Instructions outline crucial steps to take in case of an overdose or severe side effects from STRATTERA.\", \"keywords\": \"safety measures,user guidance\", \"weight\": 9.0, \"rank\": 124, \"created_at\": \"2025-05-19 17:07:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\STRATTERA_ATOMOXETINE_HYDROCHLORIDE_CAPSULE_ORAL_21411_LILLY_01-06-2022.pdf\"}, {\"id\": \"96\", \"entity1\": \"Dosing Range\", \"entity2\": \"VANTRELA ER\", \"description\": \"The Dosing Range of VANTRELA ER needs to be carefully determined to prevent adverse effects such as respiratory depression.\", \"keywords\": \"medication management,safety\", \"weight\": 8.0, \"rank\": 122, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"97\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"XENAZINE\", \"description\": \"The Dosage and Administration section outlines how to correctly prescribe XENAZINE for various patients based on individual needs.\", \"keywords\": \"prescribing information,treatment protocol\", \"weight\": 7.0, \"rank\": 122, \"created_at\": \"2025-05-19 15:52:43\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf\"}, {\"id\": \"98\", \"entity1\": \"BENLYSTA\", \"entity2\": \"MEDICATION GUIDE\", \"description\": \"The MEDICATION GUIDE provides essential information about using BENLYSTA safely and effectively.\", \"keywords\": \"medication instructions,patient education\", \"weight\": 9.0, \"rank\": 119, \"created_at\": \"2025-05-19 15:26:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BENLYSTA_BELIMUMAB_INJECTABLE_INJECTION_761043_GLAXOSMITHKLINE_LLC_05-16-2024.pdf\"}, {\"id\": \"99\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"RITUXAN HYCELA\", \"description\": \"Dosage and administration instructions are essential for ensuring effective and safe use of RITUXAN HYCELA.\", \"keywords\": \"effective treatment,medical guidelines\", \"weight\": 8.0, \"rank\": 118, \"created_at\": \"2025-05-19 15:59:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\RITUXAN_HYCELA_RITUXIMAB__HYALURONIDASE_(HUMAN_RECOMBINANT)_SOLUTION_SUBCUTANEOUS_761064_GENENTECH_INC_06-10-2021.pdf\"}, {\"id\": \"100\", \"entity1\": \"EMBEDA\", \"entity2\": \"IR Morphine Sulfate\", \"description\": \"EMBEDA was compared to IR Morphine Sulfate in Study 1 to evaluate differences in drug effects and abuse potential.\", \"keywords\": \"pharmaceutical comparison,study evaluation\", \"weight\": 9.0, \"rank\": 117, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"101\", \"entity1\": \"EMBEDA\", \"entity2\": \"Instructions for Administration\", \"description\": \"Instructions for Administration detail how to take EMBEDA safely and effectively to prevent serious side effects, ensuring proper patient compliance.\", \"keywords\": \"risk reduction,usage guidelines\", \"weight\": 9.0, \"rank\": 116, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"102\", \"entity1\": \"Dosage Guidelines\", \"entity2\": \"TUXARIN ER\", \"description\": \"Dosage guidelines specify that TUXARIN ER should only be administered to adults, emphasizing the importance of adherence to prescribed limits.\", \"keywords\": \"dosage instruction,safety regulation\", \"weight\": 9.0, \"rank\": 115, \"created_at\": \"2025-05-19 16:23:37\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf\"}, {\"id\": \"103\", \"entity1\": \"Diarrhea\", \"entity2\": \"XENAZINE\", \"description\": \"Diarrhea can occur as an adverse reaction in patients treated with XENAZINE, indicating gastrointestinal side effects.\", \"keywords\": \"adverse reaction,gastrointestinal health\", \"weight\": 8.0, \"rank\": 115, \"created_at\": \"2025-05-19 15:52:43\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XENAZINE_TETRABENAZINE_TABLET_ORAL_21894_BAUSCH_09-13-2017.pdf\"}, {\"id\": \"104\", \"entity1\": \"Dosage and Administration Guidelines\", \"entity2\": \"TUXARIN ER\", \"description\": \"The guidelines provide critical information for the safe prescribing and administration of TUXARIN ER, reducing the risk of overdose and adverse effects.\", \"keywords\": \"prescribing guidelines,safety information\", \"weight\": 9.0, \"rank\": 113, \"created_at\": \"2025-05-19 16:24:02\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TUXARIN_ER_CHLORPHENIRAMINE_MALEATE__CODEINE_PHOSPHATE_TABLET,_EXTENDED_RELEASE_ORAL_206323_MAINPOINTE_12-15-2023.pdf\"}, {\"id\": \"105\", \"entity1\": \"BRIVIACT\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information provides essential guidelines regarding the risks and safe usage of BRIVIACT.\", \"keywords\": \"medication guidance,patient safety\", \"weight\": 7.0, \"rank\": 107, \"created_at\": \"2025-05-19 16:47:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"106\", \"entity1\": \"OPANA ER\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information is crucial for educating patients about the risks associated with OPANA ER.<SEP>Patient Counseling Information provides essential guidelines on how to use OPANA ER safely to mitigate risks of misuse and overdose.\", \"keywords\": \"guidelines,patient education,safety,safety instructions\", \"weight\": 17.0, \"rank\": 104, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"107\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"ULTRACET\", \"description\": \"The patient counseling information provides essential guidelines and safety instructions for using ULTRACET properly.\", \"keywords\": \"medication guidelines,patient safety\", \"weight\": 10.0, \"rank\": 104, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf\"}, {\"id\": \"108\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"ULTRACET\", \"description\": \"The Dosage and Administration section provides critical guidelines for prescribing ULTRACET effectively, indicating proper usage and safety precautions.\", \"keywords\": \"guidelines,medication safety\", \"weight\": 9.0, \"rank\": 102, \"created_at\": \"2025-05-19 17:17:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf\"}, {\"id\": \"109\", \"entity1\": \"Constipation\", \"entity2\": \"SEROQUEL\", \"description\": \"Constipation is listed as an adverse reaction that can occur in patients using SEROQUEL.\", \"keywords\": \"medication evaluation,side effects\", \"weight\": 8.0, \"rank\": 101, \"created_at\": \"2025-05-19 16:34:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\SEROQUEL_XR_QUETIAPINE_FUMARATE_TABLET,_EXTENDED_RELEASE_ORAL_22047_ASTRAZENECA_01-22-2025.pdf\"}, {\"id\": \"110\", \"entity1\": \"Ulcerative Colitis\", \"entity2\": \"adalimumab\", \"description\": \"Adalimumab is also indicated for treating ulcerative colitis, further underlining its efficacy in gastrointestinal disorders.<SEP>Adalimumab is indicated for patients with ulcerative colitis to control inflammation in the colon.<SEP>Adalimumab is specifically used to treat adult patients with moderately to severely active ulcerative colitis.\", \"keywords\": \"autoimmune treatment,inflammatory bowel disease,medication use,therapeutic application,treatment\", \"weight\": 27.0, \"rank\": 100, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"111\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"OPANA ER\", \"description\": \"OPANA ER may pose risks to patients with gastrointestinal disorders due to potential complications like obstruction.\", \"keywords\": \"drug contraindication,patient safety\", \"weight\": 9.0, \"rank\": 99, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"112\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"LUMOXITI\", \"description\": \"Gastrointestinal disorders are observed as side effects of LUMOXITI treatment, showing the impact on digestive health.\", \"keywords\": \"adverse effects,treatment impact\", \"weight\": 7.0, \"rank\": 99, \"created_at\": \"2025-05-19 15:43:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"113\", \"entity1\": \"FDA-approved patient labeling\", \"entity2\": \"XYOSTED\", \"description\": \"The FDA-approved patient labeling provides critical information regarding the administration and risks associated with using XYOSTED.\", \"keywords\": \"patient guidance,safety information\", \"weight\": 10.0, \"rank\": 96, \"created_at\": \"2025-05-19 15:40:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\XYOSTED_(AUTOINJECTOR)_TESTOSTERONE_ENANTHATE_SOLUTION_SUBCUTANEOUS_209863_ANTARES_PHARMA_INC_11-19-2019.pdf\"}, {\"id\": \"114\", \"entity1\": \"ENTYVIO\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient counseling information ensures that patients understand how to use ENTYVIO safely and what side effects to expect.\", \"keywords\": \"patient education,safety\", \"weight\": 9.0, \"rank\": 95, \"created_at\": \"2025-05-19 16:12:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf\"}, {\"id\": \"115\", \"entity1\": \"BRIVIACT\", \"entity2\": \"Dosage Instructions\", \"description\": \"Dosage Instructions provide essential guidance for patients on how to properly use BRIVIACT for effective treatment.\", \"keywords\": \"administration guidelines,medication usage\", \"weight\": 7.0, \"rank\": 94, \"created_at\": \"2025-05-19 16:47:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"116\", \"entity1\": \"BANZEL\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient counseling information for BANZEL highlights the importance of adherence to dosing and awareness of side effects.\", \"keywords\": \"medication adherence,patient education\", \"weight\": 9.0, \"rank\": 93, \"created_at\": \"2025-05-19 16:57:03\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf\"}, {\"id\": \"117\", \"entity1\": \"BRIVIACT\", \"entity2\": \"Dosage Forms and Strengths\", \"description\": \"BRIVIACT comes in multiple dosage forms and strengths, ensuring flexibility in treatment for patients.\", \"keywords\": \"medication formulation,treatment flexibility\", \"weight\": 8.0, \"rank\": 93, \"created_at\": \"2025-05-19 16:47:41\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"118\", \"entity1\": \"Dosage Instructions\", \"entity2\": \"OPANA ER\", \"description\": \"Dosage instructions are essential for the safe administration of OPANA ER, helping to avoid complications from incorrect usage.\", \"keywords\": \"administration guidelines,medication safety\", \"weight\": 9.0, \"rank\": 91, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"119\", \"entity1\": \"BANZEL\", \"entity2\": \"Dosage and Administration\", \"description\": \"The Dosage and Administration section provides important guidelines for the use of BANZEL in treatment.\", \"keywords\": \"treatment instructions,usage guidelines\", \"weight\": 9.0, \"rank\": 91, \"created_at\": \"2025-05-19 16:57:03\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf\"}, {\"id\": \"120\", \"entity1\": \"LUMOXITI\", \"entity2\": \"Recommended Dosage\", \"description\": \"The recommended dosage details are essential for the safe administration of LUMOXITI to patients.\", \"keywords\": \"dosing guidelines,safety\", \"weight\": 9.0, \"rank\": 91, \"created_at\": \"2025-05-19 15:43:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"121\", \"entity1\": \"Dosage Guidelines\", \"entity2\": \"ULTRACET\", \"description\": \"Dosage guidelines inform the safe prescription of ULTRACET to minimize risks associated with opioid use.\", \"keywords\": \"patient safety,prescription practices\", \"weight\": 9.0, \"rank\": 89, \"created_at\": \"2025-05-19 17:17:18\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ULTRACET_ACETAMINOPHEN__TRAMADOL_HYDROCHLORIDE_TABLET_ORAL_21123_JANSSEN_PHARMS_02-13-2023.pdf\"}, {\"id\": \"122\", \"entity1\": \"Recommended Dosage\", \"entity2\": \"TURALIO\", \"description\": \"The recommended dosage provides essential guidelines on how to effectively take TURALIO to minimize risks and enhance treatment outcomes.\", \"keywords\": \"dosage guidelines,treatment protocols\", \"weight\": 9.0, \"rank\": 89, \"created_at\": \"2025-05-19 17:09:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf\"}, {\"id\": \"123\", \"entity1\": \"Administration Instructions\", \"entity2\": \"LUMOXITI\", \"description\": \"Administration Instructions provide vital guidelines for the safe and effective administration of LUMOXITI, essential for clinical use.\", \"keywords\": \"medication use,safety guidelines\", \"weight\": 10.0, \"rank\": 88, \"created_at\": \"2025-05-19 15:43:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"124\", \"entity1\": \"Dosing Schedule\", \"entity2\": \"LUMOXITI\", \"description\": \"The dosing schedule for LUMOXITI specifies the timing and parameters for its administration during treatment cycles.\", \"keywords\": \"administration protocol,treatment planning\", \"weight\": 9.0, \"rank\": 88, \"created_at\": \"2025-05-19 15:43:45\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LUMOXITI_MOXETUMOMAB_PASUDOTOX-TDFK_INJECTABLE_INJECTION_761104_INNATE_PHARMA_08-20-2020.pdf\"}, {\"id\": \"125\", \"entity1\": \"OPANA ER\", \"entity2\": \"Storage and Disposal Instructions\", \"description\": \"Storage and disposal instructions are provided for OPANA ER to inform patients how to properly handle the medication.\", \"keywords\": \"medication safety,patient guidelines\", \"weight\": 8.0, \"rank\": 87, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"126\", \"entity1\": \"ENTYVIO\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"ENTYVIO is indicated for the treatment of moderately to severely active Ulcerative Colitis in adults.<SEP>ENTYVIO is specifically indicated for the treatment of moderately to severely active ulcerative colitis.\", \"keywords\": \"medication indication,therapeutic use,treatment,treatment indication\", \"weight\": 18.0, \"rank\": 85, \"created_at\": \"2025-05-19 16:12:15\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf\"}, {\"id\": \"127\", \"entity1\": \"Healthcare Provider\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Healthcare Providers use Patient Counseling Information to educate patients on how to properly use medications like DAYTRANA.\", \"keywords\": \"education,patient care\", \"weight\": 7.0, \"rank\": 85, \"created_at\": \"2025-05-19 15:11:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DAYTRANA_METHYLPHENIDATE_SYSTEM_TRANSDERMAL_21514_NOVEN_PHARMACEUTICALS,_INC_11-29-2024.pdf\"}, {\"id\": \"128\", \"entity1\": \"ENTYVIO\", \"entity2\": \"FDA-approved patient labeling\", \"description\": \"The FDA-approved patient labeling provides essential information regarding the use and safety of ENTYVIO for patients.\", \"keywords\": \"patient safety,regulatory information\", \"weight\": 10.0, \"rank\": 83, \"created_at\": \"2025-05-19 16:12:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ENTYVIO_VEDOLIZUMAB_INJECTABLE_INJECTION_125476_TAKEDA_PHARMS_USA_04-18-2024.pdf\"}, {\"id\": \"129\", \"entity1\": \"ADDERALL\", \"entity2\": \"Dosage Instructions\", \"description\": \"Dosage instructions are essential for the safe use of ADDERALL based on individual patient requirements.\", \"keywords\": \"guidance,treatment protocols\", \"weight\": 8.0, \"rank\": 83, \"created_at\": \"2025-05-19 16:03:24\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ADDERALL_10_AMPHETAMINE_ASPARTATE__AMPHETAMINE_SULFATE__DEXTROAMPHETAMINE_SACCHARATE__DEXTROAMPHETAMINE_SULFATE_TABLET_ORAL_11522_TEVA_WOMENS_10-13-2023.pdf\"}, {\"id\": \"130\", \"entity1\": \"DIACOMIT\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information is essential for understanding how to use DIACOMIT safely and effectively.\", \"keywords\": \"medication management,patient safety\", \"weight\": 7.0, \"rank\": 76, \"created_at\": \"2025-05-19 17:19:59\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\DIACOMIT_STIRIPENTOL_CAPSULE_ORAL_206709_BIOCODEX_SA_08-20-2018.pdf\"}, {\"id\": \"131\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"ZENPEP\", \"description\": \"The dosage and administration guidelines are critical for ensuring the effective use of ZENPEP in patients.\", \"keywords\": \"effective usage,treatment guidelines\", \"weight\": 9.0, \"rank\": 75, \"created_at\": \"2025-05-19 16:04:30\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"132\", \"entity1\": \"Adalimumab\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"Adalimumab serves as a treatment for Ulcerative Colitis, emphasizing its role in managing bowel inflammation.<SEP>Adalimumab serves as a treatment for Ulcerative Colitis, representing its relevance in gastrointestinal inflammatory diseases.\", \"keywords\": \"autoimmune management,gastrointestinal treatment,inflammatory bowel disease,treatment indication\", \"weight\": 20.0, \"rank\": 73, \"created_at\": \"2025-05-19 17:04:27\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\HULIO_ADALIMUMAB-FKJP_INJECTABLE_INJECTION_761154_MYLAN_PHARMS_INC_02-05-2025.pdf\"}, {\"id\": \"133\", \"entity1\": \"Dosage Instructions\", \"entity2\": \"Healthcare Provider\", \"description\": \"The healthcare provider gives specific dosage instructions for BRIVIACT to ensure patient safety and effectiveness of treatment.\", \"keywords\": \"dosage guidance,medical instruction\", \"weight\": 9.0, \"rank\": 72, \"created_at\": \"2025-05-19 16:47:44\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}, {\"id\": \"134\", \"entity1\": \"ALKINDI SPRINKLE\", \"entity2\": \"Dosage and Administration\", \"description\": \"Dosage and administration provides necessary guidance for the proper use of ALKINDI SPRINKLE in treating patients.\", \"keywords\": \"medication guidance,safety monitoring\", \"weight\": 9.0, \"rank\": 71, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf\"}, {\"id\": \"135\", \"entity1\": \"Dosing Instructions\", \"entity2\": \"Healthcare Provider\", \"description\": \"Healthcare Providers give Dosing Instructions to ensure patients take BANZEL correctly for maximum safety and effectiveness.\", \"keywords\": \"medication management,patient education\", \"weight\": 8.0, \"rank\": 71, \"created_at\": \"2025-05-19 16:57:03\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BANZEL_RUFINAMIDE_SUSPENSION_ORAL_201367_EISAI_INC_05-30-2023.pdf\"}, {\"id\": \"136\", \"entity1\": \"FDA-approved patient labeling\", \"entity2\": \"ZENPEP\", \"description\": \"The FDA-approved patient labeling contains critical information about taking ZENPEP as prescribed by healthcare professionals.\", \"keywords\": \"patient information,regulatory compliance\", \"weight\": 10.0, \"rank\": 65, \"created_at\": \"2025-05-19 16:04:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"137\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"FOSRENOL\", \"description\": \"Dosage and Administration guidelines offer essential instructions on how to properly dose and use FOSRENOL for it to be effective.<SEP>The Dosage and Administration section outlines recommended practices for effective use of FOSRENOL.\", \"keywords\": \"administration,dosing guidelines,usage guidelines,usage instructions\", \"weight\": 17.0, \"rank\": 64, \"created_at\": \"2025-05-19 15:06:11\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\FOSRENOL_LANTHANUM_CARBONATE_POWDER_ORAL_204734_TAKEDA_PHARMS_USA_08-29-2024.pdf\"}, {\"id\": \"138\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"Study 1\", \"description\": \"Study 1 reports gastrointestinal adverse events observed when administering ZENPEP, highlighting the potential reactions linked to this treatment.\", \"keywords\": \"adverse events,treatment outcome\", \"weight\": 8.0, \"rank\": 64, \"created_at\": \"2025-05-19 16:04:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"139\", \"entity1\": \"Dosing Instructions\", \"entity2\": \"ZENPEP\", \"description\": \"Dosing instructions provide essential guidelines on how ZENPEP should be administered for effective enzyme replacement therapy.\", \"keywords\": \"dosing protocol,guideline compliance\", \"weight\": 9.0, \"rank\": 63, \"created_at\": \"2025-05-19 16:04:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"140\", \"entity1\": \"LAMISIL Tablets\", \"entity2\": \"Patient Counseling Information\", \"description\": \"Patient Counseling Information advises patients on how to safely use LAMISIL Tablets and what symptoms to monitor.\", \"keywords\": \"guidance,patient safety\", \"weight\": 9.0, \"rank\": 63, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"141\", \"entity1\": \"FDA label\", \"entity2\": \"Plavix\", \"description\": \"The FDA label contains essential information and guidelines for prescribing Plavix to prevent misuse and side effects.\", \"keywords\": \"information resource,prescribing guidelines\", \"weight\": 9.0, \"rank\": 60, \"created_at\": \"2025-05-19 15:50:01\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\PLAVIX_CLOPIDOGREL_BISULFATE_TABLET_ORAL_20839_SANOFI_AVENTIS_US_03-01-2021.pdf\"}, {\"id\": \"142\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"EPZICOM\", \"description\": \"The Dosage and Administration guidelines provide essential instructions for the proper use of EPZICOM in patients.\", \"keywords\": \"medical guidelines,usage instructions\", \"weight\": 8.0, \"rank\": 58, \"created_at\": \"2025-05-19 16:26:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf\"}, {\"id\": \"143\", \"entity1\": \"ALKINDI SPRINKLE\", \"entity2\": \"Prescription Information\", \"description\": \"Prescription information outlines critical instructions for the safe and effective use of ALKINDI SPRINKLE, focusing on dosages and administration.\", \"keywords\": \"guidelines,medication safety\", \"weight\": 9.0, \"rank\": 57, \"created_at\": \"2025-05-19 17:11:22\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf\"}, {\"id\": \"144\", \"entity1\": \"ALKINDI SPRINKLE\", \"entity2\": \"dosage adjustments\", \"description\": \"Dosage adjustments of ALKINDI SPRINKLE are required during acute illnesses, surgeries, or traumatic events.\", \"keywords\": \"specific conditions,treatment management\", \"weight\": 9.0, \"rank\": 57, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf\"}, {\"id\": \"145\", \"entity1\": \"Study 1\", \"entity2\": \"Table 12\", \"description\": \"Table 12 outlines MMF dosage patterns observed during Study 1 on patients treated with ASTAGRAF XL.\", \"keywords\": \"clinical data,treatment analysis\", \"weight\": 6.0, \"rank\": 57, \"created_at\": \"2025-05-19 16:53:00\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ASTAGRAF_XL_TACROLIMUS_CAPSULE,_EXTENDED_RELEASE_ORAL_210115_ASTELLAS_09-14-2023.pdf\"}, {\"id\": \"146\", \"entity1\": \"Colloidal Silicon Dioxide\", \"entity2\": \"Trazodone Hydrochloride\", \"description\": \"Colloidal silicon dioxide is used as an inactive ingredient in trazodone hydrochloride tablets to maintain their stability and effectiveness.\", \"keywords\": \"formulation,inactive ingredients\", \"weight\": 7.0, \"rank\": 55, \"created_at\": \"2025-05-19 16:07:54\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf\"}, {\"id\": \"147\", \"entity1\": \"FDA Warnings and Precautions\", \"entity2\": \"Trazodone Hydrochloride\", \"description\": \"FDA warnings provide crucial information on the safety and risks associated with trazodone hydrochloride treatment.\", \"keywords\": \"patient information,regulatory compliance\", \"weight\": 10.0, \"rank\": 53, \"created_at\": \"2025-05-19 16:07:54\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf\"}, {\"id\": \"148\", \"entity1\": \"IR Morphine Sulfate\", \"entity2\": \"Study 1\", \"description\": \"Study 1 specifically analyzes the effects of EMBEDA against IR Morphine Sulfate in terms of user response to drug liking and high scores.\", \"keywords\": \"clinical trial,drug evaluation\", \"weight\": 8.0, \"rank\": 53, \"created_at\": \"2025-05-19 15:46:46\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EMBEDA_MORPHINE_SULFATE__NALTREXONE_HYDROCHLORIDE_CAPSULE,_EXTENDED_RELEASE_ORAL_22321_ALPHARMA_PHARMS_10-07-2019.pdf\"}, {\"id\": \"149\", \"entity1\": \"Therapeutic Doses\", \"entity2\": \"Trazodone Hydrochloride\", \"description\": \"Therapeutic Doses of Trazodone Hydrochloride are carefully determined to balance efficacy and minimize side effects for patients.\", \"keywords\": \"dosage,therapeutic use\", \"weight\": 8.0, \"rank\": 53, \"created_at\": \"2025-05-19 16:07:54\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TRAZODONE_HYDROCHLORIDE_TRAZODONE_HYDROCHLORIDE_TABLET_ORAL_71196_APOTEX_INC_04-20-2020.pdf\"}, {\"id\": \"150\", \"entity1\": \"Patient Counseling Information\", \"entity2\": \"Warnings and Precautions\", \"description\": \"Patient Counseling Information should include warnings and precautions regarding safe usage and signs of misuse of VANTRELA ER.\", \"keywords\": \"counseling,patient safety\", \"weight\": 8.0, \"rank\": 50, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"151\", \"entity1\": \"Corticosteroids\", \"entity2\": \"Gastrointestinal Disorders\", \"description\": \"Patients with certain Gastrointestinal Disorders are at increased risk of complications when treated with corticosteroids.\", \"keywords\": \"health risks,treatment precautions\", \"weight\": 7.0, \"rank\": 50, \"created_at\": \"2025-05-19 17:11:29\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ALKINDI_SPRINKLE_Hydrocortisone_GRANULE_ORAL_213876_ETON_06-05-2024.pdf\"}, {\"id\": \"152\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"Hydrocodone\", \"description\": \"The Dosage and Administration section provides guidelines on the use of hydrocodone, such as dosing and potential side effects.\", \"keywords\": \"treatment protocol,usage guidelines\", \"weight\": 9.0, \"rank\": 48, \"created_at\": \"2025-05-19 16:40:21\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\VANTRELA_ER_HYDROCODONE_BITARTRATE_TABLET,_EXTENDED_RELEASE_ORAL_207975_TEVA_BRANDED_PHARM_05-26-2017.pdf\"}, {\"id\": \"153\", \"entity1\": \"Gastrointestinal Disorders\", \"entity2\": \"Study 2\", \"description\": \"Similar gastrointestinal adverse events were reported in Study 2, reinforcing issues encountered in clinical trials with ZENPEP.\", \"keywords\": \"adverse events,clinical findings\", \"weight\": 8.0, \"rank\": 48, \"created_at\": \"2025-05-19 16:04:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\ZENPEP_PANCRELIPASE_LIPASE_PROTEASE_AMYLASE_CAPSULE,_DELAYED_RELEASE_ORAL_22210_AIMMUNE_02-28-2024.pdf\"}, {\"id\": \"154\", \"entity1\": \"LAMISIL Tablets\", \"entity2\": \"Prescription Information\", \"description\": \"The prescription information provides crucial guidelines for the safe and effective use of LAMISIL Tablets.\", \"keywords\": \"medical guidelines,usage information\", \"weight\": 9.0, \"rank\": 47, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"155\", \"entity1\": \"Dosage and Administration\", \"entity2\": \"Oxymorphone\", \"description\": \"Oxymorphone is administered according to guidelines outlined in the Dosage and Administration event for effective pain management.\", \"keywords\": \"administration,medication guidelines\", \"weight\": 8.0, \"rank\": 47, \"created_at\": \"2025-05-19 15:39:23\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\OPANA_ER_OXYMORPHONE_HYDROCHLORIDE_TABLET,_EXTENDED_RELEASE_ORAL_201655_ENDO_PHARMS_10-07-2019.pdf\"}, {\"id\": \"156\", \"entity1\": \"LAMISIL Tablets\", \"entity2\": \"Prescription Instructions\", \"description\": \"Prescription instructions must be followed when taking LAMISIL Tablets to ensure proper treatment and management of side effects.\", \"keywords\": \"patient safety,treatment guidelines\", \"weight\": 9.0, \"rank\": 46, \"created_at\": \"2025-05-19 16:02:33\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"157\", \"entity1\": \"Recommended Dosage\", \"entity2\": \"Renal Impairment\", \"description\": \"\\\"Dosage modifications for patients with renal impairment are crucial to ensure safe administration of TURALIO.\", \"keywords\": \"health conditions,safety adaptations\", \"weight\": 7.0, \"rank\": 45, \"created_at\": \"2025-05-19 17:09:36\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\TURALIO_PEXIDARTINIB_HYDROCHLORIDE_CAPSULE_ORAL_211810_DAIICHI_SANKYO_INC_01-03-2025.pdf\"}, {\"id\": \"158\", \"entity1\": \"Infliximab\", \"entity2\": \"Ulcerative Colitis\", \"description\": \"Infliximab is also used as a treatment for Ulcerative Colitis, indicating its role in managing this condition.\\\".\", \"keywords\": \"medical application,treatment indication\", \"weight\": 10.0, \"rank\": 44, \"created_at\": \"2025-05-19 16:44:34\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"159\", \"entity1\": \"EPZICOM\", \"entity2\": \"ZICOM\", \"description\": \"ZICOM and EPZICOM both refer to the same medication; EPZICOM is an important context in which ZICOM is used.\\\"<<\\\"medication identification\", \"keywords\": \"8\", \"weight\": 8.0, \"rank\": 43, \"created_at\": \"2025-05-19 16:26:35\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\EPZICOM_ABACAVIR_SULFATE__LAMIVUDINE_TABLET_ORAL_21652_VIIV_HLTHCARE_12-10-2021.pdf\"}]\n",
      "```\n",
      "\n",
      "-----Document Chunks(DC)-----\n",
      "\n",
      "```json\n",
      "[{\"id\": \"1\", \"content\": \"Dosea \\nThree-Dose Inductionb \\nPlacebo \\nMaintenance \\nREMICADE Maintenance \\nq8 wks \\n5 mg/kg \\n10 mg/kg \\nWeek 30 \\n25/102 \\n41/104 \\n48/105 \\nClinical remission \\n25% \\n39% \\n46% \\nP-valuec \\n0.022 \\n0.001 \\nWeek 54 \\n6/54 \\n14/56 \\n18/53 \\nPatients in remission able to discontinue \\ncorticosteroid used \\n11% \\n25% \\n34% \\nP-valuec \\n0.059 \\n0.005 \\na \\nREMICADE at Week 0 \\nb \\nREMICADE 5 mg/kg administered at Weeks 0, 2 and 6 \\nc \\nP-values represent pairwise comparisons to placebo \\nd \\nOf those receiving corticosteroids at baseline \\nReference ID: 5540648 \\n31 \\nQ) \\nVJ \\n~ \\n0 \\nD.. \\nVJ \\nQ) \\n0:: \\n....... \\nVJ \\n.9 \\n0 z \\n\\\"C \\n('ti \\n.r: \\n0 \\n..c \\n~ \\n./:2 \\nc;;; \\nCl) \\nrJ \\nao \\n60 \\n40 \\n20 \\nCompared to placebo maintenance: \\nRemicade 1 o mgi/kg; p < 0.001 \\nRem,ioade 5 mgJlkg: \\np = 0.004 \\nCL \\nQ -+--,---,---,-----.---------.--------.--------.-------.--------.---' \\n0 2 \\n6 \\n110 \\n14 \\n22 \\n30 \\n--0--\\nPlacebo \\nmaintenance \\nStudy Week \\n------\\n5 mg.lkg Remicade \\nmaintenance \\n38 \\n----\\n10 mg.lkg Remicade \\nmaintenance \\n(') \\nN \\nra \\nPatients in the REMICADE maintenance groups (5 mg/kg and 10 mg/kg) had a longer time \\nto loss of response than patients in the placebo maintenance group (Figure 1). At Weeks 30 \\nand 54, significant improvement from baseline was seen among the 5 mg/kg and 10 mg/kg \\nREMICADE-treated groups compared to the placebo group in the disease-specific \\ninflammatory bowel disease questionnaire (IBDQ), particularly the bowel and systemic \\ncomponents, and in the physical component summary score of the general health-related \\nquality of life questionnaire SF-36. \\nFigure 1: \\nKaplan-Meier Estimate of the Proportion of Adults with CD Who Had Not Lost Response \\nThrough Week 54 (Study Crohn’s I) \\nIn a subset of 78 patients who had mucosal ulceration at baseline and who participated in an \\nendoscopic substudy, 13 of 43 patients in the REMICADE maintenance group had \\nendoscopic evidence of mucosal healing compared to 1 of 28 patients in the placebo group at \\nWeek 10. Of the REMICADE-treated patients showing mucosal healing at Week 10, 9 of \\n12 patients also showed mucosal healing at Week 54. \\nPatients who achieved a response and subsequently lost response were eligible to receive \\nREMICADE on an episodic basis at a dose that was 5 mg/kg higher than the dose to which \\nthey were randomized. The majority of such patients responded to the higher dose. Among \\npatients who were not in response at Week 2, 59% (92/157) of REMICADE maintenance \\npatients responded by Week 14 compared to 51% (39/77) of placebo maintenance patients. \\nAmong patients who did not respond by Week 14, additional therapy did not result in \\nsignificantly more responses [see Dosage and Administration (2)]. \\nFistulizing Crohn’s Disease in Adults \\nThe safety and efficacy of REMICADE were assessed in 2 randomized, double-blind, \\nplacebo-controlled studies in adult patients with fistulizing CD with fistula(s) that were of at \\nleast 3 months duration. Concurrent use of stable doses of corticosteroids, 5-aminosalicylates, \\nantibiotics, MTX, 6-mercaptopurine (6-MP) and/or azathioprine (AZA) was permitted. \\nReference ID: 5540648 \\n32 \\n~ \\n;,g \\n~ 100 \\nQ) \\n(J) \\nC \\n0 a. \\n80 \\n(J) \\nQ) \\na: \\n1n \\n60 \\n0 \\n---' \\n0 z \\n40 \\n1J \\\"' \\n.s:::: \\n0 \\n.s:::: \\n20 \\n~ \\n\\\"' \\n(\\\\J \\n(J) \\nCompared to placebo maintenance: \\n0 \\nc \\n'<l\\\" \\nQ) \\nRem icade 5 mg/kg: p = 0.001 \\n\\\"' \\n~ \\n0 \\na.. \\n0 2 \\n6 \\n10 14 \\n22 \\n30 \\n38 \\n46 \\n54 \\nStudy Week \\n--0- Placebo maintenance --- 5 mg/kg Remicade maintenance \\nIn the first trial, 94 adult patients received 3 doses of either placebo or REMICADE at \\nWeeks 0, 2 and 6. Fistula response (≥50% reduction in number of enterocutaneous fistulas \\ndraining upon gentle compression on at least 2 consecutive visits without an increase in \\nmedication or surgery for CD) was seen in 68% (21/31) of patients in the 5 mg/kg \\nREMICADE group (P=0.002) and 56% (18/32) of patients in the 10 mg/kg REMICADE \\ngroup (P=0.021) vs. 26% (8/31) of patients in the placebo arm. The median time to onset of \\nresponse and\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"2\", \"content\": \"REMICADE \\n10 mg/kg \\nREMICADE \\nPlacebo \\n5 mg/kg \\nREMICADE \\n10 mg/kg \\nREMICADE \\nPatients \\nrandomized \\n121 \\n121 \\n122 \\n123 \\n121 \\n120 \\nClinical Responsea, d \\nWeek 8 \\n37% \\n69%* \\n62%* \\n29% \\n65%* \\n69%* \\nWeek 30 \\n30% \\n52%* \\n51%** \\n26% \\n47%* \\n60%* \\nWeek 54 \\n20% \\n45%* \\n44%* \\nNA \\nNA \\nNA \\nSustained Responsed \\n(Clinical response \\nat both Weeks 8 \\nand 30) \\n23% \\n49%* \\n46%* \\n15% \\n41%* \\n53%* \\n(Clinical response \\nat \\nWeeks 8, \\n30, \\nand 54) \\n14% \\n39%* \\n37%* \\nNA \\nNA \\nNA \\nClinical Remissionb, d \\nWeek 8 \\n15% \\n39%* \\n32%** \\n6% \\n34%* \\n28%* \\nWeek 30 \\n16% \\n34%** \\n37%* \\n11% \\n26%** \\n36%* \\nWeek 54 \\n17% \\n35%** \\n34%** \\nNA \\nNA \\nNA \\nSustained Remissiond \\n(Clinical remission \\nat both Weeks 8 \\nand 30) \\n8% \\n23%** \\n26%* \\n2% \\n15%* \\n23%* \\n(Clinical remission \\nat Weeks 8, 30 and \\n54)\\n7% \\n20%** \\n20%** \\nNA \\nNA \\nNA \\nMucosal Healingc, d \\nWeek 8 \\n34% \\n62%* \\n59%* \\n31% \\n60%* \\n62%* \\nWeek 30 \\n25% \\n50%* \\n49%* \\n30% \\n46%** \\n57%* \\nWeek 54 \\n18% \\n45%* \\n47%* \\nNA \\nNA \\nNA \\n* P<0.001,** P<0.01 \\na \\nDefined as a decrease from baseline in the Mayo score by ≥30% and ≥3 points, accompanied by a decrease \\nin the rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1. (The Mayo score consists of the \\nsum of four subscores: stool frequency, rectal bleeding, physician’s global assessment and endoscopy \\nfindings). \\nb \\nDefined as a Mayo score ≤2 points, no individual subscore >1. \\nc \\nDefined as a 0 or 1 on the endoscopy subscore of the Mayo score. \\nd \\nPatients who had a prohibited change in medication, had an ostomy or colectomy, or discontinued study \\ninfusions due to lack of efficacy are considered to not be in clinical response, clinical remission or mucosal \\nhealing from the time of the event onward. \\nThe improvement with REMICADE was consistent across all Mayo subscores through \\nWeek 54 (Study UC I shown in Table 6; Study UC II through Week 30 was similar). \\nReference ID: 5540648 \\n36 \\n \\n \\nTable 6: \\nProportion of Adult UC Patients in Study UC I with Mayo Subscores Indicating Inactive or \\nMild Disease Through Week 54 \\nStudy UC I \\nREMICADE \\nPlacebo \\n5 mg/kg \\n10 mg/kg \\n(n=121) \\n(n=121) \\n(n=122) \\nStool frequency \\nBaseline \\n17% \\n17% \\n10% \\nWeek 8 \\n35% \\n60% \\n58% \\nWeek 30 \\n35% \\n51% \\n53% \\nWeek 54 \\n31% \\n52% \\n51% \\nRectal bleeding \\nBaseline \\n54% \\n40% \\n48% \\nWeek 8 \\n74% \\n86% \\n80% \\nWeek 30 \\n65% \\n74% \\n71% \\nWeek 54 \\n62% \\n69% \\n67% \\nPhysician’s Global Assessment \\nBaseline \\n4% \\n6% \\n3% \\nWeek 8 \\n44% \\n74% \\n64% \\nWeek 30 \\n36% \\n57% \\n55% \\nWeek 54 \\n26% \\n53% \\n53% \\nEndoscopy findings \\nBaseline \\n0% \\n0% \\n0% \\nWeek 8 \\n34% \\n62% \\n59% \\nWeek 30 \\n26% \\n51% \\n52% \\nWeek 54 \\n21% \\n50% \\n51% \\n14.4 Pediatric Ulcerative Colitis \\nThe safety and effectiveness of REMICADE for reducing signs and symptoms and inducing \\nand maintaining clinical remission in pediatric patients aged 6 years and older with \\nmoderately to severely active UC who have had an inadequate response to conventional \\ntherapy are supported by evidence from adequate and well-controlled studies of REMICADE \\nin adults. Additional safety and pharmacokinetic data were collected in an open-label \\npediatric UC trial in 60 pediatric patients aged 6 through 17 years (median age 14.5 years) \\nwith moderately to severely active UC (Mayo score of 6 to 12; Endoscopic subscore ≥2) and \\nan inadequate response to conventional therapies. At baseline, the median Mayo score was 8, \\n53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of \\npatients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone \\nequivalents). Discontinuation of immunomodulators and corticosteroid taper were permitted \\nafter Week 0.\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\REMICADE_INFLIXIMAB_VIAL_103772_CENTOCOR_INC_02-28-2025.pdf\"}, {\"id\": \"3\", \"content\": \"HIGHLIGHTS OF PRESCRIBING INFORMATION \\nThese highlights do not include all the information needed to use \\nIBSRELA® safely and effectively. See full prescribing information for \\nIBSRELA. \\nIBSRELA (tenapanor) tablets, for oral use \\nInitial U.S. Approval: 2019 \\nWARNING:  RISK OF SERIOUS DEHYDRATION IN \\nPEDIATRIC PATIENTS \\nSee full prescribing information for complete boxed warning. \\n• IBSRELA is contraindicated in patients less than 6 years of age; in \\nyoung juvenile rats, tenapanor caused death presumed to be due to \\ndehydration. (4, 8.4) \\n• Avoid use of IBSRELA in patients 6 years to less than 12 years of \\nage. (5.1, 8.4) \\n• The safety and effectiveness of IBSRELA have not been established \\nin pediatric patients less than 18 years of age. (8.4) \\n------------------------INDICATIONS AND USAGE-------------------------------­\\nIBSRELA is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for \\ntreatment of irritable bowel syndrome with constipation (IBS-C) in adults. (1) \\n-------------------DOSAGE AND ADMINISTRATION---------------------------­\\n• The recommended dosage in adults is 50 mg, orally twice daily. (2) \\n• Take immediately prior to breakfast or the first meal of the day and \\nimmediately prior to dinner. (2) \\n------------------DOSAGE FORMS AND STRENGTHS----------------­\\nTablets: 50 mg tenapanor. (3) \\n--------------------------CONTRAINDICATIONS-------------------------­\\n• Pediatric patients less than 6 years of age. (4, 5.1, 8.4) \\n• Patients with known or suspected mechanical gastrointestinal \\nobstruction. (4) \\n--------------------WARNINGS AND PRECAUTIONS------------------­\\nDiarrhea: Patients may experience severe diarrhea. If severe diarrhea \\noccurs, suspend dosing and rehydrate patient. (5.2) \\n---------------------------ADVERSE REACTIONS-------------------------­\\nMost common adverse reactions (≥2%) are diarrhea, abdominal \\ndistension, flatulence and dizziness. (6.1) \\nTo report SUSPECTED ADVERSE REACTIONS, contact \\nArdelyx at 1-844-427-7352 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch. \\n---------------------------DRUG INTERACTIONS-------------------------­\\nOATP2B1 Substrates: Potential for reduced exposure of the \\nconcomitant drug (e.g., enalapril). Monitor for signs related to loss of \\nefficacy and adjust the dosage of the concomitantly administered drug \\nas needed. (7.1) \\nSee 17 for PATIENT COUNSELING INFORMATION and \\nMedication Guide. \\nRevised: 1/2025 \\nFULL PRESCRIBING INFORMATION: CONTENTS* \\nWARNING:  RISK OF SERIOUS DEHYDRATION IN PEDIATRIC \\nPATIENTS \\n1 \\nINDICATIONS AND USAGE \\n2 \\nDOSAGE AND ADMINISTRATION \\n3 \\nDOSAGE FORMS AND STRENGTHS \\n4 \\nCONTRAINDICATIONS \\n5 \\nWARNINGS AND PRECAUTIONS \\n5.1 Risk of Serious Dehydration in Pediatric Patients \\n5.2 Diarrhea \\n6 \\nADVERSE REACTIONS \\n6.1 Clinical Trials Experience \\n6.2 Postmarketing Experience \\n7 \\nDRUG INTERACTIONS \\n7.1 OATP2B1 Substrates \\n8 \\nUSE IN SPECIFIC POPULATIONS \\n8.1 Pregnancy \\n8.2 Lactation \\n8.4 Pediatric Use \\n8.5 Geriatric Use \\n10 OVERDOSAGE \\n11 DESCRIPTION \\n12 CLINICAL PHARMACOLOGY \\n12.1 Mechanism of Action \\n12.2 Pharmacodynamics \\n12.3 Pharmacokinetics \\n13 NONCLINICAL TOXICOLOGY \\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility \\n14 CLINICAL STUDIES \\n16 HOW SUPPLIED / STORAGE AND HANDLING \\n17 PATIENT COUNSELING INFORMATION \\n* Sections or subsections omitted from the full prescribing information \\nare not listed \\nPage 1 \\nReference ID: 5509314 \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n  \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n<5 \\nFULL PRESCRIBING INFORMATION \\nWARNING:  RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS \\n• IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical \\nstudies in young juvenile rats administration of tenapanor caused deaths \\npresumed to be due to dehydration [see Contraindications (4), Use in Specific \\nPopulations (8.4)]. \\n• Avoid use of IBSRELA in patients 6 years to less than 12 years of age \\n[see Warnings and Precautions (5.1), Use in Specific Populations (8.4)]. \\n• \\nThe safety and effectiveness of IBSRELA have not been established in patients \\nless than 18 years of age [see Use in Specific Populations (8.4)]. \\n1 INDICATIONS AND USAGE \\nIBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. \\n2 DOSAGE AND ADMINISTRATION \\nThe recommended dosage of IBSRELA in adults is 50 mg orally twice daily. \\nAdministration Instructions \\n• Take IBSRELA immediately prior\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"4\", \"content\": \"°C (77°F); in a tight container. Protect from light. \\n17 \\nPATIENT COUNSELING INFORMATION \\nAdvise the patient to read the FDA-Approved Medication Guide. \\nPatients taking LAMISIL Tablets should receive the following information and instructions: \\n  Advise patients to immediately report to their physician or get emergency help if they experience any of the following \\nsymptoms: hives, mouth sores, blistering and peeling of skin, swelling of face, lips, tongue, or throat, difficulty \\nswallowing or breathing. LAMISIL Tablets treatment should be discontinued. \\n  Advise patients to immediately report to their physician any symptoms of persistent nausea, anorexia, fatigue, \\nvomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. LAMISIL Tablets treatment should be \\ndiscontinued. \\nReference ID: 4044199 \\nThis label may not be the latest approved by FDA.  \\nFor current labeling information, please visit https://www.fda.gov/drugsatfda\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  Advise patients to report to their physician any signs of taste disturbance, smell disturbance and/or depressive \\nsymptoms, fever, skin eruption, lymph node enlargement, erythema, scaling, loss of pigment, and unusual \\nphotosensitivity that can result in a rash. LAMISIL Tablets treatment should be discontinued. \\n  Advise patients to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using \\nLAMISIL Tablets. \\n  Advise patients that if they forget to take LAMISIL Tablets, to take their tablets as soon as they remember, unless it is \\nless than 4 hours before the next dose is due. \\n  Advise patients to call their physician if they take too many LAMISIL Tablets. \\nDistributed by: \\nNovartis Pharmaceuticals Corporation \\nEast Hanover, New Jersey 07936  \\n© Novartis \\nT2017-17 \\nJanuary 2017 \\nReference ID: 4044199 \\nThis label may not be the latest approved by FDA.  \\nFor current labeling information, please visit https://www.fda.gov/drugsatfda\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nMEDICATION GUIDE \\nLAMISIL® (lam-i-sil) \\n(terbinafine hydrochloride) Tablets \\nWhat is the most important information I should know about LAMISIL Tablets? \\nLAMISIL Tablets may cause serious side effects, including: \\n Liver problems that can lead to the need for a liver transplant or death. This can happen in people who have \\nliver problems and in people who have never had liver problems. Tell your doctor right away if you get any of these \\nsymptoms of  liver problems: \\no nausea \\no poor appetite \\no tiredness  \\no vomiting \\no upper right stomach-area (abdomen) pain \\no yellowing of your skin or eyes (jaundice) \\no dark (tea-colored) urine    \\no pale or light colored stools \\nYour doctor should do a blood test to check you for liver problems before you start treatment with LAMISIL Tablets. \\nYour doctor may also check you for liver problems during treatment, and tell you to stop taking LAMISIL Tablets if \\nyou develop liver problems.  \\nWhat are LAMISIL Tablets? \\nLAMISIL Tablets is a prescription medicine used to treat fungal infections of the fingernails and toenails \\n(onychomycosis).  \\nYour doctor should do tests to check you for fungal infection of your nails before you start LAMISIL Tablets. \\nIt is not known if LAMISIL Tablets are safe and effective in children for the treatment of onychomycosis. \\nWho should not take LAMISIL Tablets?  \\nDo not take LAMISIL Tablets if you: \\n \\nhave had a severe allergic reaction to terbinafine hydrochloride when taken by mouth.  \\n \\nhave had liver disease for a long time (chronic) or have active liver disease. \\nWhat should I tell my doctor before taking LAMISIL Tablets? \\nBefore taking LAMISIL Tablets, tell your doctor about all of your medical conditions, including if you: \\n \\nhave or had liver problems \\n \\nhave a weakened immune system (immunocompromised) \\n \\nhave lupus (an autoimmune disease) \\n \\nare pregnant or plan to become pregnant. It is not known if LAMISIL Tablets will harm your unborn baby. You \\nshould not start taking LAMISIL Tablets during pregnancy. \\n \\nare breastfeeding or plan to breastfeed. LAMISIL passes into your breast milk and may harm your baby. You \\nshould not breastfeed while taking LAMISIL Tablets. Talk to your doctor about the best way to feed your baby if \\nyou take LAMISIL Tablets.  \\nTell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, \\nand herbal supplements.  LAMISIL Tablets may affect the way other medicines work and other medicines may affect \\nhow LAMISIL Tablets work. \\nHow should I take LAMISIL Tablets? \\n Take LAMISIL Tablets exactly as your doctor tells you to take it. \\n LAMISIL comes as a tablet that you take by mouth. \\n LAMISIL Tablets are usually taken:  \\no 1 time each day for 6 weeks to treat fungal infections of your fingernail, or  \\no 1 time each day for 12 weeks to treat fungal infections of your toenail \\n LAMISIL Tablets can be taken with or without food.\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\LAMISIL_TERBINAFINE_HYDROCHLORIDE_GRANULE_ORAL_22071_NOVARTIS_03-29-2019.pdf\"}, {\"id\": \"5\", \"content\": \"IBSRELA immediately prior to breakfast or the first meal of the day and \\nimmediately before dinner [see Dosage and Administration (2)]. \\n• \\nIf a dose is missed, skip the missed dose and take the next dose at the regular time. \\nDo not take 2 doses at the same time [see Dosage and Administration (2)]. \\n• \\nTo keep IBSRELA in a dry place. Protect from moisture. Keep in the original bottle. Do not \\nremove desiccant from the bottle. Do not subdivide or repackage. Keep bottles tightly closed \\n[see How Supplied/Storage and Handling (16)]. \\nManufactured for and distributed by Ardelyx, Inc. \\nWaltham, MA 02451 USA \\nIBSRELA® is a registered trademark of Ardelyx, Inc. \\nPatent: www.IBSRELA-patents.com \\nPage 13 \\nReference ID: 5509314 \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n   \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n   \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n  \\n \\n \\n \\n \\n \\n \\n      \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nMedication Guide \\nIBSRELA® (ibs rel`a)\\n(tenapanor) \\ntablets, for oral use \\nWhat is the most important information I should know about IBSRELA? \\n• \\nDo not give IBSRELA to children who are less than 6 years of age. It may harm them. \\n• \\nYou should not give IBSRELA to patients 6 years to less than 18 years of age. It may harm them. \\nIBSRELA can cause severe diarrhea and your child could get severe dehydration (loss of a large amount of body water \\nand salt). \\nSee “What are the possible side effects of IBSRELA?” for more information about side effects. \\nWhat is IBSRELA? \\nIBSRELA is a prescription medicine used in adults to treat: \\n• \\nIrritable bowel syndrome with constipation (IBS-C). \\nIt is not known if IBSRELA is safe and effective in children less than 18 years of age. \\nWho should not take IBSRELA? \\n• \\nDo not give IBSRELA to children who are less than 6 years of age. IBSRELA can cause severe diarrhea and \\nyour child could get severe dehydration (loss of a large amount of body water and salt). \\n• \\nDo not take IBSRELA if a doctor has told you that you have a bowel blockage (intestinal obstruction). \\nBefore you take IBSRELA, tell your doctor about all your medical conditions, including if you: \\n• \\nare pregnant or plan to become pregnant. It is not known if IBSRELA will harm your unborn baby. \\n• \\nare breastfeeding or plan to breastfeed. It is not known if IBSRELA passes into your breast milk. Talk with your \\ndoctor about the best way to feed your baby if you take IBSRELA. \\nTell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins \\nand herbal supplements. \\nHow should I take IBSRELA? \\n• \\nTake IBSRELA exactly as your doctor tells you to take it. \\n• \\nTake 1 IBSRELA tablet by mouth, 2 times each day. \\n• \\nTake IBSRELA immediately before breakfast or the first meal of the day and immediately before dinner. \\n• \\nIf a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take 2 doses at the \\nsame time. \\nWhat are the possible side effects of IBSRELA?\\nIBSRELA can cause serious side effects, including: \\n• \\nSee “What is the most important information I should know about IBSRELA?” \\n• \\nDiarrhea is the most common side effect of IBSRELA, and it can sometimes be severe. Stop taking \\nIBSRELA and call your doctor if you develop severe diarrhea. \\nThe other most common side effects of IBSRELA include: \\n• \\nswelling, or a feeling of fullness or pressure in your abdomen (distension). \\n• \\ngas (flatulence). \\n• \\ndizziness. \\nThese are not all the possible side effects of IBSRELA. Call your doctor for medical advice about side effects. You may \\nreport side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch. \\nHow should I store IBSRELA? \\n• \\nStore IBSRELA at room temperature, between 68°F and 77°F (20°C and 25°C). \\n• \\nKeep IBSRELA in the original container and protect from moisture. Keep the container of IBSRELA tightly closed \\nand in a dry place. \\n• \\nDo not put IBSRELA in another container (repackage). \\n•\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\"}, {\"id\": \"6\", \"content\": \"IACT may affect the way other medicines work, and other medicines may affect \\nhow BRIVIACT works. Do not start a new medicine without first talking with your healthcare provider. Know the medicines \\nyou take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. \\nHow should I take BRIVIACT? \\n• \\nTake BRIVIACT exactly as your healthcare provider tells you. \\n• \\nYour healthcare provider will tell you how much BRIVIACT to take and when to take it. \\n• \\nYour healthcare provider may change your dose if needed. Do not change your dose without talking to your \\nReference ID: 5174249\\nThis label may not be the latest approved by FDA.  \\nFor current labeling information, please visit https://www.fda.gov/drugsatfda\\n \\n \\nhealthcare provider. \\n• \\nTake BRIVIACT with or without food. \\n• \\nSwallow BRIVIACT tablets whole with a liquid. Do not chew or crush BRIVIACT tablets before swallowing. \\n• \\nIf your healthcare provider has prescribed BRIVIACT oral solution, be sure to ask your pharmacist for a medicine \\ndropper or medicine cup to help you measure the correct amount of BRIVIACT oral solution. Do not use a household \\nteaspoon or tablespoon. Ask your pharmacist for instructions on how to use the measuring device the right way. \\n• \\nBRIVIACT injection can be given to you by intravenous (IV) infusion into your vein, as prescribed by your healthcare \\nprovider. \\n• \\nIf you take too much BRIVIACT, call your Poison Control Center or go to the nearest emergency room right away. \\nWhat should I avoid while taking BRIVIACT? \\nDo not drive or operate machinery until you know how BRIVIACT affects you. BRIVIACT may cause drowsiness, \\ntiredness, dizziness, and problems with your balance and coordination. \\nWhat are the possible side effects of BRIVIACT? \\nBRIVIACT may cause serious side effects, including: \\n• \\nSee “What is the most important information I should know about BRIVIACT?”  \\n• \\nNervous system problems. Drowsiness, tiredness, and dizziness are common with BRIVIACT, but can be severe. \\nSee “What should I avoid while taking BRIVIACT?” BRIVIACT can also cause problems with balance and \\ncoordination. \\n• \\nMental (psychiatric) symptoms. BRIVIACT can cause mood and behavior changes such as aggression, agitation, \\nanger, anxiety, apathy, mood swings, depression, hostility, and irritability. Irritability and anxiety are common with \\nBRIVIACT, and can be severe. People who take BRIVIACT can also get psychotic symptoms such as hallucinations \\n(seeing or hearing things that are really not there), delusions (false or strange thoughts or beliefs), and unusual \\nbehavior. \\nThe most common side effects of BRIVIACT in adults include: \\n• sleepiness \\n• dizziness \\n• \\nfeeling tired \\n• \\nnausea and vomiting \\nSide effects of BRIVIACT in children 1 month to less than 16 years of age are similar to those seen in adults. \\nThese are not all the possible side effects of BRIVIACT. For more information, ask your healthcare provider or \\npharmacist. Tell your healthcare provider about any side effect that bothers you or that does not go away. Call your doctor \\nfor medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. \\nHow should I store BRIVIACT? \\n• \\nStore BRIVIACT at room temperature between 59°F to 86°F (15°C to 30°C). \\n• \\nDo not freeze BRIVIACT oral solution. \\n• \\nSafely throw away any opened bottle of BRIVIACT oral solution after 5 months of first opening the bottle, even if there \\nis medicine left in the bottle. \\nKeep BRIVIACT and all medicines out of the reach of children. \\nGeneral information about the safe and effective use of BRIVIACT. \\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BRIVIACT for \\na condition for which it was not prescribed. Do not give BRIVIACT to other people, even if they have the same symptoms \\nthat you have. It may harm them. \\nThis Medication Guide summarizes the most important information about BRIVIACT. If you would like more information, \\ntalk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about BRIVIACT \\nthat is written for health professionals. \\nWhat are the ingredients in BRIVIACT? \\nActive ingredient: brivaracetam \\nTablet inactive ingredients: croscarmellose sodium, lactose monohydrate, betadex (β-cyclodextrin), anhydrous lactose, \\nand magnesium stearate. The tablet film coating contains the inactive ingredients listed below: \\n• \\n10 mg tablets: polyvinyl alcohol, talc, polyethylene glycol 3350, titanium dioxide \\n• \\n25 mg and 100 mg tablets: polyvinyl alcohol, talc, polyethylene glycol 3350, titanium dioxide, yellow iron oxide, black \\niron oxide \\n• \\n50 mg tablets: polyvinyl alcohol, talc, polyethylene glycol 3350, titanium dioxide, yellow iron oxide, red iron oxide \\n• \\n75 mg tablets: polyvinyl alcohol, talc, polyethylene glycol 3350, titanium dioxide, yellow iron oxide, red iron oxide, \\nblack iron oxide \\nOral solution inactive\", \"file_path\": \"C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\BRIVIACT_BRIVARACETAM_SOLUTION_INTRAVENOUS_205837_UCB_INC_05-17-2023.pdf\"}]\n",
      "```\n",
      "\n",
      "\n",
      "\n",
      "🔍 Querying RAG:\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO: Local query uses 52 entites, 143 relations, 3 chunks\n",
      "INFO: Query edges: IBSRELA, Standard dosage, Medication, top_k: 60, cosine: 0.2\n",
      "INFO: Global query uses 15 entites, 60 relations, 3 chunks\n",
      "INFO:  == LLM cache == saving hybrid: c63d461276932e058e0df314ca197888\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🧠 Answer:\n",
      "### Standarddosierung von IBSRELA\n",
      "\n",
      "Die empfohlene Dosierung von IBSRELA (tenapanor) für Erwachsene beträgt 50 mg, die oral zweimal täglich eingenommen werden sollte. Es wird empfohlen, IBSRELA unmittelbar vor dem Frühstück oder der ersten Mahlzeit des Tages sowie unmittelbar vor dem Abendessen einzunehmen. \n",
      "\n",
      "### Hinweise zur Einnahme\n",
      "- Wenn eine Dosis vergessen wurde, sollte diese ausgelassen und die nächste Dosis zum regulären Zeitpunkt eingenommen werden. Es ist nicht ratsam, zwei Dosen gleichzeitig zu verwenden.\n",
      "\n",
      "Diese Dosierungsinformationen sind entscheidend für die sichere und effektive Anwendung des Medikaments.\n",
      "\n",
      "### Contraindikation\n",
      "IBSRELA ist kontraindiziert bei Patienten unter 6 Jahren aufgrund des Risikos schwerer Dehydration.\n",
      "\n",
      "### Zusammenfassung\n",
      "Daher ist die Standarddosierung von IBSRELA 50 mg, zwei Mal täglich, vorzugsweise vor den Mahlzeiten.\n",
      "\n",
      "### References\n",
      "- [KG] C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\n",
      "- [KG] C:\\\\Users\\\\FahRe\\\\Desktop\\\\agentic-LLM-app\\\\backend\\\\data\\\\MedicationGuides_2025_05_19\\\\IBSRELA_TENAPANOR_HYDROCHLORIDE_TABLET_ORAL_211801_ARDELYX_INC_01-10-2025.pdf\n"
     ]
    }
   ],
   "source": [
    "query = \"Was ist die standard dosierung von  IBSRELA \"\n",
    "context = rag.query(query, param=QueryParam(mode=\"hybrid\", only_need_context=True))\n",
    "print(\"\\n📄 Retrieved Context:\")\n",
    "print(context)\n",
    "print(\"\\n🔍 Querying RAG:\")\n",
    "answer = rag.query(query, param=QueryParam(mode=\"hybrid\"))\n",
    "print(\"\\n🧠 Answer:\")\n",
    "print(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "13615d11",
   "metadata": {},
   "outputs": [
    {
     "ename": "AttributeError",
     "evalue": "'str' object has no attribute 'metadata'",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mAttributeError\u001b[39m                            Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[80]\u001b[39m\u001b[32m, line 48\u001b[39m\n\u001b[32m     43\u001b[39m     documents.append(Document(page_content=text.strip(), metadata=data))\n\u001b[32m     45\u001b[39m llm = ChatOpenAI(model=\u001b[33m\"\u001b[39m\u001b[33mgpt-3.5-turbo\u001b[39m\u001b[33m\"\u001b[39m, temperature=\u001b[32m0\u001b[39m)\n\u001b[32m     46\u001b[39m db = Chroma.from_documents(\n\u001b[32m     47\u001b[39m     documents=[\n\u001b[32m---> \u001b[39m\u001b[32m48\u001b[39m         Document(page_content=doc.page_content, metadata=\u001b[43mfilter_complex_metadata\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdoc\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m)\u001b[49m)\n\u001b[32m     49\u001b[39m         \u001b[38;5;28;01mfor\u001b[39;00m doc \u001b[38;5;129;01min\u001b[39;00m documents\n\u001b[32m     50\u001b[39m     ],\n\u001b[32m     51\u001b[39m     embedding=embedding_function\n\u001b[32m     52\u001b[39m )\n",
      "\u001b[36mFile \u001b[39m\u001b[32mc:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\.venv\\Lib\\site-packages\\langchain_community\\vectorstores\\utils.py:66\u001b[39m, in \u001b[36mfilter_complex_metadata\u001b[39m\u001b[34m(documents, allowed_types)\u001b[39m\n\u001b[32m     64\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m document \u001b[38;5;129;01min\u001b[39;00m documents:\n\u001b[32m     65\u001b[39m     filtered_metadata = {}\n\u001b[32m---> \u001b[39m\u001b[32m66\u001b[39m     \u001b[38;5;28;01mfor\u001b[39;00m key, value \u001b[38;5;129;01min\u001b[39;00m \u001b[43mdocument\u001b[49m\u001b[43m.\u001b[49m\u001b[43mmetadata\u001b[49m.items():\n\u001b[32m     67\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(value, allowed_types):\n\u001b[32m     68\u001b[39m             \u001b[38;5;28;01mcontinue\u001b[39;00m\n",
      "\u001b[31mAttributeError\u001b[39m: 'str' object has no attribute 'metadata'"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders import JSONLoader\n",
    "from langchain.embeddings.sentence_transformer import SentenceTransformerEmbeddings\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain.schema import Document\n",
    "from langchain_community.vectorstores.utils import filter_complex_metadata\n",
    "\n",
    "import json\n",
    "    \n",
    "embedding_function = SentenceTransformerEmbeddings(model_name=\"all-MiniLM-L6-v2\")\n",
    "\n",
    "loader = JSONLoader(\n",
    "    file_path=r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\atc2.json\",\n",
    "    jq_schema=\".ATC_Codes[]\",\n",
    "    text_content=False  # Important: this avoids the ValueError you hit\n",
    ")\n",
    "\n",
    "# Load raw documents\n",
    "raw_docs = loader.load()\n",
    "documents = []\n",
    "\n",
    "\n",
    "\n",
    "for doc in raw_docs:\n",
    "    if isinstance(doc.page_content, str):\n",
    "        data = json.loads(doc.page_content)\n",
    "    elif isinstance(doc.page_content, dict):\n",
    "        data = doc.page_content\n",
    "    else:\n",
    "        raise ValueError(\"Unsupported page_content type\")\n",
    "\n",
    "    text = f\"\"\"\n",
    "    Product-Medikament: {data.get(\"Product-Medikament\")}\n",
    "    Beschreibung: {data.get(\"Beschreibung\")}\n",
    "    Anwendung: {data.get(\"Anwendung\")}\n",
    "    Gruppe: {data.get(\"Gruppe\")}\n",
    "    Hauptkategorie ATC: {data.get(\"ATC Oberkategorie\")}\n",
    "    Unterkategorie ATC: {data.get(\"ATC Unterkategorie\")}\n",
    "    \"\"\"\n",
    "    \n",
    "    documents.append(Document(page_content=text.strip(), metadata=data))\n",
    "\n",
    "llm = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)\n",
    "db = Chroma.from_documents(\n",
    "    documents=[\n",
    "        Document(page_content=doc.page_content, metadata=filter_complex_metadata(doc.metadata))\n",
    "        for doc in documents\n",
    "    ],\n",
    "    embedding=embedding_function\n",
    ")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "id": "60105171",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import JSONLoader\n",
    "from langchain.embeddings.sentence_transformer import SentenceTransformerEmbeddings\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain.schema import Document\n",
    "import json\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "\n",
    "# ✅ Utility to clean metadata\n",
    "def clean_metadata(metadata: dict) -> dict:\n",
    "    \"\"\"Ensure all metadata values are Chroma-compatible (str, int, float, bool, None).\"\"\"\n",
    "    allowed_types = (str, int, float, bool, type(None))\n",
    "    cleaned = {}\n",
    "    for k, v in metadata.items():\n",
    "        if isinstance(v, allowed_types):\n",
    "            cleaned[k] = v\n",
    "        elif isinstance(v, list):\n",
    "            cleaned[k] = \", \".join(map(str, v))  # Convert list to CSV string\n",
    "        else:\n",
    "            cleaned[k] = str(v)  # Fallback: convert everything else to string\n",
    "    return cleaned\n",
    "\n",
    "# Step 1: Initialize embedding model\n",
    "#embedding_function = SentenceTransformerEmbeddings(model_name=\"all-MiniLM-L6-v2\")\n",
    "embedding_function = OpenAIEmbeddings(model=\"text-embedding-ada-002\", openai_api_key=OPENAI_API_KEY)\n",
    "\n",
    "\n",
    "# Step 2: Load JSON\n",
    "loader = JSONLoader(\n",
    "    file_path=r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\atc2.json\",\n",
    "    jq_schema=\".ATC_Codes[]\",\n",
    "    text_content=False\n",
    ")\n",
    "\n",
    "# Step 3: Load raw documents\n",
    "raw_docs = loader.load()\n",
    "documents = []\n",
    "\n",
    "# Step 4: Build cleaned Documents\n",
    "for doc in raw_docs:\n",
    "    data = json.loads(doc.page_content) if isinstance(doc.page_content, str) else doc.page_content\n",
    "\n",
    "    # Format the readable content\n",
    "    text = f\"\"\"\n",
    "    Product-Medikament: {data.get(\"Product-Medikament\")}\n",
    "    Beschreibung: {data.get(\"Beschreibung\")}\n",
    "    Anwendung: {data.get(\"Anwendung\")}\n",
    "    Gruppe: {data.get(\"Gruppe\")}\n",
    "    ATC Oberkategorie: {data.get(\"ATC Oberkategorie\")}\n",
    "    ATC Unterkategorie: {data.get(\"ATC Unterkategorie\")}\n",
    "    \"\"\"\n",
    "    safe_metadata = clean_metadata(data)\n",
    "    safe_metadata[\"source\"] = \"atc2.json - ATC-Code sortierte Textbausteine aktuell\"\n",
    "    \n",
    "    documents.append(Document(page_content=text.strip(), metadata=safe_metadata))\n",
    "\n",
    "# Step 5: Create vectorstore\n",
    "db = Chroma.from_documents(documents, embedding_function, persist_directory = r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\chroma_db_openai2\" )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "9b64df9b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- Top-1 Similar Doc ---\n",
      "Product-Medikament: Chlorhexamed / Chlorhexamed forte\n",
      "    Beschreibung: Lösung: Enthält den Wirkstoff Chlorhexidin und ist ein Mund- und Rachendesinfiziens zur vorübergehenden unterstützenden Behandlung bei Zahnfleischentzündungen (Gingivitis) und nach parodontalchirurgischen Eingriffen (Eingriffe am Zahnfleisch).\n",
      "    Anwendung: Chlorhexamed (forte) Lösung: Nach dem Zähneputzen mindestens 5 Minuten warten bis zur Anwendung. Mit der unverdünnten Lösung den Mund spülen oder gurgeln.\n",
      "    Gruppe: None\n",
      "    ATC Oberkategorie: A Alimentäres System und Stoffwechsel\n",
      "    ATC Unterkategorie: A01 Stomatologika\n",
      "\n",
      "--- Top-2 Similar Doc ---\n",
      "Product-Medikament: Chlorhexamed / Chlorhexamed forte\n",
      "    Beschreibung: Gel: Zur Behandlung und Vorbeugung von bakteriellen und mykotischen Entzündungen der Mundschleimhaut, des Zahnfleisches, des Zahnbettes und bei Aphten verwendet.\n",
      "    Anwendung: Chlorhexamed Gel: Mit einem Wattestäbchen eine kleine Menge direkt auf die entzündete Stelle im Mund auftragen oder Gel auf die nasse Zahnbürste geben und Zähne und/oder Zunge sanft bürsten, ausspucken. Möglichst wenig mit Wasser nachspülen (Depotwirkung).\n",
      "    Gruppe: None\n",
      "    ATC Oberkategorie: A Alimentäres System und Stoffwechsel\n",
      "    ATC Unterkategorie: A01 Stomatologika\n",
      "\n",
      "--- Top-3 Similar Doc ---\n",
      "Product-Medikament: Merfen wässrige Lösung\n",
      "    Beschreibung: Desinfektionsmittel mit den Wirkstoffen Chlorhexidindiglukonat und Benzoxoniumchlorid. Es wirkt auf die für eine Entzündung verantwortlichen Mikroorganismen, auch in Gegenwart von Blut und Eiter. Zur Desinfektion von Wunden und Verletzungen, wie Kratz- und Schürfwunden, Schnittwunden, leichten Verbrennungen (oberflächlichen, kleinflächigen Verbrennungen 1. Grades), sowie von Insektenstichen.\n",
      "    Anwendung: None\n",
      "    Gruppe: None\n",
      "    ATC Oberkategorie: D Dermatika\n",
      "    ATC Unterkategorie: D08 Antiseptika und Desinfektionsmittel\n",
      "\n",
      "Antwort: Nach dem Zähneputzen mindestens 5 Minuten warten bis zur Anwendung. Mit der unverdünnten Lösung den Mund spülen oder gurgeln.\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.vectorstores import Chroma\n",
    "db = Chroma(persist_directory = r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\chroma_db_openai2\", embedding_function=embedding_function)\n",
    "query = \"Wie sollte ich Chlorhexamed forte answenden?\"\n",
    "docs = db.similarity_search(query, k=3)\n",
    "retrieved_text = \"\\n\".join([doc.page_content for doc in docs])\n",
    "top_source = f\"{docs[0].metadata.get('source', 'unbekannt')} (Seite {docs[0].metadata.get('page', '?')})\"\n",
    "\n",
    "\n",
    "# Optional: print context\n",
    "for i, d in enumerate(docs):\n",
    "    print(f\"\\n--- Top-{i+1} Similar Doc ---\\n{d.page_content}\")\n",
    "\n",
    "# Prompt and chain\n",
    "prompt = PromptTemplate(\n",
    "    input_variables=[\"context\", \"question\", \"source\"],\n",
    "    template=\"\"\"\n",
    "    Du bist ein medizinischer Assistent. Nutze den folgenden Kontext, um die Frage so präzise wie möglich zu beantworten.\n",
    "    Wenn die Antwort nicht im Kontext enthalten ist, gib das ehrlich an. Antworte kurz und sachlich.\n",
    "\n",
    "    Kontext: {context}\n",
    "    \n",
    "    Quelle:\n",
    "    {source}\n",
    "\n",
    "    Frage: {question}\n",
    "    Antwort:\n",
    "    \"\"\"\n",
    ")\n",
    "qa_chain = LLMChain(llm=llm, prompt=prompt)\n",
    "response = qa_chain.run({\n",
    "    \"context\": retrieved_text,\n",
    "    \"source\": top_source,\n",
    "    \"question\": query\n",
    "})\n",
    "\n",
    "print(\"\\nAntwort:\", response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b80fde42",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "Created a chunk of size 9698, which is longer than the specified 8000\n",
      "Created a chunk of size 15270, which is longer than the specified 8000\n",
      "Created a chunk of size 8758, which is longer than the specified 8000\n",
      "Created a chunk of size 11226, which is longer than the specified 8000\n",
      "Created a chunk of size 8639, which is longer than the specified 8000\n",
      "Created a chunk of size 10245, which is longer than the specified 8000\n",
      "Created a chunk of size 11622, which is longer than the specified 8000\n",
      "Created a chunk of size 12239, which is longer than the specified 8000\n",
      "Created a chunk of size 13803, which is longer than the specified 8000\n",
      "Created a chunk of size 13682, which is longer than the specified 8000\n",
      "Created a chunk of size 11496, which is longer than the specified 8000\n",
      "Created a chunk of size 10869, which is longer than the specified 8000\n",
      "Created a chunk of size 8642, which is longer than the specified 8000\n",
      "Created a chunk of size 13449, which is longer than the specified 8000\n",
      "Created a chunk of size 13033, which is longer than the specified 8000\n",
      "Created a chunk of size 12407, which is longer than the specified 8000\n",
      "Created a chunk of size 22557, which is longer than the specified 8000\n",
      "Created a chunk of size 28778, which is longer than the specified 8000\n",
      "Created a chunk of size 18002, which is longer than the specified 8000\n",
      "Created a chunk of size 11317, which is longer than the specified 8000\n",
      "Created a chunk of size 17515, which is longer than the specified 8000\n",
      "Created a chunk of size 18484, which is longer than the specified 8000\n",
      "Created a chunk of size 8250, which is longer than the specified 8000\n",
      "Created a chunk of size 10405, which is longer than the specified 8000\n",
      "Created a chunk of size 24529, which is longer than the specified 8000\n",
      "Created a chunk of size 17968, which is longer than the specified 8000\n",
      "Created a chunk of size 8506, which is longer than the specified 8000\n",
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_45464\\2629379980.py:58: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embedding_function = SentenceTransformerEmbeddings(model_name=\"all-MiniLM-L6-v2\")\n",
      "c:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\.venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.document_loaders.excel import UnstructuredExcelLoader\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain.text_splitter import CharacterTextSplitter\n",
    "import os\n",
    "from langchain.embeddings.sentence_transformer import SentenceTransformerEmbeddings\n",
    "\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "file_path = r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\Interaktionen nach IA-Nummern.xlsx\"\n",
    "file_path2 = r\"C:\\Users\\FahRe\\Desktop\\agentic-LLM-app\\backend\\data\\ATC-Code sortierte Textbausteine aktuell.xlsx\"\n",
    "loader1 = UnstructuredExcelLoader(file_path=file_path, sheet_name=\"Tabelle1\")\n",
    "loader2 = UnstructuredExcelLoader(file_path=file_path, sheet_name=\"Tabelle2\")\n",
    "loader3 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"A\")\n",
    "loader4 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"B\")\n",
    "loader5 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"C\")\n",
    "loader6 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"D\")\n",
    "loader7 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"G\")\n",
    "loader8 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"H\")\n",
    "loader9 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"J\")\n",
    "loader10 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"L\")\n",
    "loader11 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"M\")\n",
    "loader12 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"N\")\n",
    "loader13 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"P\")\n",
    "loader14 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"R\")\n",
    "loader15 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"S\")\n",
    "loader16 = UnstructuredExcelLoader(file_path=file_path2, sheet_name=\"V\")\n",
    "\n",
    "\n",
    "docs_sheet1 = loader1.load()\n",
    "docs_sheet2 = loader2.load()\n",
    "docs_sheet3 = loader3.load()\n",
    "docs_sheet4 = loader4.load()\n",
    "docs_sheet5 = loader5.load()\n",
    "docs_sheet6 = loader6.load()\n",
    "docs_sheet7 = loader7.load()\n",
    "docs_sheet8 = loader8.load()\n",
    "docs_sheet9 = loader9.load()\n",
    "docs_sheet10 = loader10.load()\n",
    "docs_sheet11 = loader11.load()\n",
    "docs_sheet12 = loader12.load()\n",
    "docs_sheet13 = loader13.load()\n",
    "docs_sheet14 = loader14.load()\n",
    "docs_sheet15 = loader15.load()\n",
    "docs_sheet16 = loader16.load()\n",
    "\n",
    "\n",
    "docs = docs_sheet1 + docs_sheet2 + docs_sheet3  + docs_sheet4  + docs_sheet5  + docs_sheet6 + docs_sheet7 + docs_sheet8 + docs_sheet9 + docs_sheet10  + docs_sheet11 + docs_sheet12 + docs_sheet13 + docs_sheet14 + docs_sheet15 + docs_sheet16\n",
    "text_splitter = CharacterTextSplitter(\n",
    "    separator=\"\\n\",\n",
    "    chunk_size=8000,\n",
    "    chunk_overlap=1000,\n",
    "    length_function=len\n",
    ")\n",
    "split_docs = text_splitter.split_documents(docs)\n",
    "#embedding_function = OpenAIEmbeddings(api_key=api_key, model=\"text-embedding-ada-002\")\n",
    "embedding_function = SentenceTransformerEmbeddings(model_name=\"all-MiniLM-L6-v2\")\n",
    "db = FAISS.from_documents(split_docs, embedding_function)\n",
    "retriever = db.as_retriever(search_kwargs={\"k\": 1})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "4ac386ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\FahRe\\AppData\\Local\\Temp\\ipykernel_45464\\3738164229.py:9: LangChainDeprecationWarning: The method `Chain.__call__` was deprecated in langchain 0.1.0 and will be removed in 1.0. Use :meth:`~invoke` instead.\n",
      "  result = qa({\"query\": query})\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "In den bereitgestellten Informationen ist keine Angabe zur Einnahme von Vita Hepa enthalten. Daher kann ich Ihnen leider keine genaue Auskunft zur Einnahme von Vita Hepa geben. Bitte konsultieren Sie die Packungsbeilage des Medikaments oder wenden Sie sich an Ihren Arzt oder Apotheker für genaue Anweisungen zur Einnahme.\n"
     ]
    }
   ],
   "source": [
    "qa = RetrievalQA.from_chain_type(\n",
    "    llm=ChatOpenAI(temperature=0, model=\"gpt-4.1-mini\", max_tokens=1000),\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=retriever,\n",
    "    return_source_documents=True,)\n",
    "\n",
    "\n",
    "query = \"Wie sollte ich Vita Hepa einnehmen?\"\n",
    "result = qa({\"query\": query})\n",
    "print(result['result'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a64098bc",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
